<SEC-DOCUMENT>0001193125-20-187279.txt : 20200706
<SEC-HEADER>0001193125-20-187279.hdr.sgml : 20200706
<ACCEPTANCE-DATETIME>20200706063252
ACCESSION NUMBER:		0001193125-20-187279
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20200702
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200706
DATE AS OF CHANGE:		20200706

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vir Biotechnology, Inc.
		CENTRAL INDEX KEY:			0001706431
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				812730369
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39083
		FILM NUMBER:		201012112

	BUSINESS ADDRESS:	
		STREET 1:		499 ILLINOIS STREET
		STREET 2:		SUITE 500
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		415-906-4324

	MAIL ADDRESS:	
		STREET 1:		499 ILLINOIS STREET
		STREET 2:		SUITE 500
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d939163d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of The Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): July&nbsp;2, 2020 </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Vir Biotechnology, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-39083</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">81-2730369</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>499 Illinois Street, Suite 500 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>San Francisco, California 94158 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(415) <FONT STYLE="white-space:nowrap">906-4324</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or former address, if changed since last report) </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&nbsp;12(b) of the Act: </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of each class</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Trading</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Symbol(s)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of each exchange<BR>on which registered</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Common Stock, $0.0001 par value</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>VIR</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Nasdaq Global Select Market</B></TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (&#167;&nbsp;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 (&#167; <FONT STYLE="white-space:nowrap">240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Appointment of Director </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;2, 2020, upon the recommendation of its Nominating and Corporate Governance Committee (the &#147;Nominating Committee&#148;), the Board of
Directors (the &#147;Board&#148;) of Vir Biotechnology, Inc. (the &#147;Company&#148;) increased the size of the Board from nine (9)&nbsp;to ten (10)&nbsp;members, and appointed Dr.&nbsp;Elliott Sigal to fill the newly created vacancy, to serve on
the Board as a Class&nbsp;I director until the Company&#146;s 2023 annual meeting of stockholders, and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal effective upon the closing of the
Company&#146;s proposed underwritten public offering of common stock pursuant to a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> expected to be filed with the Securities and Exchange Commission (the &#147;SEC&#148;)
today (such public offering closing date, the &#147;Effective Date&#148;). Based upon the further recommendation of its Nominating Committee, the Board also appointed Dr.&nbsp;Sigal to serve as a member of its Compensation Committee, with such
appointment effective upon his appointment to the Board. Dr.&nbsp;Sigal was not selected by the Board to serve as a director pursuant to any arrangement or understanding with any persons. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Director Independence </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based upon information requested
from and provided by Dr.&nbsp;Sigal concerning his background, employment and affiliations, including family relationships, the Nominating Committee and the Board have determined that Dr.&nbsp;Sigal does not have any relationships that would
interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that Dr.&nbsp;Sigal is &#147;independent&#148; as that term is defined under the applicable rules and regulations of the SEC and the listing
requirements of The Nasdaq Stock Market LLC Marketplace Rules, and that Dr.&nbsp;Sigal will be a <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> director&#148; as defined in Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated
under the Securities Exchange Act of 1934, as amended. In making this determination, the Nominating Committee and the Board considered the current and prior relationships that Dr.&nbsp;Sigal has with the Company and all other facts and circumstances
the Nominating Committee and the Board deemed relevant in determining Dr.&nbsp;Sigal&#146;s independence. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Director Background </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Sigal, age 68, served as Chief Scientific Officer of Bristol-Myers Squibb Company (&#147;BMS&#148;) from October 2004 until his retirement in June
2013 and was a member of its board of directors from March 2011 to June 2013. Dr.&nbsp;Sigal joined BMS in 1997 and held positions of increasing responsibility in drug discovery and development and was a member of the executive committee from
September 2001 through June 2013. Prior to BMS, he was Vice President of R&amp;D and Chief Executive Officer for the genomics firm Mercator Genetics Inc. Dr.&nbsp;Sigal currently serves as a member of the board of directors of Adaptimmune
Therapeutics plc, a role he has held since 2014. Dr.&nbsp;Sigal has also served as a member of the board of directors of Surface Oncology, Inc. since 2018 and is a member of its nominating and corporate governance committee. In addition,
Dr.&nbsp;Sigal is an advisor to the life sciences venture firm New Enterprise Associates and consults for select biopharmaceutical companies. Dr.&nbsp;Sigal holds B.S., M.S. and Ph.D. degrees in industrial engineering from Purdue University and an
M.D. from the University of Chicago. He completed his training in internal medicine and pulmonary medicine at the University of California, San Francisco (&#147;UCSF&#148;). He received his research training at the Cardiovascular Research Institute
at UCSF, where he served on the faculty of the UCSF Department of Medicine. The Nominating Committee and the Board believe that Dr.&nbsp;Sigal is qualified to serve on the Board because of his extensive experience in the life sciences industry and
his extensive leadership experience. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Director Compensation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Sigal will receive compensation as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director in accordance with the Company&#146;s <FONT
STYLE="white-space:nowrap">non-employee</FONT> director compensation policy that took effect in October 2019, as described in the Company&#146;s definitive proxy statement for the 2020 Annual Meeting of Stockholders, filed with the SEC on
April&nbsp;6, 2020. Pursuant to the automatic grant program under such policy, Dr.&nbsp;Sigal will be granted an option to purchase 57,777 shares of the Company&#146;s common stock under the Company&#146;s 2019 Equity Incentive Plan on the Effective
Date. <FONT STYLE="white-space:nowrap">One-third</FONT> of the shares subject to such stock option will vest on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of his initial appointment and thereafter the remainder of the shares
subject to such stock option will vest monthly over a <FONT STYLE="white-space:nowrap">two-year</FONT> period, subject to the director&#146;s continued service as a director through the applicable vesting dates, and acceleration in the event of a
change of control as defined in the plan. Such option grant will have an exercise price equal to the closing sale price of the Company&#146;s common stock on the Effective Date as reported on The Nasdaq Global Select Market and a term of 10 years,
subject to earlier termination for cessation of continuous service. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Director Indemnification Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the aforementioned appointment to the Board, the Company will enter into its standard indemnification agreement with Dr.&nbsp;Sigal, which
form indemnity agreement is filed as Exhibit 10.1 to the Company&#146;s registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-233604)</FONT> filed with the SEC on
September&nbsp;3, 2019, which requires the Company, under the circumstances and to the extent provided for therein, to indemnify the indemnitee to the fullest extent permitted by applicable law against certain expenses and other amounts incurred by
him as a result of being made a party to certain actions, suits, investigations and other proceedings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;8.01 Other Events. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is filing certain information for the purpose of updating descriptions of the Company&#146;s business and risk factors contained in the
Company&#146;s other filings with the SEC. Copies of the additional disclosures are attached as Exhibits 99.1 and 99.2 to this report and incorporated herein by reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01 Financial Statements and Exhibits </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(d)
Exhibits </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d939163dex991.htm">Updated Business Description </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d939163dex992.htm">Updated Risk Factors </A></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> contains forward-looking statements about the Company
and its industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this report, including statements regarding the effectiveness of Dr.&nbsp;Sigal&#146;s appointment to the
Company&#146;s Board, the Company&#146;s proposed underwritten public offering of common stock, the Company&#146;s strategy, future financial condition, future operations, research and development, planned clinical trials and preclinical studies,
technology platforms, the timing and likelihood of regulatory filings and approvals for the Company&#146;s product candidates, its ability to commercialize its product candidates, the potential benefits of collaborations, projected costs, prospects,
plans, objectives of management and expected market growth, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#147;aim,&#148; &#147;anticipate,&#148; &#147;assume,&#148;
&#147;believe,&#148; &#147;contemplate,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;design,&#148; &#147;due,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;goal,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;objective,&#148;
&#147;plan,&#148; &#147;positioned,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;seek,&#148; &#147;should,&#148; &#147;target,&#148; &#147;will,&#148; &#147;would&#148; and other similar expressions that are predictions of or indicate
future events and future trends, or the negative of these terms or other comparable terminology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has based these forward-looking statements
largely on its current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. These forward-looking statements
are subject to a number of known and unknown risks, uncertainties and assumptions described in the Company&#146;s filings with the SEC, including the section titled &#147;Risk Factors&#148; in Exhibit 99.2 attached to this report. Moreover, the
Company operates in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for the Company&#146;s management to predict all risk factors nor can the Company assess the impact of all
factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future
events. Although the Company believes that it has a reasonable basis for each forward-looking statement contained in this report, the Company cannot guarantee that the future results, levels of activity, performance or events and circumstances
reflected in the forward-looking statements will be achieved or occur at all. You should refer to the section titled &#147;Risk Factors&#148; in Exhibit 99.2 attached to this report for a discussion of important factors that may cause the
Company&#146;s actual results to differ materially from those expressed or implied by the Company&#146;s forward-looking statements. Furthermore, if the Company&#146;s forward-looking statements prove to be inaccurate, the inaccuracy may be
material. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Vir Biotechnology, Inc.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: July&nbsp;6, 2020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Howard Horn</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Howard Horn</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d939163dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BUSINESS SUMMARY </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Business Summary
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Our mission is to create a world without infectious disease </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent
serious infectious diseases. Infectious diseases are one of the leading causes of death worldwide and can cause trillions of dollars of direct and indirect economic burden each year &#150; as evidenced by the current coronavirus disease 2019, or <FONT
STYLE="white-space:nowrap">COVID-19,</FONT> pandemic. We believe that now is the time to apply the recent and remarkable advances in immunology to combat infectious diseases. Our approach begins with identifying the limitations of the immune system
in combating a particular pathogen, the vulnerabilities of that pathogen and the reasons why previous approaches have failed. We then bring to bear powerful technologies that we believe, individually or in combination, will lead to effective
therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have assembled four technology platforms, focused on antibodies, T cells, innate immunity and small interfering ribonucleic
acid, or siRNA, through internal development, collaborations and acquisitions. Our current development pipeline consists of product candidates targeting severe acute respiratory syndrome coronavirus 2, or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">SARS-CoV-2,</FONT></FONT> the virus that causes <FONT STYLE="white-space:nowrap">COVID-19,</FONT> hepatitis B virus, or HBV, influenza A, human immunodeficiency virus, or HIV, and tuberculosis, or TB. For <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2,</FONT></FONT> <FONT STYLE="white-space:nowrap">VIR-7831,</FONT> a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2-</FONT></FONT></FONT> neutralizing monoclonal antibody, or mAb, is planned to start a Phase 2/3 clinical trial program in August&nbsp;2020
and we anticipate initial clinical data to be available before the end of the year. <FONT STYLE="white-space:nowrap">VIR-7832,</FONT> a vaccinal
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2-neutralizing</FONT></FONT></FONT> mAb, is planned to initiate a Phase 2 clinical trial later this year.
<FONT STYLE="white-space:nowrap">VIR-2703,</FONT> a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2-targeting</FONT></FONT></FONT> siRNA, is in preclinical studies. For HBV, <FONT
STYLE="white-space:nowrap">VIR-2218,</FONT> an <FONT STYLE="white-space:nowrap">HBV-targeting</FONT> siRNA, is currently in an ongoing Phase 2 clinical trial. Initial Phase 2 data have demonstrated substantial, durable, and dose dependent reduction
of hepatitis B virus surface antigen, or HBsAg, and <FONT STYLE="white-space:nowrap">VIR-2218</FONT> has been generally well-tolerated. We recently initiated a Phase 2 clinical trial to combine <FONT STYLE="white-space:nowrap">VIR-2218</FONT> with
pegylated interferon-alpha, or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PEG-IFN-&#945;,</FONT></FONT> an approved immune modulatory agent. In addition, we recently initiated a Phase 1 clinical trial for <FONT
STYLE="white-space:nowrap">VIR-3434,</FONT> an <FONT STYLE="white-space:nowrap">HBV-neutralizing</FONT> mAb. For influenza A, <FONT STYLE="white-space:nowrap">VIR-2482,</FONT> a mAb designed for the prevention of influenza A, is currently in a Phase
1/2 clinical trial and has been generally well-tolerated. For HIV, <FONT STYLE="white-space:nowrap">VIR-1111,</FONT> an HIV T cell vaccine based on HCMV, is planned to initiate a Phase 1 trial in the second half of this year. We have built an
industry-leading team that has deep experience in immunology, infectious diseases and product development. Given the global impact of infectious diseases, we are committed to developing cost-effective treatments that can be delivered at scale. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Technology Platforms </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our four
current technology platforms are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. We are using our platforms to advance our current product candidates and generate additional
product candidates for multiple indications. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Antibody Platform</I></B>: We have established a robust method for capitalizing on unusually
successful immune responses naturally occurring in people who are protected from, or have recovered from, infectious diseases. We identify rare antibodies from survivors that have the potential to treat and prevent rapidly evolving and/or previously
untreatable pathogens via direct pathogen neutralization and immune system stimulation. The fully-human antibodies that we discover may also be modified to enhance their therapeutic potential. We have applied these methods to identify mAbs for a
range of pathogens including Ebola, HBV, influenza A and influenza B virus, SARS-CoV-2, RSV and malaria, and bacterial pathogens, including <I>clostridium difficile, Staphylococcus aureus</I>, <I>Klebsiella pneumoniae</I>, and <I>Acinetobacter
spp</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>T Cell Platform</I></B>: We are exploiting the unique immunology of human cytomegalovirus, or HCMV, a commonly occurring virus in humans,
as a vaccine vector to potentially treat and prevent infection by pathogens refractory to current vaccine technologies. This approach is based on fundamental observations made in <FONT STYLE="white-space:nowrap">non-human</FONT> primates, or NHPs,
with rhesus cytomegalovirus, or RhCMV. We believe that this platform may also have applicability beyond infectious diseases, to areas such as cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Innate Immunity Platform</I></B>: Moving beyond more traditional approaches that are used to evoke adaptive immunity or that directly target pathogens,
where the development of resistance can occur, we plan to target host proteins as a means of creating host-directed therapies with high barriers to resistance. We believe that by leveraging the power of innate immunity, we can create medicines that
break the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;one-drug-for-one-bug&#148;</FONT></FONT></FONT></FONT> paradigm to produce <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;one-drug-for-multiple-bugs.&#148;</FONT></FONT></FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>siRNA Platform</I></B>: We are harnessing the power of siRNA to inhibit pathogen replication, eliminate key host factors necessary for pathogen survival
and remove microbial immune countermeasures. Our collaboration with Alnylam Pharmaceuticals, Inc., or Alnylam, includes <FONT STYLE="white-space:nowrap">VIR-2218</FONT> for HBV, <FONT STYLE="white-space:nowrap">VIR-2703</FONT> for <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> and up to seven additional programs for infectious diseases. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our
Development Pipeline </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current product candidates are summarized in the chart below: </P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g939163g34b40.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>*</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><I><FONT STYLE="white-space:nowrap">VIR-1111</FONT> is a vaccine designed to establish proof of concept in Phase
(Ph) 1 clinical trial to determine whether unique immune response observed in NHPs can be replicated in humans; ultimately, any candidates we advance as a potential HIV vaccine will require modifications to
<FONT STYLE="white-space:nowrap">VIR-1111</FONT> before further clinical development. </I></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2:</FONT></FONT>
</I></B>The substantial impact of viral outbreaks and the need for global preparedness have been highlighted by the current <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. As of June&nbsp;19, 2020, the virus had spread to 188 countries,
there were over 8.5&nbsp;million recorded infections and over 450,000 recorded deaths. We have moved rapidly to address this global health challenge. Our focus is on treating and preventing <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">SARS-CoV-2,</FONT></FONT> as well as potential future coronavirus outbreaks. To do so, we are taking multiple approaches: antibodies <FONT STYLE="white-space:nowrap">(VIR-7831</FONT> and
<FONT STYLE="white-space:nowrap">VIR-7832),</FONT> siRNA <FONT STYLE="white-space:nowrap">(VIR-2703),</FONT> applying our innate immunity platform to identify cellular host genes necessary for virus replication, and vaccines. We anticipate that the
initial registration populations for our product candidates will include those at high risk of contracting <FONT STYLE="white-space:nowrap">COVID-19</FONT> and those in need of treatment for <FONT STYLE="white-space:nowrap">COVID-19.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">VIR-7831</FONT> and <FONT STYLE="white-space:nowrap">VIR-7832</FONT></I></B> are <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2-neutralizing</FONT></FONT></FONT> mAbs. For <FONT STYLE="white-space:nowrap">VIR-7831,</FONT> we plan to submit an Investigational New Drug
Application, or IND, and thereafter commence a Phase 2/3 clinical trial program in August&nbsp;2020. <FONT STYLE="white-space:nowrap">VIR-7832</FONT> is planned to initiate a Phase 2 clinical trial later this year. Both <FONT
STYLE="white-space:nowrap">VIR-7831</FONT> and <FONT STYLE="white-space:nowrap">VIR-7832</FONT> are based on a parent antibody, S309, which was derived from samples previously gathered for research on
<FONT STYLE="white-space:nowrap">pan-coronavirus-neutralizing</FONT> mAbs. S309 has demonstrated high affinity and avidity for the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> spike protein and the
ability to potently neutralize <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> in multiple live-virus cellular assays. S309 binds to an epitope on <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> that is shared with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-1</FONT></FONT> (also commonly known as &#145;SARS&#146;), indicating that the epitope is highly
conserved. We believe the conservation of this epitope will make it more difficult for escape mutants to develop and result in a high barrier to resistance. S309 also exhibits potent effector function in vitro, potentially allowing the engagement
and recruitment of immune cells to kill off already infected cells. <FONT STYLE="white-space:nowrap">VIR-7831</FONT> and <FONT STYLE="white-space:nowrap">VIR-7832</FONT> have both been engineered with &#147;LS&#148; mutations within the Fc region of
the mAbs, for the purpose of increasing lung tissue bioavailability and extending their half-life. <FONT STYLE="white-space:nowrap">VIR-7832</FONT> has been further engineered with &#147;XX2&#148; mutations in the Fc region of the mAb to potentially
allow it to function as a T cell vaccine. We anticipate initial clinical data from our Phase 2/3 trial of <FONT STYLE="white-space:nowrap">VIR-7831</FONT> to be available before the end of the year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Phase 2/3 trial program for VIR-7831 will be comprised of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g939163g12i79.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To accelerate the progress of <FONT STYLE="white-space:nowrap">VIR-7831</FONT> and <FONT
STYLE="white-space:nowrap">VIR-7832,</FONT> we have signed a number of collaboration agreements to aid in their manufacture and potential commercialization. Specifically, we are collaborating on clinical manufacturing with WuXi Biologics (Hong Kong)
Limited, or WuXi, and Biogen Inc., or Biogen. We are collaborating on commercial manufacturing with WuXi and Samsung Biologics Co., Ltd., or Samsung, and we anticipate commercial supply of approximately 10-15 million doses in 2021, depending on
titer, yield and dose amount. And we are collaborating on potential commercialization with WuXi for greater China and GlaxoSmithKline plc, or GSK, for all other countries. See the section titled &#147;Recent <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> Activities&#148; for a description of these and other collaborations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT
STYLE="white-space:nowrap">VIR-2703</FONT> </I></B>is an inhaled <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2-targeting</FONT></FONT></FONT> siRNA for which we are conducting
preclinical studies that are expected to be completed by the end of 2020. In vitro, <FONT STYLE="white-space:nowrap">VIR-2703</FONT> has demonstrated the ability to significantly reduce
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> live virus replication. It is designed to degrade the viral genome, leading to inhibition of viral protein synthesis and blocking the production of infectious
virus. It targets a nucleic acid sequence in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> genome that is highly conserved amongst currently available viral sequences and is also conserved in <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-1.</FONT></FONT> <FONT STYLE="white-space:nowrap">VIR-2703</FONT> leverages Alnylam&#146;s latest advances in lung delivery of siRNAs and is the first development candidate
selected in our expanded collaboration with Alnylam for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> and other coronaviruses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>HBV</I></B>: Approximately 290&nbsp;million people globally are chronically infected with HBV and
approximately 900,000 of them die from <FONT STYLE="white-space:nowrap">HBV-associated</FONT> complications each year. There is a significant unmet medical need for more effective therapies that lead to life-long control of the virus after a finite
duration of therapy, which is the definition of a functional cure. For a registrational trial to demonstrate a functional cure, the formal endpoint accepted by the U.S. Food and Drug Administration, or the FDA, is undetectable HBsAg, defined as less
than 0.05 international units per milliliter, or IU/ml, as well as HBV DNA less than the lower limit of quantification, in the blood six months after the end of therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <FONT STYLE="white-space:nowrap">VIR-2218</FONT> and <FONT STYLE="white-space:nowrap">VIR-3434</FONT> for the functional
cure of HBV. Each of these product candidates has the potential to stimulate an effective immune response and also has direct antiviral activity against HBV. We believe that a functional cure for HBV will require an effective immune response, in
addition to antiviral activity, based on the observation that severe immunosuppression can reactivate HBV disease. While monotherapy with <FONT STYLE="white-space:nowrap">VIR-2218</FONT> and <FONT STYLE="white-space:nowrap">VIR-3434</FONT> may
provide a functional cure in some patients, we believe combination therapy will be necessary for a functional cure in many patients. We are planning trials that combine <FONT STYLE="white-space:nowrap">VIR-2218</FONT> and <FONT
STYLE="white-space:nowrap">VIR-3434,</FONT> which we believe have the potential to act in concert by removing potentially tolerogenic HBV proteins and stimulating new HBV specific T cells. We also recently initiated a trial that combines <FONT
STYLE="white-space:nowrap">VIR-2218</FONT> with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PEG-IFN-&#945;</FONT></FONT> and are evaluating additional combinations with other immunotherapy agents and direct acting antiviral
agents. We anticipate that the initial registration population for these product candidates will be patients chronically infected with HBV. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">VIR-2218</FONT></I></B> is a subcutaneously administered
<FONT STYLE="white-space:nowrap">HBV-targeting</FONT> siRNA that is currently in a Phase&nbsp;2 clinical trial. By targeting a conserved region of the HBV genome, it is designed to inhibit the production of all HBV proteins: X, polymerase, S, and
core. Suppression of HBV proteins, particularly HBsAg, is hypothesized to remove the inhibition of T&nbsp;cell and B&nbsp;cell activity directed against HBV, allowing <FONT STYLE="white-space:nowrap">VIR-2218</FONT> to potentially result in a
functional cure. <FONT STYLE="white-space:nowrap">VIR-2218</FONT> was the first siRNA in the clinic to include Alnylam&#146;s ESC+ technology, which has the potential to enhance the therapeutic index. In total, 37 healthy volunteers have received <FONT
STYLE="white-space:nowrap">VIR-2218</FONT> and 12 healthy volunteers have received placebo. In addition, 24&nbsp;patients with chronic HBV on nucleotide/nucleoside reverse transcriptase inhibitors, or NRTIs, have received <FONT
STYLE="white-space:nowrap">VIR-2218,</FONT> and eight patients with chronic HBV on NRTIs have received placebo. The data suggest that <FONT STYLE="white-space:nowrap">VIR-2218</FONT> is generally well-tolerated in healthy volunteers given as a
single dose up to 900&nbsp;mg and in patients given as two doses of 20&nbsp;mg, 50&nbsp;mg, 100&nbsp;mg or 200&nbsp;mg each dose. The data also demonstrate substantial, dose dependent reductions in HBsAg in patients at doses ranging from 20&nbsp;mg
to 200&nbsp;mg, which are durable at the higher doses for at least six months. We recently initiated a Phase&nbsp;2 combination trial of <FONT STYLE="white-space:nowrap">VIR-2218</FONT> and <FONT STYLE="white-space:nowrap">PEG-IFN-&#945;,</FONT> and
anticipate initial clinical data to be available in 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trial design for the Phase 2 combination trial of VIR-2218 and
PEG-IFN-&#945; is shown below: </P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g939163g28p24.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">VIR-3434</FONT></I></B> is a subcutaneously
administered <FONT STYLE="white-space:nowrap">HBV-neutralizing</FONT> mAb currently in a Phase 1 clinical trial. By targeting a conserved region of HBsAg, it is designed to block entry of all 10 genotypes of HBV into liver cells called hepatocytes
and reduce the level of virions and subviral particles in the blood. We have also engineered <FONT STYLE="white-space:nowrap">VIR-3434</FONT> to have an extended half-life and to potentially function as a therapeutic T cell vaccine for chronic HBV
infection. These modifications are intended to enhance its potential to result in an HBV functional cure. We anticipate clinical data from our Phase 1 trial will enable us to initiate a Phase 2 clinical trial of
<FONT STYLE="white-space:nowrap">VIR-3434</FONT> in combination with <FONT STYLE="white-space:nowrap">VIR-2218</FONT> in 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Influenza</I></B>:<B> </B>On average, each year the influenza virus infects 5% to 10% of the world&#146;s population and results in an estimated 500,000
deaths. In the 2017-2018 flu season, it is now estimated that 61,000 people died from influenza in the United States alone. Influenza vaccines have historically had limited success, with an average efficacy of 40%. This limited efficacy results from
incomplete coverage against seasonal strains and the lack of an effective immune response in many individuals after receiving the vaccine. We are developing <FONT STYLE="white-space:nowrap">VIR-2482</FONT> as a universal prophylactic for influenza A
and have designed it to overcome both limitations of flu vaccines, which we believe will lead to meaningfully higher levels of protection. We anticipate that the initial registration population for <FONT STYLE="white-space:nowrap">VIR-2482</FONT>
will be individuals at high risk of influenza A complications, such as the elderly with chronic lung disease or congestive heart failure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">VIR-2482</FONT></I></B> is an intramuscularly administered influenza
<FONT STYLE="white-space:nowrap">A-neutralizing</FONT> mAb currently in a Phase&nbsp;1/2 clinical trial. In vitro, <FONT STYLE="white-space:nowrap">VIR-2482</FONT> has been shown to cover all major strains of influenza A that have arisen since the
1918 Spanish flu pandemic. We believe that <FONT STYLE="white-space:nowrap">VIR-2482</FONT> has the potential to provide superior protection to flu vaccines and be able to be used year after year because it has broad strain coverage as opposed to
the limited strain coverage generated by vaccines. We also believe that it provides passive immunity rather than relying on a person to generate active immunity via a functional immune response, an ability that is known to decline with age. <FONT
STYLE="white-space:nowrap">VIR-2482</FONT> has been engineered to increase lung tissue bioavailability and to extend its half-life so that a single intramuscular dose has the potential to last the entire flu season, which is typically five to six
months long. VIR-2482 is estimated to have a half-life of 58 days based on preliminary data. <FONT STYLE="white-space:nowrap">VIR-2482</FONT> has been generally well-tolerated in the approximately 100 healthy volunteers dosed in the Phase&nbsp;1
portion of the clinical trial. We anticipate initiating the Phase 2 portion of the clinical trial in the northern hemisphere in the fourth quarter of 2020, followed by a second northern hemisphere season if necessary. Data from an interim analysis
of the first flu season of the Phase 2 clinical trial are anticipated to be available in the first half of 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>HIV</I></B>: Each year there are
approximately 1.8&nbsp;million new cases of HIV and approximately 1.0&nbsp;million <FONT STYLE="white-space:nowrap">HIV-related</FONT> deaths globally. Current prevention approaches such as behavioral modification and pharmacological intervention
have had only a modest effect on HIV transmission globally, leaving a high unmet medical need for a safe and effective vaccine for the billions of individuals who are or may become sexually active. <FONT STYLE="white-space:nowrap">VIR-1111</FONT> is
a proof of concept HIV vaccine designed to elicit a type of immune response that is different from other vaccines. We anticipate the initial registration population for our eventual HIV vaccine will be individuals at high risk of contracting HIV.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">VIR-1111</FONT></I></B> is a subcutaneously administered HIV T cell vaccine based on HCMV for
which we plan to submit an IND in the second half of 2020 and thereafter commence a Phase 1 clinical trial. <FONT STYLE="white-space:nowrap">VIR-1111</FONT> has been designed to elicit T cells that recognize HIV epitopes that are different from
those recognized by prior HIV vaccines and to stimulate a different and specific type of T cell immune response to HIV, known as an <FONT STYLE="white-space:nowrap">HLA-E</FONT> restricted immune response. An
<FONT STYLE="white-space:nowrap">HLA-E</FONT> restricted immune response has been shown to be associated with protection of NHPs from simian immunodeficiency virus, or SIV, the NHP equivalent of HIV. <FONT STYLE="white-space:nowrap">VIR-1111</FONT>
is a vaccine designed solely to establish proof of concept in a Phase 1 clinical trial to determine whether the unique immune response observed in NHPs can be replicated in humans. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TB</I></B>: Globally, nearly two billion people are latently infected with TB, and each year there are
approximately 10&nbsp;million new active cases of TB and approximately 1.6&nbsp;million <FONT STYLE="white-space:nowrap">TB-related</FONT> deaths. There is a high unmet medical need for a safe and effective vaccine that prevents active pulmonary TB
in adolescents and adults, as they represent the key sources of TB<I> </I>transmission and are the primary contributors to overall disease burden. <FONT STYLE="white-space:nowrap">VIR-2020</FONT> is a vaccine designed to provide a type of immune
response that is different from other vaccines and lead to meaningful levels of protection from active TB. We anticipate that the initial registration population for <FONT STYLE="white-space:nowrap">VIR-2020</FONT> will be people at high risk of
developing active TB, such as those who have latent TB infection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">VIR-2020</FONT></I></B> is a
subcutaneously administered TB T cell vaccine based on HCMV for which we plan to submit an IND in 2023 and thereafter commence a Phase 1 clinical trial. <FONT STYLE="white-space:nowrap">VIR-2020</FONT> is designed to stimulate T cells that reside in
the lung and to recognize TB epitopes that are different from those recognized by prior TB vaccines. In preclinical studies, a T cell vaccine based on RhCMV has been shown to provide protection of NHPs from TB. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> Activities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since February 2020, we have entered into a number of collaboration agreements to accelerate the development, manufacture, and potential
commercialization of therapies to treat and prevent <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> and other coronaviruses. We have also made substantial efforts to protect our intellectual property in
this area, as evidenced by our recent expansion of our patent portfolio. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Development and Commercialization </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>GSK Collaboration Agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2020,
we entered into a definitive collaboration agreement with Glaxo Wellcome UK Limited and Beecham S.A. of GSK (and collectively referred to as GSK), pursuant to which we agreed to collaborate to research, develop and commercialize products for the
prevention, treatment and prophylaxis of diseases caused by <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> and potentially other coronaviruses. The collaboration is focused on the development and
commercialization of three types of collaboration products under three programs: (1)&nbsp;antibodies targeting <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2,</FONT></FONT> and potentially other coronaviruses, or the
Antibody Program; (2)&nbsp;vaccines targeting <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2,</FONT></FONT> and potentially other coronaviruses, or the Vaccine Program, and (3)&nbsp;products based on genome-wide CRISPR
screening of host targets expressed in connection with exposure to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2,</FONT></FONT> or the Functional Genomics Program. The initial antibodies under the Antibody Program will
be <FONT STYLE="white-space:nowrap">VIR-7831</FONT> and <FONT STYLE="white-space:nowrap">VIR-7832,</FONT> which have demonstrated high affinity for the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> spike
protein and are highly potent in neutralizing <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> in live-virus cellular assays. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are primarily responsible for the development and clinical manufacturing activities for the Antibody Program, and for conducting the
initial development activities directed to a vaccine in the Vaccine Program. GSK will be primarily responsible for the commercialization activities for the Antibody Program (except in connection with sales of antibody products licensed to WuXi in
greater China), the later-stage development, manufacturing and commercialization activities for the Vaccine Program and the development, manufacturing and commercialization activities for the Functional Genomics Program. We and GSK are required to
use commercially reasonable efforts to conduct the activities assigned to each party under each development plan and to seek and obtain regulatory approval for collaboration products that arise from such activities in the United States and specified
major markets. Subject to an <FONT STYLE="white-space:nowrap">opt-out</FONT> mechanism, we and GSK will share all development costs, manufacturing costs and costs and expenses for the commercialization of the collaboration products, with us bearing
72.5% of such costs for the antibody products, 27.5% of such costs for the vaccine products, and we and GSK sharing equally all such costs for the functional genomics products, and all profits will be shared in the same ratios. If we and GSK elect
to conduct a technology transfer of manufacturing technology under our agreements with WuXi (as further described below) and Biogen, we will bear 72.5% of the costs related to such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
manufacturing technology transfer and for commercial manufacturing of the antibody products under such agreements with WuXi and Biogen, and GSK will bear 27.5% of such costs. The parties will
also share the committed costs for the reservation of manufacturing capacity for the drug substance for antibody products in the foregoing ratio under our agreement with Samsung as well as such costs relating to committed manufacturing capacity for
antibody products as are approved by the joint steering committee from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On an antibody <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">product-by-antibody</FONT></FONT> product basis, we have a <FONT STYLE="white-space:nowrap">co-promotion</FONT> right with respect to such antibody product in the United States, pursuant to which we will have the right to
perform up to 20% of details in connection with such antibody product. GSK will lead commercialization and book all sales and is required to use commercially reasonable efforts to commercialize each collaboration product following regulatory
approval in the United States and specified major markets. This definitive agreement superseded and replaced the April 2020 preliminary agreement with GSK. In connection with the GSK collaboration, we also entered into a stock purchase agreement in
April 2020, pursuant to which we issued 6,626,027 shares of our common stock to an affiliate of GSK at a price per share of $37.73, for an aggregate purchase price of approximately $250.0&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expansion of Alnylam Collaboration and License Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March and April 2020, we entered into two further amendments to our collaboration and license agreement with Alnylam, dated October&nbsp;16,
2017, to expand our existing collaboration of five infectious disease targets to nine, including one targeting SARS-CoV-2 and potentially other coronaviruses, and up to three targeting human host factors for SARS-CoV-2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to both recent amendments, we and Alnylam will each be responsible for <FONT STYLE="white-space:nowrap">pre-clinical</FONT>
development costs incurred by such party in performing its allocated responsibilities under an agreed-upon initial <FONT STYLE="white-space:nowrap">pre-clinical</FONT> development plan for each of the four new targets. We and Alnylam will equally
share costs incurred in connection with the manufacture of <FONT STYLE="white-space:nowrap">non-GMP</FONT> drug product required for <FONT STYLE="white-space:nowrap">pre-clinical</FONT> development prior to filing of an IND. Following the completion
of initial <FONT STYLE="white-space:nowrap">pre-clinical</FONT> development activities, if we exercise our option to progress one or more candidates arising from the coronavirus program into further development, we will be responsible for conducting
all development, manufacturing and commercialization activities at our sole expense, subject to Alnylam&#146;s right to <FONT STYLE="white-space:nowrap">opt-in,</FONT> during a specified period, to share equally with us the profits and losses in
connection with development and commercialization of a coronavirus product. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Manufacturing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consistent with our corporate manufacturing strategy of building internal capabilities in chemistry, manufacturing and control, or CMC, and
working with contract development and manufacturing organizations, or CDMOs, to supply clinical and commercial batches of our product candidates, we have entered into the following agreements to date in support of our
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> program: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>WuXi Manufacturing Agreements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2020, we entered into a development and manufacturing collaboration agreement with WuXi, for the clinical development,
manufacturing, and commercialization of our proprietary antibodies developed for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2.</FONT></FONT> Under the agreement, WuXi will conduct cell-line development, process and
formulation development, and initial manufacturing for clinical development. WuXi will have the right to commercialize products incorporating such antibodies in greater China pursuant to an exclusive license granted for the selected antibodies that
have been developed. We will have the right to commercialize such products in all other markets worldwide. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WuXi will perform mutually agreed development and manufacturing activities, under individual
statements of work. In addition, the parties agreed that WuXi will pay us tiered royalties at percentages ranging from the high single-digits to <FONT STYLE="white-space:nowrap">mid-teens</FONT> on annual net sales of all products sold by WuXi in
greater China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;15, 2020, we entered into a binding letter of intent with WuXi, pursuant to which WuXi will perform certain
development and manufacturing services for our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> antibody program. Under the terms of the letter of intent, we have committed to purchase a firm and binding
capacity reservation for the manufacture of a specified number of batches of drug substance of our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> antibody in 2020 and 2021. In addition, we have the right
to order an additional specified number of batches of drug substance, provided we make such election by a specified date in the fourth calendar quarter in 2020. WuXi is obligated to reserve such manufacturing slots on a <FONT
STYLE="white-space:nowrap">non-cancellable</FONT> basis, and will manufacture the agreed number of batches of drug substance in accordance with an agreed manufacturing schedule. We are obligated to pay a total of approximately $130.0&nbsp;million
for such capacity reservation, if all batches are manufactured, inclusive of estimated raw material costs, with between 70% and 80% of the batch production fees owed to WuXi on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">take-or-pay</FONT></FONT> basis regardless of whether we utilize such manufacturing slots. The amounts will be payable during 2020 and 2021 and invoiced on a <FONT
STYLE="white-space:nowrap">per-batch</FONT> basis. The <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> antibody drug substance contemplated to be manufactured in accordance with the terms of the letter of
intent will be utilized in connection with progressing the development and commercialization of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> antibody product under our collaboration with GSK. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and WuXi will continue to negotiate additional terms in a definitive commercial manufacturing and supply agreement and will use
commercially reasonable efforts to execute such definitive agreement before July&nbsp;30, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will bear 72.5% of the costs under the
development and manufacturing collaboration agreement and letter of intent with WuXi and GSK will bear 27.5% of such costs pursuant to our collaboration agreement with GSK, subject to certain conditions and exceptions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Biogen Clinical Development and Manufacturing Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2020, we entered into a clinical development and manufacturing agreement with Biogen pursuant to which Biogen will perform process
development activities and specified manufacturing services under agreed statements of work for <FONT STYLE="white-space:nowrap">certain&nbsp;pre-commercial&nbsp;and</FONT> clinical supply of&nbsp;our <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">SARS-CoV-2&nbsp;mAbs.</FONT></FONT> We also agreed to collaborate with Biogen to develop highly productive clonal cell lines and clinical and commercial manufacturing processes for our <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> mAbs. These processes are designed to be transferrable to global biomanufacturing facilities designed for advanced biologics production. Under the agreement, Biogen will conduct cGMP clinical
manufacturing in the United States and provide technical support to facilitate process transfer to Samsung, and potentially other large-scale biomanufacturing facilities in the United States and other regions of the world to enable us to obtain
reliable supply of a potential commercial product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Biogen agreement, we have agreed to pay fees for Biogen&#146;s
performance of services as provided in each applicable statement of work, including costs to third parties on a pass-through basis. We entered into three statements of work with Biogen for the process development and certain clinical manufacturing
services simultaneously with the execution of the agreement, with the cost of activities under such agreed statements of work totaling approximately $13.8&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Biogen agreement provides us the right to request a technology transfer of all manufacturing technology and processes developed under the
agreement to us or any third party designated by us to conduct manufacturing of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;SARS-CoV-2&nbsp;antibody</FONT></FONT> using such technology, including applicable licenses to
us under Biogen&#146;s relevant intellectual property rights. In connection with any such technology transfer, we have also agreed to pay an &#147;access fee&#148; to Biogen for each successful batch <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">of&nbsp;SARS-CoV-2&nbsp;antibody</FONT></FONT> drug substance manufactured using </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
certain improvements relating to increases in batch yield developed under the agreement, whether such manufacturing is performed by us, our affiliates, or third parties. If we successfully
manufacture all batches <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">of&nbsp;SARS-CoV-2&nbsp;antibody</FONT></FONT> drug substance for which we are currently committed under the Samsung letter agreement, based on our current
working assumptions of manufacturing yield per batch, the access fee payable to Biogen in connection with the Samsung manufacturing will total approximately $100.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will bear 72.5% of the costs under the Biogen agreement and GSK will bear 27.5% of such costs pursuant to our collaboration agreement with
GSK, subject to certain conditions and exceptions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Samsung Manufacturing Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2020, we entered into a binding letter agreement with Samsung pursuant to which Samsung will perform development and manufacturing
services for our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2&nbsp;mAbs.</FONT></FONT> Under the terms of the letter agreement, we have committed to purchase a firm and binding capacity reservation for a specified
number of drug substance manufacturing slots in 2021 and 2022. Samsung will reserve such manufacturing slots on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;non-cancellable,&nbsp;non-adjustable&nbsp;basis</FONT></FONT>
and will not offer such manufacturing slots under our capacity reservation to third parties. We are obligated to pay a total of approximately $362.0&nbsp;million for such capacity reservation on <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">a&nbsp;take-or-pay&nbsp;basis</FONT></FONT> regardless of whether such manufacturing slots are utilized by us. The amounts will be payable during 2021 and 2022 and invoiced on
<FONT STYLE="white-space:nowrap">a&nbsp;per-batch&nbsp;basis,</FONT> with shortfalls invoiced at the end of the year in which such shortfall occurs. Samsung began performing services for us upon execution of the letter agreement, and we agreed to
pay fees <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">and&nbsp;out-of-pocket&nbsp;costs</FONT></FONT> for the services performed thereunder. Samsung is expected to commence manufacturing on our behalf as early as October 2020
with the first engineering run. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will bear 72.5% of the costs under the Samsung letter agreement and GSK will bear 27.5% of such costs
pursuant to our collaboration agreement with GSK, subject to certain conditions and exceptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We continue to negotiate a definitive
agreement with Samsung, to expand upon the letter agreement, and agreed to use best efforts to execute such definitive agreement before July&nbsp;31, 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual Property </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT
STYLE="white-space:nowrap">VIR-7831</FONT> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap">VIR-7831</FONT> intellectual property portfolio
includes multiple United States provisional patent applications. These applications include composition of matter claims, pharmaceutical composition claims, and method of treatment claims. The <FONT STYLE="white-space:nowrap">20-year</FONT> term of
any patents issuing from these provisional patent applications is presently estimated to expire in 2041, absent any available patent term adjustments or extensions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Licensed Patents </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our <FONT
STYLE="white-space:nowrap">VIR-7831</FONT> intellectual property portfolio also includes patents and patent applications that we have <FONT STYLE="white-space:nowrap">non-</FONT> exclusively licensed from Xencor, Inc., or Xencor. As of
February&nbsp;15, 2020, these patents and applications include seven issued patents in the United States directed to composition of matter claims, methods of extending antibody serum half-life claims, pharmaceutical composition claims and process
(methods of producing) claims. The <FONT STYLE="white-space:nowrap">20-year</FONT> term of these patents is presently estimated to expire between 2021 and 2025, absent any available patent term adjustments or extensions. Additionally, as of
February&nbsp;15, 2020, these patents and applications include 70 issued patents in Australia, Austria, Belgium, Canada, China, Croatia, Czech Republic, Estonia, Finland, France, Germany, Hungary, Iceland, India, Ireland, Israel, Italy, Japan, South
Korea, Lithuania, Luxembourg, Malta, Monaco, Netherlands, Poland, Russia, Slovenia, Spain, Sweden, Switzerland, Turkey and the United Kingdom directed to composition of matter claims, pharmaceutical composition claims, method of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
treatment claims, composition for use in treatment claims and process (methods of producing) claims. The <FONT STYLE="white-space:nowrap">20-year</FONT> term of these patents is presently
estimated to expire between 2021 and 2028, absent any available patent term adjustments or extensions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patents and applications we
have <FONT STYLE="white-space:nowrap">non-exclusively</FONT> licensed from Xencor also include, as of February&nbsp;15, 2020, a pending patent application in the United States and five patent applications pending in Brazil, Canada, China, Europe and
Russia directed to composition of matter claims, pharmaceutical composition claims, composition for use in treatment claims, and process (methods of producing) claims. The <FONT STYLE="white-space:nowrap">20-year</FONT> term of any patents issuing
from these patent applications is presently estimated to expire between 2021 and 2028, absent any available patent term adjustments or extensions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT
STYLE="white-space:nowrap">VIR-7832</FONT> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap">VIR-7832</FONT> intellectual property portfolio
includes multiple United States provisional patent applications. These applications include composition of matter claims, pharmaceutical composition claims, and method of treatment claims. The <FONT STYLE="white-space:nowrap">20-year</FONT> term of
any patents issuing from these provisional patent applications is presently estimated to expire in 2041, absent any available patent term adjustments or extensions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Licensed Patents </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our <FONT
STYLE="white-space:nowrap">VIR-7832</FONT> intellectual property portfolio includes a patent family that we have exclusively licensed from Rockefeller, which includes, as of February&nbsp;15, 2020, one pending patent application in the United
States, one pending PCT patent application and one pending patent application in Europe. The applications in this family include composition of matter claims, pharmaceutical composition claims, method of treatment claims, composition for use in
treatment claims and process (methods of producing) claims. The <FONT STYLE="white-space:nowrap">20-year</FONT> term of any patents issuing from the application in this family is presently estimated to expire in 2038, absent any available patent
term adjustments or extensions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap">VIR-7832</FONT> intellectual property portfolio also includes
patents and patent applications that we have <FONT STYLE="white-space:nowrap">non-</FONT> exclusively licensed from Xencor. As of February&nbsp;15, 2020, these patents and applications include seven issued patents in the United States directed to
composition of matter claims, methods of extending antibody serum half-life claims, pharmaceutical composition claims and process (methods of producing) claims. The <FONT STYLE="white-space:nowrap">20-year</FONT> term of these patents is presently
estimated to expire between 2021 and 2025, absent any available patent term adjustments or extensions. Additionally, as of February&nbsp;15, 2020, these patents and applications include 70 issued patents in Australia, Austria, Belgium, Canada,
China, Croatia, Czech Republic, Estonia, Finland, France, Germany, Hungary, Iceland, India, Ireland, Israel, Italy, Japan, South Korea, Lithuania, Luxembourg, Malta, Monaco, Netherlands, Poland, Russia, Slovenia, Spain, Sweden, Switzerland, Turkey
and the United Kingdom directed to composition of matter claims, pharmaceutical composition claims, method of treatment claims, composition for use in treatment claims and process (methods of producing) claims. The
<FONT STYLE="white-space:nowrap">20-year</FONT> term of these patents is presently estimated to expire between 2021 and 2028, absent any available patent term adjustments or extensions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patents and applications we have <FONT STYLE="white-space:nowrap">non-exclusively</FONT> licensed from Xencor also include, as of
February&nbsp;15, 2020, a pending patent application in the United States and five patent applications pending in Brazil, Canada, China, Europe and Russia directed to composition of matter claims, pharmaceutical composition claims, composition for
use in treatment claims, and process (methods of producing) claims. The <FONT STYLE="white-space:nowrap">20-year</FONT> term of any patents issuing from these patent applications is presently estimated to expire between 2021 and 2028, absent any
available patent term adjustments or extensions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">VIR-2703</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Licensed Patents </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our <FONT
STYLE="white-space:nowrap">VIR-2703</FONT> intellectual property portfolio includes multiple United States provisional patent applications that we have exclusively licensed from Alnylam. These applications include composition of matter claims,
pharmaceutical composition claims, and method of treatment claims. The <FONT STYLE="white-space:nowrap">20-year</FONT> term of any patents issuing from these provisional patent applications is presently estimated to expire in 2041, absent any
available patent term adjustments or extensions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d939163dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RISK FACTORS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>An
investment in shares of our common stock involves a high degree of risk. You should carefully consider the following risk factors, together with the information contained in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for
the year ended December&nbsp;31, 2019 filed with the Securities and Exchange Commission on March&nbsp;26, 2020 and our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31, 2020 filed with the
Securities and Exchange Commission on May&nbsp;12, 2020, including our consolidated financial statements and the related notes, before deciding whether to invest in our common stock. The occurrence of any of the events or developments described
below could harm our business, financial condition, results of operations and/or prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from
time to time. In such an event, the market price of our common stock could decline and you may lose all or part of your investment. You should consider all of the risk factors described when evaluating our business. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Financial Position and Capital Needs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred significant net losses since inception and anticipate that we will continue to incur substantial net losses for the foreseeable future
and may never achieve or maintain profitability. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception in April 2016, we have incurred significant net losses and have
never generated any revenue from product sales. Our net loss was $77.2&nbsp;million and $28.7&nbsp;million for the three months ended March&nbsp;31, 2020 and 2019, respectively. As of March&nbsp;31, 2020, we had an accumulated deficit of
$445.8&nbsp;million. Although we completed our initial public offering, or IPO, in October 2019 raising net proceeds of $126.4&nbsp;million after deducting underwriting discounts, commissions and offering expenses and issued 6,626,027 shares of our
common stock to Glaxo Group Limited (an affiliate of GlaxoSmithKline plc), or GGL, in April 2020 for an aggregate purchase price of approximately $250.0&nbsp;million, we expect to continue to incur significant expenses and increasing net losses for
the foreseeable future. Since inception, we have devoted substantially all of our efforts to identifying, researching and conducting preclinical and clinical activities of our product candidates, acquiring and developing our technology platforms and
product candidates, organizing and staffing our company, business planning, raising capital and establishing our intellectual property portfolio. To date, we have never obtained regulatory approval for, or commercialized, any products. It could be
several years, if ever, before we have a commercialized product. The net losses we incur may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially if, and as, we: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue the ongoing and planned development of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiate, conduct and complete any ongoing, anticipated or future preclinical studies and clinical trials for our
current and future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek marketing approvals for any product candidates that successfully complete clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish a sales, marketing, manufacturing and distribution infrastructure to commercialize any current or
future product candidate for which we may obtain marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek to discover and develop additional product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue to build a portfolio of product candidates through the acquisition or
<FONT STYLE="white-space:nowrap">in-license</FONT> of products, product candidates or technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain, protect and expand our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make milestone payments if we successfully achieve certain predetermined milestones under existing or future
agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hire additional clinical, regulatory and scientific personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add operational, financial and management information systems and personnel, including personnel to support our
product development and planned future commercialization efforts; </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience delays or interruptions to preclinical studies, clinical trials, our receipt of services from
third-party service providers or our supply chain due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incur additional costs associated with operating as a public company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To become and remain profitable, we must succeed in developing and eventually commercializing products that generate significant revenue. This
will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials of our current and future product candidates, obtaining regulatory approval, procuring commercial-scale
manufacturing, marketing and selling any products for which we obtain regulatory approval (including through third parties), as well as discovering or acquiring and developing additional product candidates. We are only in the preliminary stages of
most of these activities. We may never succeed in these activities and, even if we do, may never generate revenue that is sufficient to offset our expenses and achieve profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and uncertainties associated with biopharmaceutical product development, we are unable to accurately predict the
timing or amount of expenses or when, or if, we will be able to achieve profitability. If we are required by regulatory authorities to perform studies in addition to those currently expected, or if there are any delays in the initiation and
completion of our clinical trials or the development of any of our product candidates, our expenses could increase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we do achieve
profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our
research and development efforts, expand our business or continue our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our limited operating history may make it difficult for you to
evaluate the success of our business to date and to assess our future viability. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage company founded in April
2016 and our operations to date have been largely focused on identifying, researching and conducting preclinical and clinical activities of our product candidates, acquiring and developing our technology platforms and product candidates, organizing
and staffing our company, business planning, raising capital and establishing our intellectual property portfolio. As an organization, we have not yet demonstrated an ability to successfully complete clinical development, obtain regulatory
approvals, manufacture a commercial-scale product or conduct sales and marketing activities necessary for successful commercialization or arrange for a third party to conduct these activities on our behalf. Consequently, any predictions about our
future success or viability may not be as accurate as they could be if we had a longer operating history. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have four
technology platforms and eight product candidates in our development pipeline. We may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving our business objectives, including with respect
to our technology platforms and product candidates. We will need to transition at some point from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a
transition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will require substantial additional funding to finance our operations. If we are unable to raise
capital when needed, we could be forced to delay, reduce or terminate certain of our development programs or other operations. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As
of March&nbsp;31, 2020, excluding restricted cash, we had cash, cash equivalents and investments of $361.8&nbsp;million. We believe that our existing cash, cash equivalents and investments as of March&nbsp;31, 2020 and the proceeds from our
subsequent sale of common stock to GGL in April 2020 will fund our current operating plans through at least the next 12&nbsp;months from the issuance date of our condensed consolidated financial statements for the period ended March&nbsp;31, 2020.
However, our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned. Moreover, it is particularly difficult to estimate with certainty our future expenses given the
dynamic and rapidly evolving nature of our business and the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic environment generally. We will also need to raise additional capital to complete the development and commercialization of our
product candidates and fund certain of our existing manufacturing and other commitments. We expect to finance our cash needs through public or private equity or debt financings, third-party (including government) funding and marketing and
distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or any combination of these approaches. Our future capital requirements will depend on many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing, progress and results of our ongoing preclinical studies and clinical trials of our product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials of
other product candidates that we may pursue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish and maintain collaboration, license, grant and other similar arrangements, and the
financial terms of any such arrangements, including timing and amount of any future milestones, royalty or other payments due thereunder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs, timing and outcome of regulatory review of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales
and distribution, for any of our product candidates for which we receive marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing
approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our
intellectual property rights and defending any intellectual property-related claims; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any expenses needed to attract, hire and retain skilled personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of operating as a public company; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other companies&#146;
product candidates and technologies. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Identifying potential product candidates and conducting preclinical testing and
clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and achieve product sales. In addition, our product
candidates, if approved, may not achieve commercial success. Our commercial revenue, if any, will be derived from sales of products that we do not expect to be commercially available for several years, if at all. Accordingly, we will need to
continue to rely on additional financing to achieve our business objectives. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic continues to rapidly evolve
and has already resulted in a significant disruption of global financial markets. If the disruption persists and deepens, we could experience an inability to access additional capital, which could in the future negatively affect our capacity for
certain corporate development transactions or our ability to make other important, opportunistic investments. Adequate additional financing may not be available to us on acceptable terms, or at all. If we are unable to raise capital when needed or
on attractive terms, we could be forced to delay, reduce or altogether terminate our research and development programs or future commercialization efforts, which may adversely affect our business, financial condition, results of operations and
prospects. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our product candidates.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through public or
private equity or debt financings, third-party (including government) funding and collaborations and strategic alliances, or any combination of these approaches. To the extent that we raise additional capital through the sale of equity or
convertible debt securities, your ownership interest in our company may be diluted and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a stockholder. Debt and equity financings, if
available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as redeeming our shares, making investments, incurring additional debt, making capital expenditures, declaring dividends or
placing limitations on our ability to acquire, sell or license intellectual property rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we raise additional capital through
future collaborations or strategic alliances, we may have to relinquish valuable rights to our intellectual property, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we
are unable to raise additional capital when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise
develop and market ourselves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our pursuit of a potential therapy for <FONT STYLE="white-space:nowrap">COVID-19,</FONT> the disease caused by the
virus <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2,</FONT></FONT> is at an early stage, and we are committing substantial financial resources and personnel and making substantial capital commitments with third parties
in furtherance thereof. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In response to the recent outbreak of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> the disease
caused by the virus <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2,</FONT></FONT> we are pursuing various potential therapies to address the disease, including through mAbs using our antibody platform (in collaboration
with several partners), such as <FONT STYLE="white-space:nowrap">VIR-7831</FONT> and <FONT STYLE="white-space:nowrap">VIR-7832,</FONT> and siRNA using our siRNA platform (in collaboration with Alnylam), such as
<FONT STYLE="white-space:nowrap">VIR-2703.</FONT> Our testing and development of these potential therapies is in early stages, and we may be unable to produce a therapy that successfully treats the virus in a timely manner, if at all. For example,
we have not yet initiated any clinical trials for <FONT STYLE="white-space:nowrap">VIR-7831,</FONT> <FONT STYLE="white-space:nowrap">VIR-7832</FONT> or <FONT STYLE="white-space:nowrap">VIR-2703,</FONT> although we plan to commence a Phase 2/3
clinical trial in August 2020 for <FONT STYLE="white-space:nowrap">VIR-7831,</FONT> for which we anticipate initial clinical data to be available before the end of the year, commence a Phase 2 clinical trial later this year for <FONT
STYLE="white-space:nowrap">VIR-7832</FONT> and continue <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies for <FONT STYLE="white-space:nowrap">VIR-2703.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also committing substantial financial resources, both internally and externally, and personnel to the development of a potential
therapy for <FONT STYLE="white-space:nowrap">COVID-19,</FONT> which may cause delays in or otherwise negatively impact our other development programs, despite uncertainties surrounding the longevity and extent of
<FONT STYLE="white-space:nowrap">COVID-19</FONT> as a global health concern. In particular, our ability to develop an effective therapy will depend on the success of our manufacturing capabilities, for which we are dependent on third-party
manufacturing organizations and which will require significant additional funding. For example, in April 2020 we entered into a binding letter agreement with Samsung Biologics Co. Ltd., or Samsung, pursuant to which we are obligated to pay a total
of approximately $362.0&nbsp;million for a firm and binding capacity reservation for a specified number of manufacturing slots in 2021 and 2022 for our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT>
antibody program regardless of whether we utilize such manufacturing slots. In May 2020, we entered into a clinical development and manufacturing agreement with Biogen Inc., or Biogen, pursuant to which we could be required to pay approximately
$100.0&nbsp;million to Biogen as an &#147;access fee&#148; based on our current working assumptions of manufacturing yield per batch if we successfully manufacture all batches of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> antibody drug substance for which we are committed under our Samsung letter agreement, in addition to other payments to Biogen pursuant to statements of work
under the Biogen agreement. In June 2020, we entered into a binding letter of intent with WuXi Biologics (Hong&nbsp;Kong) Limited, or WuXi, pursuant to which we have committed to purchase a firm and binding capacity reservation for the manufacture
of a specified number of batches of drug substance of our SARS-CoV-2 antibody in 2020 and 2021. We are obligated to pay a total of approximately $130.0 million for such capacity reservation, if all batches are manufactured, inclusive of estimated
raw material costs, with between 70% and 80% of the batch production fees owed to WuXi on a take-or-pay basis regardless of whether we utilize such manufacturing slots. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we believe securing such manufacturing capacity and technological expertise is crucial
to the potential success of our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> antibody development programs, such capital commitments, in the aggregate, currently exceed our available cash and cash
equivalents and short-term investments.&nbsp;We may also need to enter into additional manufacturing arrangements in the future in order to create an effective supply chain for our <FONT STYLE="white-space:nowrap">COVID-19</FONT> product candidates
that will adequately support demand. We will need to raise substantial additional capital to fund the development of our product candidates and meet our capital commitments to our manufacturing partners in connection therewith. There can be no
assurance that sufficient funds will be available to us on attractive terms or at all. If we are unable to obtain additional funding from these or other sources, it may be necessary to significantly reduce our rate of spending through reductions in
staff and delaying, scaling back, or stopping certain research and development programs. Insufficient liquidity may also require us to relinquish rights to product candidates at an earlier stage of development or on less favorable terms than we
would otherwise choose. Our business could be negatively impacted by our allocation of significant resources to a global health threat that is unpredictable and could rapidly dissipate or against which our potential therapies, if developed, may not
be partially or fully effective, and may ultimately prove unsuccessful or unprofitable. Furthermore, there are no assurances that our therapy will be approved for inclusion in government stockpile programs, which may be material to the commercial
success of the approved product candidate, either in the United States or abroad. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">In addition, another party may be successful in
producing a more efficacious therapy for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> or in producing a therapy in a more timely manner, which may also lead to the diversion of funding away from us and
toward other companies or lead to decreased demand for our potential therapies. There are efforts by several public and private entities to develop a therapy for <FONT STYLE="white-space:nowrap">COVID-19,</FONT> including Johnson&nbsp;&amp; Johnson,
AstraZeneca plc, Sanofi S.A., Pfizer Inc. and Moderna, Inc., some of which are further along in the clinical development process than we are. These other entities may be more successful at developing, manufacturing or commercializing a therapy for <FONT
STYLE="white-space:nowrap">COVID-19.</FONT> Several of these other organizations are much larger than we are and have access to larger pools of capital, including U.S. government funding, and broader manufacturing infrastructure. The success or
failure of other entities, or perceived success or failure, may adversely impact our ability to obtain any future funding for our development and manufacturing efforts or to ultimately commercialize a therapy for
<FONT STYLE="white-space:nowrap">COVID-19,</FONT> if approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Development and Commercialization of Our Product Candidates
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future success is substantially dependent on the successful clinical development, regulatory approval and commercialization of our product
candidates in a timely manner. If we are not able to obtain required regulatory approvals, we will not be able to commercialize our product candidates and our ability to generate product revenue will be adversely affected. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have invested a significant portion of our time and financial resources in the development of our product candidates. Our business is
dependent on our ability to successfully complete development of, obtain regulatory approval for, and, if approved, successfully commercialize our product candidates in a timely manner. We may face unforeseen challenges in our product development
strategy, and we can provide no assurances that our product candidates will be successful in clinical trials or will ultimately receive regulatory approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have only recently initiated clinical trials for three product candidates. We have not obtained regulatory approval for any product
candidate, and it is possible that any product candidates we may seek to develop in the future will not obtain regulatory approval. Neither we nor any current or future collaborator is permitted to market any product candidates in the United States
or abroad until we receive regulatory approval from the U.S. Food and Drug Administration, or the FDA, or applicable foreign regulatory agency. The time required to obtain approval or other marketing authorizations by the FDA and comparable foreign
regulatory authorities is unpredictable and typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval
policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#146;s clinical development and may vary among jurisdictions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to obtaining approval to commercialize any product candidate in the United States or
abroad, we must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidate is safe and effective for its intended uses.
Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we believe that the preclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the
FDA and other regulatory authorities. The FDA may also require us to conduct additional preclinical studies or clinical trials for our product candidates either prior to or post-approval, or it may object to elements of our clinical development
program, requiring their alteration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Of the large number of products in development, only a small percentage successfully complete the
FDA&#146;s or comparable foreign regulatory authorities&#146; approval processes and are commercialized. The lengthy approval or marketing authorization process as well as the unpredictability of future clinical trial results may result in our
failing to obtain regulatory approval or marketing authorization to market our product candidates, which would significantly harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we eventually complete clinical testing and receive approval of a new drug application, or NDA, biologics license application, or BLA,
or foreign marketing application for our product candidates, the FDA or the comparable foreign regulatory authorities may grant approval or other marketing authorization contingent on the performance of costly additional clinical trials, including
post-market clinical trials. The FDA or the comparable foreign regulatory authorities also may approve or authorize for marketing a product candidate for a more limited indication or patient population than we originally request, and the FDA or
comparable foreign regulatory authorities may not approve or authorize the labeling that we believe is necessary or desirable for the successful commercialization of a product candidate. Any delay in obtaining, or inability to obtain, applicable
regulatory approval or other marketing authorization would delay or prevent commercialization of that product candidate and would adversely impact our business and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the FDA or comparable foreign regulatory authorities may change their policies, adopt additional regulations or revise existing
regulations or take other actions, which may prevent or delay approval of our future product candidates under development on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability
to obtain approvals, increase the costs of compliance or restrict our ability to maintain any marketing authorizations we may have obtained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, even if we obtain regulatory approval for our product candidates, we may still need to develop a commercial organization,
establish a commercially viable pricing structure and obtain approval for coverage and adequate reimbursement from third-party and government payors, including government health administration authorities. If we are unable to successfully
commercialize our product candidates, we may not be able to generate sufficient revenue to continue our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The development of additional
product candidates is risky and uncertain, and we can provide no assurances that we will be able to replicate our approach for other diseases. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A core element of our business strategy is to expand our product pipeline. Efforts to identify, acquire or
<FONT STYLE="white-space:nowrap">in-license,</FONT> and then develop product candidates require substantial technical, financial and human resources, whether or not any product candidates are ultimately identified. Our efforts may initially show
promise in identifying potential product candidates, yet fail to yield product candidates for clinical development, approved products or commercial revenue for many reasons, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the methodology used may not be successful in identifying potential product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competitors may develop alternatives that render any product candidates we develop obsolete;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any product candidates we develop may be covered by third parties&#146; patents or other exclusive rights;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a product candidate may be shown to have harmful side effects or other characteristics that indicate it is
unlikely to be effective or otherwise does not meet applicable regulatory criteria; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at
all; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a product candidate may not be accepted as safe and effective by physicians, patients, the medical community or
third-party payors. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have limited financial and management resources and, as a result, we may forego or delay
pursuit of opportunities with other product candidates or for other indications that later prove to have greater market potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable
market opportunities. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty
arrangements in circumstances under which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. In addition, we may not be successful in replicating our approach to development
for other disease indications. If we are unsuccessful in identifying and developing additional product candidates or are unable to do so, our business may be harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are developing, and in the future may develop, other product candidates in combination with other therapies, which exposes us to additional risks.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <FONT STYLE="white-space:nowrap">VIR-2218</FONT> and <FONT STYLE="white-space:nowrap">VIR-3434</FONT> for the
functional cure of hepatitis B virus, or HBV. Each of these product candidates has the potential to stimulate an effective immune response and also has direct antiviral activity against HBV. We believe that a functional cure for HBV will require an
effective immune response, in addition to antiviral activity, based on the observation that severe immunosuppression can reactivate HBV disease. Monotherapy with each of these agents may provide a functional cure in some patients, while combination
therapy may be necessary for others. We recently initiated a Phase 2 clinical trial to combine <FONT STYLE="white-space:nowrap">VIR-2218</FONT> with pegylated interferon-alpha and we are planning trials that combine
<FONT STYLE="white-space:nowrap">VIR-2218</FONT> with <FONT STYLE="white-space:nowrap">VIR-3434.</FONT> We are also evaluating additional combinations with other immunotherapy agents and direct acting antiviral agents. Even if any product candidate
we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or similar regulatory authorities outside of the United States could
revoke approval of the therapy used in combination with our product candidate. There is also a risk that safety, efficacy, manufacturing or supply issues could arise with these other existing therapies. This could result in our own products being
removed from the market or being less successful commercially. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also evaluate our future product candidates in combination with one
or more other therapies that have not yet been approved for marketing by the FDA or similar regulatory authorities outside of the United States. We will not be able to market any product candidate we develop in combination with any such unapproved
therapies that do not ultimately obtain marketing approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA or similar regulatory authorities outside of the United States do
not approve these other drugs or revoke their approval of, or if safety, efficacy, manufacturing or supply issues arise with, the drugs we choose to evaluate in combination with any product candidate we develop, we may be unable to obtain approval.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials and we cannot assure you that
any ongoing, planned or future clinical trials will lead to results sufficient for the necessary regulatory approvals. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Success in
preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate. Preclinical studies and Phase
1 clinical trials are primarily designed to test safety, to study pharmacokinetics and pharmacodynamics and to understand the side effects of product candidates at various doses and schedules. Success in preclinical studies and earlier clinical
trials does not ensure that later efficacy trials will be successful, nor does it predict final results. Our product candidates may fail to show the desired characteristics in clinical development sufficient to obtain regulatory approval, despite
positive results in preclinical studies or having successfully advanced through earlier clinical trials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A trial design that is considered appropriate for regulatory approval includes a
sufficiently large sample size with appropriate statistical power, as well as proper control of bias, to allow a meaningful interpretation of the results. The preliminary results of trials with smaller sample sizes can be disproportionately
influenced by the impact the treatment had on a few individuals, which limits the ability to generalize the results across a broader community, making the trial results less reliable than trials with a larger number of patients. As a result, there
may be less certainty that such product candidates would achieve a statistically significant effect in any future clinical trials. If we conduct clinical trials with a small number of patients, we may not achieve a statistically significant result
or the same level of statistical significance, if any, that would have been possible to achieve in a larger trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the
design of a clinical trial can determine whether its results will support approval of a product, and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. As an organization, we have limited
experience designing clinical trials and may be unable to design and execute a clinical trial to support regulatory approval. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical
trials even after achieving promising results in preclinical testing and earlier clinical trials. Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval.
In addition, we may experience regulatory delays or rejections as a result of many factors, including changes in regulatory policy during the period of our product candidate development. Any such delays could negatively impact our business,
financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical product development involves a lengthy and expensive process. We may incur
additional costs and encounter substantial delays or difficulties in our clinical trials. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not commercialize, market,
promote or sell any product candidate without obtaining marketing approval from the FDA or other comparable regulatory authority, and we may never receive such approvals. It is impossible to predict when or if any of our product candidates will
prove effective or safe in humans and will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must complete preclinical development and then conduct extensive
clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, is difficult to design and implement, can take many years to complete and is uncertain as to outcome. We cannot guarantee that
any clinical trials will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage of testing. Moreover, preclinical and clinical data are often susceptible to varying
interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may experience numerous unforeseen events prior to, during, or as a result of, clinical trials that could delay or prevent our ability to
receive marketing approval or commercialize our product candidates, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to generate sufficient preclinical, toxicology, or other in vivo or in vitro data to support the
initiation or continuation of clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in reaching a consensus with regulatory authorities on the design or implementation of our clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulators or institutional review boards and ethics committees may not authorize us or our investigators to
commence a clinical trial or conduct a clinical trial at a prospective trial site; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in reaching agreement on acceptable terms with prospective clinical research organizations, or CROs, and
clinical trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or failures by our manufacturing partners to comply with current good manufacturing practices, or cGMP;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of patients required for clinical trials of our product candidates may be larger than we anticipate,
enrollment in these clinical trials may be slower than we anticipate, participants may drop out of these clinical trials at a higher rate than we anticipate or fail to return for post-treatment <FONT STYLE="white-space:nowrap">follow-up</FONT> or we
may fail to recruit suitable patients to participate in a trial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulty collaborating with patient groups and investigators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure by our CROs, other third parties, or us to adhere to clinical trial requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trials of our product candidates may produce negative or inconclusive results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">imposition of a clinical hold by regulatory authorities as a result of a serious adverse event, concerns with a
class of product candidates, after an inspection of our clinical trial operations, trial sites or manufacturing facilities, after review of an IND or amendment, CTA or amendment, or equivalent application or amendment or the finding that the
investigational protocol or plan is clearly deficient to meet its stated objectives; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">occurrence of serious adverse events associated with the product candidate that are viewed to outweigh its
potential benefits; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the standard of care on which a clinical development plan was based, which may require new or
additional trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development
programs; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disruptions caused by <FONT STYLE="white-space:nowrap">man-made&nbsp;or</FONT> natural disasters or public health
pandemics or epidemics or other business interruptions, including the current <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and future outbreaks of the disease. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to
generate revenue from future product sales or other sources. In addition, if we make manufacturing or formulation changes to our product candidates, we may need to conduct additional testing to bridge our modified product candidate to earlier
versions. Clinical trial delays could also shorten any periods during which we may have the exclusive right to commercialize our product candidates, if approved, or allow our competitors to bring competing products to market before we do, which
could impair our ability to successfully commercialize our product candidates and may harm our business, financial condition, results of operations and prospects.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, if the results of our clinical trials are inconclusive or if there are safety concerns or serious adverse events associated with
our product candidates, we may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be delayed in obtaining marketing approval, or not obtain marketing approval at all; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain approval for indications or patient populations that are not as broad as intended or desired;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be subject to additional post-marketing testing requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be required to perform additional clinical trials to support approval or be subject to additional post-marketing
testing requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">have regulatory authorities withdraw, or suspend, their approval of the product or impose restrictions on its
distribution in the form of a risk evaluation and mitigation strategy, or REMS; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be subject to the addition of labeling statements, such as warnings or contraindications; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be sued; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience damage to our reputation. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product development costs will also increase if we experience delays in testing or
obtaining marketing approvals. We do not know whether any of our preclinical studies or clinical trials will begin as planned, need to be restructured or be completed on schedule, if at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, our product candidates are based on certain innovative technology platforms, which makes it even more difficult to predict the
time and cost of product candidate development and obtaining regulatory approval, particularly for our small interfering ribonucleic acid, or siRNA, and cytomegalovirus, or CMV, vector technologies. Relatively few siRNA product candidates have ever
been tested in humans and to date, we are only aware of two siRNAs, ONPATTRO (<I>patisiran</I>) in 2018 and Givlaari (<I>givosiran</I>) in 2019 (both developed by Alnylam Pharmaceuticals, Inc., or Alnylam), that have received regulatory approval. In
addition, the compounds we are developing may not demonstrate in patients the chemical and pharmacological properties ascribed to them in preclinical studies, and they may interact with human biological systems in unforeseen, ineffective or harmful
ways. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of our T cell platform, our approach is to use human cytomegalovirus, or HCMV, as a vaccine vector to potentially treat and
prevent pathogens refractory to current vaccine technologies because HCMV may induce potent and long-lasting T cell responses to a broader range of epitopes than observed for other viral vaccines. Safety and toxicity studies for this technology have
so far only been conducted in animal species, in which HCMV has limited ability to replicate. If our first clinical trial for <FONT STYLE="white-space:nowrap">VIR-1111</FONT> or <FONT STYLE="white-space:nowrap">VIR-2020</FONT> causes unexpected side
effects that are not tolerable in the treatment of the relevant patient group, the further development of the product candidates and any other potential products based on HCMV-vector technology may be significantly limited or become impossible.
Also, because our HCMV-vector technology is novel, regulatory agencies may lack experience with product candidates such as <FONT STYLE="white-space:nowrap">VIR-1111</FONT> and <FONT STYLE="white-space:nowrap">VIR-2020,</FONT> which may lengthen the
regulatory review process, increase our development costs and delay or prevent commercialization of our product candidates. In addition, our HCMV-vector technology utilizes live-attenuated, genetically-modified organisms for which the FDA, the
European Medicines Agency, or the EMA, and other comparable foreign regulatory authorities and other public health authorities, such as the Centers for Disease Control and Prevention and hospitals involved in clinical studies, have established
additional safety and contagion rules and procedures, which could establish additional hurdles for the development, manufacture or use of our vectors. These hurdles may lead to delays in the conduct of clinical trials or in obtaining regulatory
approvals for further development, manufacturing or commercialization of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, we, the FDA, a foreign
regulatory authority or an institutional review board may suspend our clinical trials at any time if it appears that we or our collaborators are failing to conduct a trial in accordance with regulatory requirements, including the FDA&#146;s current
Good Clinical Practice, or GCP, regulations, that we are exposing participants to unacceptable health risks, or if the FDA or foreign regulatory authority finds deficiencies in our INDs, or clinical trial applications, or CTAs, respectively, or the
conduct of these trials. Moreover, we may not be able to file INDs to commence additional clinical trials on the timelines we expect because our filing schedule is dependent on further preclinical and manufacturing progress. Therefore, we cannot
predict with any certainty the schedule for commencement and completion of future clinical trials. If we experience delays in the commencement or completion of our clinical trials, or if we terminate a clinical trial prior to completion, the
commercial prospects of our product candidates could be negatively impacted, and our ability to generate revenue from our product candidates may be delayed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and
could be delayed, made more difficult or rendered impossible by multiple factors outside our control. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Identifying and qualifying
patients to participate in our clinical trials is critical to our success. We are developing <FONT STYLE="white-space:nowrap">VIR-2218</FONT> and <FONT STYLE="white-space:nowrap">VIR-3434</FONT> for the treatment of HBV, <FONT
STYLE="white-space:nowrap">VIR-2482</FONT> for the prevention of influenza A, <FONT STYLE="white-space:nowrap">VIR-1111</FONT> for the prevention of human immunodeficiency virus, or HIV, <FONT STYLE="white-space:nowrap">VIR-2020</FONT> for the
prevention of tuberculosis, or TB, and <FONT STYLE="white-space:nowrap">VIR-7831,</FONT> <FONT STYLE="white-space:nowrap">VIR-7832</FONT> and <FONT STYLE="white-space:nowrap">VIR-2703</FONT> for the treatment of
<FONT STYLE="white-space:nowrap">COVID-19.</FONT> In particular, clinical trials for prophylaxes tend to require enrollment of a larger number of subjects than clinical trials for treatments. We may encounter difficulties in enrolling patients in
our clinical trials, thereby delaying or preventing development and approval of our product candidates. Even once enrolled, we may be unable to retain a sufficient number of patients to complete any of our trials. Patient enrollment and retention in
clinical trials depends on many factors, including the size of the patient population, the nature of the trial protocol, the existing body of safety and efficacy data, the number and nature of competing treatments and ongoing clinical trials of
competing therapies for the same indication, the proximity of patients to clinical sites and the eligibility criteria for the trial. In addition, enrollment and retention of patients in clinical trials could be disrupted by <FONT
STYLE="white-space:nowrap">man-made&nbsp;or</FONT> natural disasters, or public health pandemics or epidemics or other business interruptions, including, the current <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and future outbreaks of
the disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our efforts to build relationships with patient communities may not succeed, which could result in delays in patient
enrollment in our clinical trials. Any negative results we may report in clinical trials of our product candidates may make it difficult or impossible to recruit and retain patients in other clinical trials of that same product candidate. Delays or
failures in planned patient enrollment or retention may result in increased costs, program delays or both, which could have a harmful effect on our ability to develop our product candidates or could render further development impossible. In
addition, we may rely on CROs and clinical trial sites to ensure proper and timely conduct of our future clinical trials and, while we intend to enter into agreements governing their services, we will be limited in our ability to ensure their actual
performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory
approval, limit their commercial potential or result in significant negative consequences following any potential marketing approval. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the conduct of clinical trials, patients report changes in their health, including illnesses, injuries and discomforts, to their
doctor. Often, it is not possible to determine whether or not the product candidate being studied caused these conditions. Regulatory authorities may draw different conclusions or require additional testing to confirm these determinations, if they
occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, it is possible that as we test our product candidates in larger, longer and more extensive clinical trials, or as use
of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were not observed in earlier trials, as well as conditions that did not occur or went undetected
in previous trials, will be reported by subjects or patients. Many times, side effects are only detectable after investigational products are tested in large-scale pivotal trials or, in some cases, after they are made available to patients on a
commercial scale after approval. If additional clinical experience indicates that any of our product candidates have side effects or cause serious or life-threatening side effects, the development of the product candidate may fail or be delayed, or,
if the product candidate has received regulatory approval, such approval may be revoked, which would harm our business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interim, <FONT STYLE="white-space:nowrap">&#147;top-line&#148;</FONT> and preliminary data from our
clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may publish interim, <FONT STYLE="white-space:nowrap">&#147;top-line&#148;</FONT> or preliminary data from our clinical
trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or <FONT
STYLE="white-space:nowrap">&#147;top-line&#148;</FONT> data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim
and preliminary data should be viewed with caution until the final data are available. Differences between preliminary or interim data and final data could significantly harm our business prospects and may cause the trading price of our common stock
to fluctuate significantly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are a party to strategic collaboration and license agreements pursuant to which we are obligated to make substantial
payments upon achievement of milestone events and, in certain cases, have relinquished important rights over the development and commercialization of certain current and future product candidates. We also intend to explore additional strategic
collaborations, which may never materialize or may require that we relinquish rights to and control over the development and commercialization of our product candidates. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a party to various strategic collaboration and license agreements that are important to our business and to our current and future
product candidates. For example, we license a number of technologies to form our antibody platform, including technology from the Institute for Research in Biomedicine, or IRB, The Rockefeller University, or Rockefeller, and Xencor, Inc., or Xencor,
pursuant to our exclusive license agreement with IRB, or the IRB Agreement, our exclusive license agreement with Rockefeller, or the Rockefeller Agreement, and our patent license agreement with Xencor, or the Xencor Agreement. We also license
technology from Oregon Health&nbsp;&amp; Science University, or OHSU,<B> </B>pursuant to our master exclusive license agreement with OHSU, or the OHSU Agreement, to form our T cell platform. In addition, the technology we use in our siRNA technology
platform is licensed from Alnylam pursuant to a collaboration and license agreement, or the Alnylam Agreement, as amended. These agreements contain obligations that require us to make substantial payments in the event certain milestone events are
achieved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our agreements with Alnylam, OHSU, MedImmune, LLC, or MedImmune, Rockefeller and Xencor include the following milestone payment
obligations: up to $1.7&nbsp;billion in milestone payments under the Alnylam Agreement, as amended, up to $1.3&nbsp;million in milestone payments per product and up to $2.0&nbsp;million in the aggregate for all products under the OHSU Agreement, up
to $331.5&nbsp;million in milestone payments under the 2018 MedImmune Agreement, up to $48.5&nbsp;million in milestone payments per product under the Rockefeller Agreement and up to $155.5&nbsp;million in milestone payments for all licensed products
under the Xencor Agreement. We may in the future be required to make these payments, which could adversely affect our financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, pursuant to the Alnylam Agreement, as amended, Alnylam granted us an exclusive option for each of the infectious disease siRNA
programs directed to our selected targets, to obtain a worldwide, exclusive license to develop, manufacture, and commercialize siRNA products directed to the target of each such program. Our options are each exercisable during a specified period
following selection of candidates for each program, or two years following the initiation of certain activities under an agreed upon development plan, if earlier. On a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis for each product arising from the HBV or coronavirus program and, following our option exercise, the infectious disease programs, Alnylam has an
option, exercisable during a specified period during development of each such product, to negotiate and enter into a profit-sharing agreement for such product. If we do not exercise our options with respect to a particular program in a timely manner
or at all, Alnylam will retain such rights and may offer such exclusive rights to other third parties. If Alnylam exercises its profit-sharing option for a product, including <FONT STYLE="white-space:nowrap">VIR-2218</FONT> or the COV Products, we
will be required to negotiate the terms of a profit-sharing agreement with Alnylam, which will include sharing equally with Alnylam the profits and losses in connection with such product, subject to reimbursement by Alnylam of a portion of specified
development costs in certain circumstances. Because of the uncertainty associated with Alnylam&#146;s decision to exercise its profit-sharing option for <FONT STYLE="white-space:nowrap">VIR-2218</FONT> or the COV Products, we are unable to
accurately predict the timing or amount of expenses related to the development of <FONT STYLE="white-space:nowrap">VIR-2218</FONT> or the COV Products after the specified period that Alnylam is allowed to exercise its option. Furthermore, if Alnylam
does not exercise its profit-sharing option, it could damage public perceptions of <FONT STYLE="white-space:nowrap">VIR-2218</FONT> or the COV Products, which could have a substantial adverse effect on the price of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in May 2018, we entered into an option and license agreement, or the Brii
Agreement, with Brii Biosciences Limited (previously named BiiG Therapeutics Limited), or Brii Bio Parent, and Brii Biosciences Offshore Limited, or Brii Bio, pursuant to which we granted to Brii Bio, with respect to up to four of our programs, an
exclusive option to obtain exclusive rights to develop and commercialize compounds and products arising from such programs in China, Taiwan, Hong Kong and Macau, or collectively the China Territory, for the treatment, palliation, diagnosis,
prevention or cure of acute and chronic diseases of infectious pathogen origin or hosted by pathogen infection, or the Field of Use. In partial consideration for the options granted by us to Brii Bio, Brii Bio Parent and Brii Bio granted us, with
respect to up to four of Brii Bio Parent&#146;s or Brii Bio&#146;s programs, an exclusive option to be granted exclusive rights to develop and commercialize compounds and products arising from such Brii Bio programs in the United States for the
Field of Use. Neither we nor Brii Bio has exercised an option under the Brii Agreement. We cannot be certain that, following the exercise of an option by Brii Bio or by us, we will achieve any benefits from our collaboration with Brii Bio. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A core element of our business strategy also includes continuing to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> additional
technologies or product candidates for the treatment and prevention of serious infectious diseases. As a result, we intend to periodically explore a variety of possible strategic collaborations or licenses in an effort to gain access to additional
product candidates, technologies or resources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At this time, we cannot predict what form such strategic collaborations or licenses might
take in the future. We are likely to face significant competition in seeking appropriate strategic collaborators, and strategic collaborations and licenses can be complicated and time-consuming to negotiate and document. We may not be able to
negotiate strategic collaborations on acceptable terms, or at all. We are unable to predict when, if ever, we will enter into any additional strategic collaborations or licenses because of the numerous risks and uncertainties associated with
establishing them. Any delays in entering into new strategic collaborations or licenses related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications,
which would harm our business prospects, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current and future collaborations and
licenses could subject us to a number of risks, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to undertake the expenditure of substantial operational, financial and management resources;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to issue equity securities that would dilute our stockholders&#146; percentage ownership of
our company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to assume substantial actual or contingent liabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be able to control the amount and timing of resources that our strategic collaborators devote to the
development or commercialization of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not have the right to control the preparation, filing, prosecution and maintenance of patents and patent
applications covering the technology that we license, and we cannot always be certain that these patents and patent applications will be prepared, filed, prosecuted and maintained in a manner consistent with the best interests of our business;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">strategic collaborators may select indications or design clinical trials in a way that may be less successful
than if we were doing so; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">strategic collaborators may delay clinical trials, provide insufficient funding, terminate a clinical trial or
abandon a product candidate, repeat or conduct new clinical trials or require a new version of a product candidate for clinical testing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">strategic collaborators may not pursue further development and commercialization of products resulting from the
strategic collaboration arrangement or may elect to discontinue research and development programs; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">strategic collaborators may not commit adequate resources to the marketing and distribution of our product
candidates, limiting our potential revenue from these products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disputes may arise between us and our strategic collaborators that result in the delay or termination of the
research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management&#146;s attention and consumes resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">strategic collaborators may experience financial difficulties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">strategic collaborators may not properly maintain, enforce or defend our intellectual property rights or may use
our proprietary information in a manner that could jeopardize or invalidate our proprietary information or expose us to potential litigation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business combinations or significant changes in a strategic collaborator&#146;s business strategy may adversely
affect a strategic collaborator&#146;s willingness or ability to complete its obligations under any arrangement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">strategic collaborators could decide to move forward with a competing product candidate developed either
independently or in collaboration with others, including our competitors; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">strategic collaborators could terminate the arrangement or allow it to expire, which would delay the development
and may increase the cost of developing our product candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, license agreements we enter into in the
future may not provide exclusive rights to use intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and products. As a result, we may not be able to
prevent competitors from developing and commercializing competitive products in territories included in all of our licenses.<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the market
opportunities for our product candidates are smaller than we believe they are or any approval we obtain is based on a narrower definition of the patient population, our business may suffer. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently focus our product development on product candidates for the treatment and prevention of serious infectious diseases. Our eligible
patient population, pricing estimates and available coverage and reimbursement may differ significantly from the actual market addressable by our product candidates. Our estimates of both the number of people who have these diseases, as well as the
subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on our beliefs and analyses. These estimates have been derived from a variety of sources, including the scientific
literature, patient foundations or market research, and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of the diseases we are targeting. The number of patients may turn out to be lower than expected.
Likewise, the potentially addressable patient population for each of our product candidates may be limited or may not be receptive to treatment with our product candidates, and new patients may become increasingly difficult to identify or access. If
the market opportunities for our product candidates are smaller than we estimate, it could have an adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face substantial competition, which may result in others developing or commercializing products before or more successfully than us. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biopharmaceutical industry is characterized by rapidly advancing technologies, intense competition and an emphasis on proprietary
products. We face potential competition from many different sources, including pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions. Product candidates that we
successfully develop and commercialize may compete with existing therapies and new therapies that may become available in the future. In addition, regulatory incentives to develop products for treatment of infectious diseases have increased interest
and activity in this area and may lead to increased competition for clinical investigators and clinical trial subjects, as well as for future prescriptions, if any of our product candidates are successfully developed and approved. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our competitors may have significantly greater financial resources, established presence in
the market, expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement and marketing approved products than we do. These competitors also compete with us in recruiting and
retaining qualified scientific, sales, marketing and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller
or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of these factors, our competitors may achieve patent protection or obtain regulatory approval of their products before we are able
to, which may limit our ability to develop or commercialize our product candidates. Our competitors may also develop therapies that are safer, more effective, more widely accepted or less expensive than ours, and may also be more successful than we
are in manufacturing and marketing their products. These advantages could render our product candidates obsolete or <FONT STYLE="white-space:nowrap">non-competitive</FONT> before we can recover the costs of such product candidates&#146; development
and commercialization. For example, there are efforts by several public and private entities to develop a therapy for <FONT STYLE="white-space:nowrap">COVID-19,</FONT> including Johnson&nbsp;&amp; Johnson, AstraZeneca plc, Sanofi S.A., Pfizer Inc.
and Moderna, Inc., some of which are further along in the clinical development process than we are. These other entities may be more successful at developing, manufacturing or commercializing a therapy for
<FONT STYLE="white-space:nowrap">COVID-19.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mergers and acquisitions in the pharmaceutical and biotechnology industries may result
in even more resources being concentrated among a smaller number of our competitors. Smaller and early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established
companies. These third parties compete with us in recruiting and retaining qualified scientific, management and commercial personnel, establishing clinical trial sites and subject registration for clinical trials, as well as in acquiring
technologies complementary to, or necessary for, our programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if any product candidates receive marketing approval, they may fail to achieve
market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if any product candidates receive marketing approval, they may fail to gain market acceptance by physicians, patients, third-party payors
and others in the medical community. If such product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenue and may not become profitable. The degree of market acceptance of any product candidate,
if approved for commercial sale, will depend on a number of factors, including but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the convenience and ease of administration compared to alternative treatments and therapies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these
therapies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efficacy and potential advantages compared to alternative treatments and therapies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effectiveness of sales and marketing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the strength of our relationships with patient communities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of treatment in relation to alternative treatments and therapies, including any similar generic
treatments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to offer such product for sale at competitive prices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the strength of marketing and distribution support; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of third-party coverage and adequate reimbursement, and patients&#146; willingness to pay <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> in the absence of third-party coverage or adequate reimbursement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prevalence and severity of any side effects; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any restrictions on the use of the product together with other medications. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our efforts to educate physicians, patients, third-party payors and others in the medical
community on the benefits of our product candidates may require significant resources and may never be successful. Such efforts may require more resources than are typically required due to the complex and distinctive nature of our product
candidates. Because we expect sales of our product candidates, if approved, to generate substantially all of our revenue for the foreseeable future, the failure of our product candidates to find market acceptance would harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, we are developing <FONT STYLE="white-space:nowrap">VIR-2482</FONT> as a universal prophylaxis for influenza A. <FONT
STYLE="white-space:nowrap">VIR-2482</FONT> is designed to overcome the limitations of influenza vaccines and lead to meaningfully higher levels of protection. In order for <FONT STYLE="white-space:nowrap">VIR-2482</FONT> to be successful, not only
will it need to be approved for commercial sale, but it will also need to demonstrate a higher efficacy compared to influenza vaccines and be offered at a competitive price in order to receive favorable coverage and reimbursement from third-party
payors and in order for physicians to prescribe the product in lieu of the standard of care treatment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we obtain regulatory approvals for
our product candidates, they will remain subject to ongoing regulatory oversight. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we obtain regulatory approvals for our
product candidates, such approvals will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record keeping and submission of safety and other post-market information. Any
regulatory approvals that we receive for our product candidates may also be subject to a REMS, limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially
costly post-marketing testing, including Phase 4 trials, and surveillance to monitor the quality, safety and efficacy of the product. Such regulatory requirements may differ from country to country depending on where we have received regulatory
approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, biopharmaceutical manufacturers and their facilities are subject to ongoing review and periodic inspections by the
FDA and other regulatory authorities for compliance with cGMP requirements and adherence to commitments made in the NDA, BLA or foreign marketing application. If we, or a regulatory authority, discover previously unknown problems with a product,
such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured or if a regulatory authority disagrees with the promotion, marketing or labeling of that product, a regulatory authority
may impose restrictions relative to that product, the manufacturing facility or us, including requesting a recall or requiring withdrawal of the product from the market or suspension of manufacturing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to comply with applicable regulatory requirements following approval of our product candidates, a regulatory authority may: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue an untitled letter or warning letter asserting that we are in violation of the law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek an injunction or impose administrative, civil or criminal penalties or monetary fines;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspend or withdraw regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspend any ongoing clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refuse to approve a pending NDA, BLA or comparable foreign marketing application or any supplements thereto
submitted by us or our partners; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrict the marketing or manufacturing of the product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seize or detain the product or otherwise require the withdrawal of the product from the market;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refuse to permit the import or export of product candidates; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refuse to allow us to enter into supply contracts, including government contracts. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, the FDA strictly regulates the promotional claims that may be made about drug and
biologic products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#146;s approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the
promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses, and a company that is found to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses may be subject to significant civil, criminal and administrative
penalties. However, physicians may, in their independent medical judgment, prescribe legally available products for <FONT STYLE="white-space:nowrap">off-label</FONT> uses. The FDA does not regulate the behavior of physicians in their choice of
treatments, but the FDA does restrict manufacturer&#146;s communications on the subject of <FONT STYLE="white-space:nowrap">off-label</FONT> use of their products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could
generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA&#146;s and other regulatory authorities&#146; policies may change and additional government regulations may be enacted that could
prevent, limit or delay regulatory approval of our product candidates. In addition, we cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in
the United States or abroad. For example, certain policies of the Trump administration may impact our business and industry. Namely, the Trump administration has taken several executive actions, including the issuance of a number of executive
orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#146;s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and
approval of marketing applications. It is difficult to predict how these executive actions, including the executive orders, will be implemented and the extent to which they will affect the FDA&#146;s ability to exercise its regulatory authority. If
these executive actions impose constraints on the FDA&#146;s ability to engage in oversight and implementation activities in the normal course, our business, financial condition, results of operations and prospects may be negatively impacted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we
may not be successful in commercializing them, if and when they are approved. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To successfully commercialize any product candidate
that may result from our development programs, we will need to build out our sales and marketing capabilities, either on our own or with others. The establishment and development of our own commercial team or the establishment of a contract sales
force to market any product candidate we may develop will be expensive and time-consuming and could delay any product launch. Moreover, we cannot be certain that we will be able to successfully develop this capability, and have no experience as a
company in commercializing products. Establishing sales and marketing capabilities will be particularly important to the commercial success of our product candidates that target diseases with large patient populations throughout the world. We may
seek to enter into collaboration agreements with other entities to utilize their established marketing and distribution capabilities, but we may be unable to enter into such agreements on favorable terms, if at all. If any current or future
collaborators do not commit sufficient time or resources to commercialize our product candidates, or we are unable to develop the necessary capabilities on our own, we may be unable to generate sufficient revenue to sustain our business. We compete
with many companies that currently have extensive, experienced and well-funded marketing and sales operations to recruit, hire, train and retain marketing and sales personnel, and will have to compete with those companies to recruit, hire, train and
retain any of our own marketing and sales personnel. We will likely also face competition if we seek third parties to assist us with the sales and marketing efforts of our product candidates. Without an internal team or the support of a third party
to perform marketing and sales functions, we may be unable to compete successfully against these more established companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we obtain and maintain approval for our product candidates from the FDA, we may never obtain
approval outside the United States, which would limit our market opportunities. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval of a product candidate in the United
States by the FDA does not ensure approval of such product candidate by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign
countries or by the FDA. Sales of our product candidates outside the United States will be subject to foreign regulatory requirements governing clinical trials and marketing approval. Even if the FDA grants marketing approval for a product
candidate, comparable foreign regulatory authorities also must approve the manufacturing and marketing of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review
periods different from, and more onerous than, those in the United States, including additional preclinical studies or clinical trials. In many countries outside the United States, a product candidate must be approved for reimbursement before it can
be approved for sale in that country. In some cases, the price that we intend to charge for any product candidates, if approved, is also subject to approval. Obtaining approval for our product candidates in the European Union, or EU, from the
European Commission following the opinion of the EMA if we choose to submit a marketing authorization application there, would be a lengthy and expensive process. Even if a product candidate is approved, the EMA may limit the indications for which
the product may be marketed, require extensive warnings on the product labeling or require expensive and time-consuming additional clinical trials or reporting as conditions of approval. Approval of certain product candidates outside of the United
States, particularly those that target diseases that are more prevalent outside of the United States will be particularly important to the commercial success of such product candidates. Obtaining foreign regulatory approvals and compliance with
foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our product candidates in certain countries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Also, regulatory approval
for our product candidates may be withdrawn. If we fail to comply with the applicable regulatory requirements, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed and our
business, financial condition, results of operations and prospects could be harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we commercialize our product candidates outside the United
States, a variety of risks associated with international operations could harm our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to seek approval to market
our product candidates outside the United States, and may also do so for future product candidates. If we market approved products outside the United States, we expect that we will be subject to additional risks in commercialization, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">different regulatory requirements for approval of therapies in foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced protection for intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unexpected changes in tariffs, trade barriers and regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">economic weakness, including inflation or political instability in particular foreign economies and markets;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other
obligations incident to doing business in another country; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign reimbursement, pricing and insurance regimes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">workforce uncertainty in countries where labor unrest is more common than in the United States;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business interruptions resulting from geopolitical actions, including war and terrorism or natural disasters
including earthquakes, typhoons, floods and fires; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disruptions resulting from the impact of public health pandemics or epidemics (including, for example, the
ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic) on us or our strategic partners, third-party manufacturers, suppliers and other third parties upon which we rely. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have no prior experience in these areas. In addition, there are complex regulatory, tax,
labor and other legal requirements imposed by many of the individual countries in which we may operate, with which we will need to comply. Many biopharmaceutical companies have found the process of marketing their products in foreign countries to be
challenging. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Negative developments and negative public opinion of new technologies on which we rely may damage public perception of our product
candidates or adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
clinical and commercial success of our product candidates will depend in part on public acceptance of the use of new technologies for the prevention or treatment of human diseases. For example, we use CMV, a commonly occurring virus in humans, as a
vaccine vector to prevent and treat pathogens refractory to current vaccine technologies. We also use CRISPR gene-editing technology as a research tool to systematically identify human genes that control infection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Public perception may be influenced by claims that CMV technology is unsafe and products incorporating this technology may not gain the
acceptance of the public or the medical community, or that CRISPR gene-editing technology is unethical or immoral. Adverse public attitudes may adversely impact our ability to enroll clinical trials. Moreover, our success will depend upon physicians
specializing in our targeted diseases prescribing, and their patients being willing to receive, our product candidates as treatments in lieu of, or in addition to, existing, more familiar, treatments for which greater clinical data may be available.
Any increase in negative perceptions of the technologies that we rely on may result in fewer physicians prescribing our products or may reduce the willingness of patients to utilize our products or participate in clinical trials for our product
candidates.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Increased negative public opinion or more restrictive government regulations in response thereto, would have a negative effect
on our business, financial condition, results of operations or prospects and may delay or impair the development and commercialization of our product candidates or demand for such product candidates. Adverse events in our preclinical studies or
clinical trials or those of our competitors or of academic researchers utilizing similar technologies, even if not ultimately attributable to product candidates we may discover and develop, and the resulting publicity could result in increased
governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of potential product candidates we may identify and develop, stricter labeling requirements for those product candidates that are
approved, a decrease in demand for any such product candidates and a suspension or withdrawal of approval by regulatory authorities of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any product candidate that we
may develop. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face an inherent risk of product liability exposure related to the testing of our product candidates in clinical
trials and may face an even greater risk if we commercialize any product candidate that we may develop. If we cannot successfully defend ourselves against claims that any such product candidates caused injuries, we could incur substantial
liabilities. Regardless of merit or eventual outcome, liability claims may result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased demand for any product candidate that we may develop; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of revenue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial monetary awards to trial participants or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant time and costs to defend the related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of clinical trial participants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increased insurance costs; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to commercialize any product candidate that we may develop; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injury to our reputation and significant negative media attention. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any such outcomes could negatively impact our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our insurance policies may be inadequate and potentially expose us to unrecoverable risks. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we maintain product liability insurance coverage, such insurance may not be adequate to cover all liabilities that we may incur. We
anticipate that we will need to increase our insurance coverage each time we commence a clinical trial and if we successfully commercialize any product candidate. Insurance availability, coverage terms and pricing continue to vary with market
conditions. We endeavor to obtain appropriate insurance coverage for insurable risks that we identify; however, we may fail to correctly anticipate or quantify insurable risks, we may not be able to obtain appropriate insurance coverage and insurers
may not respond as we intend to cover insurable events that may occur. Conditions in the insurance markets relating to nearly all areas of traditional corporate insurance change rapidly and may result in higher premium costs, higher policy
deductibles and lower coverage limits. For some risks, we may not have or maintain insurance coverage because of cost or availability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legal,
political and economic uncertainty surrounding the exit of the United Kingdom from the European Union may be a source of instability in international markets, create significant currency fluctuations and pose additional risks to our business.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the result of a referendum in 2016, the United Kingdom left the European Union on January&nbsp;31, 2020, commonly
referred to as Brexit. Pursuant to the formal withdrawal arrangements agreed to between the United Kingdom and the European Union, the United Kingdom will be subject to a transition period until December&nbsp;31, 2020, or the Transition Period,
during which EU rules will continue to apply. Negotiations between the United Kingdom and the European Union are expected to continue in relation to the customs and trading relationship between the United Kingdom and the European Union following the
expiry of the Transition Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The uncertainty concerning the U.K&#146;s legal, political and economic relationship with the European
Union after the Transition Period may be a source of instability in the international markets, create significant currency fluctuations, and/or otherwise adversely affect trading agreements or similar cross-border
<FONT STYLE="white-space:nowrap">co-operation</FONT> arrangements (whether economic, tax, fiscal, legal, regulatory or otherwise). These developments, or the perception that any of them could occur, have had, and may continue to have, a significant
adverse effect on global economic conditions and the stability of global financial markets, and could significantly reduce global market liquidity and limit the ability of key market participants to operate in certain financial markets. In
particular, it could also lead to a period of considerable uncertainty in relation to the U.K. financial and banking markets, as well as on the regulatory process in Europe. Asset valuations, currency exchange rates and credit ratings may also be
subject to increased market volatility. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such a withdrawal from the European Union is unprecedented, and it is unclear how the United
Kingdom&#146;s access to the European single market for goods, capital, services and labor within the European Union, or single market, and the wider commercial, legal and regulatory environment, will impact our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Regulatory Compliance </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The
regulatory pathways for our product candidates targeting <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2,</FONT></FONT> the virus that causes <FONT STYLE="white-space:nowrap">COVID-19,</FONT> are continually evolving,
and may result in unexpected or unforeseen challenges. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our product candidates targeting <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">SARS-CoV-2,</FONT></FONT> the virus that causes <FONT STYLE="white-space:nowrap">COVID-19,</FONT> are in the early testing and development stages. <FONT STYLE="white-space:nowrap">VIR-7831,</FONT> a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2-neutralizing</FONT></FONT></FONT> mAb, is planned to initiate a Phase 2/3 clinical trial in August 2020,
<FONT STYLE="white-space:nowrap">VIR-7382,</FONT> also a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2-neutralizing</FONT></FONT></FONT> mAb, is planned to initiate a Phase 2 clinical
trial later this year, and <FONT STYLE="white-space:nowrap">VIR-2703,</FONT> a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2-targeting</FONT></FONT></FONT> siRNA, is planned to continue
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies. The speed at which companies and institutions are acting to create and test many therapeutics and vaccines for <FONT STYLE="white-space:nowrap">COVID-19</FONT> is
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
unusual, and evolving or changing plans or priorities within the FDA, including changes based on new knowledge of <FONT STYLE="white-space:nowrap">COVID-19</FONT> and how the disease affects the
human body, may significantly affect the regulatory timelines for our <FONT STYLE="white-space:nowrap">COVID-19</FONT> product candidates. Results from our continued development and planned clinical trials may raise new questions and require us to
redesign proposed clinical trials, including revising proposed endpoints or adding new clinical trial sites or cohorts of subjects. Discussions with the FDA regarding the design of the anticipated Phase 2/3 clinical trial for <FONT
STYLE="white-space:nowrap">VIR-7831</FONT> are ongoing and important aspects of the trial design have yet to be determined, including the number of patients to be enrolled in the trial, the specific endpoints of the trial and the methods for
obtaining and testing samples in the trial and discussions with the FDA regarding the anticipated Phase 2 clinical trial for <FONT STYLE="white-space:nowrap">VIR-7382</FONT> are in the initial stages. As part of these ongoing discussions, the FDA
may require us to conduct additional pre-clinical studies and/or clinical trials than we originally anticipated, which could result in significant delay in our development program for these product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA has the authority to grant an Emergency Use Authorization to allow unapproved medical products to be used in an emergency to diagnose, treat, or
prevent serious or life-threatening diseases or conditions when, based on the totality of scientific evidence, there is evidence of effectiveness of the medical product, and there are no adequate, approved, and available alternatives. If we are
granted an Emergency Use Authorization for one of our <FONT STYLE="white-space:nowrap">COVID-19</FONT> product candidates, we would be able to commercialize such candidate prior to FDA approval. Furthermore, the FDA may revoke an Emergency Use
Authorization where it is determined that the underlying health emergency no longer exists or warrants such authorization, and we cannot predict how long, if ever, an Emergency Use Authorization would remain in place. Such revocation could adversely
impact our business in a variety of ways, including if one of our <FONT STYLE="white-space:nowrap">COVID-19</FONT> product candidates is not yet approved by the FDA and if we and our manufacturing partners have invested in the supply chain to
provide one of our <FONT STYLE="white-space:nowrap">COVID-19</FONT> product candidates under an Emergency Use Authorization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If any of our future
small molecule product candidates obtain regulatory approval, additional competitors could enter the market with generic versions of such products, which may result in a material decline in sales of affected products. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, a pharmaceutical manufacturer may file an
abbreviated new drug application, or ANDA, seeking approval of a generic version of an approved, small molecule innovator product. Under the Hatch-Waxman Act, a manufacturer may also submit an NDA under section 505(b)(2) of the Federal Food, Drug,
and Cosmetic Act that references the FDA&#146;s prior approval of the small molecule innovator product. A 505(b)(2) NDA product may be for a new or improved version of the original innovator product. The Hatch-Waxman Act also provides for certain
periods of regulatory exclusivity, which preclude FDA approval (or in some circumstances, FDA filing and review) of an ANDA or 505(b)(2) NDA. In addition to the benefits of regulatory exclusivity, an innovator NDA holder may have patents claiming
the active ingredient, product formulation or an approved use of the drug, which would be listed with the product in the FDA publication, &#147;Approved Drug Products with Therapeutic Equivalence Evaluations,&#148; known as the Orange Book. If there
are patents listed in the Orange Book for a product, a generic or 505(b)(2) applicant that seeks to market its product before expiration of the patents must include in their applications what is known as a &#147;Paragraph IV&#148; certification,
challenging the validity or enforceability of, or claiming <FONT STYLE="white-space:nowrap">non-infringement</FONT> of, the listed patent or patents. Notice of the certification must be given to the patent owner and NDA holder and if, within 45 days
of receiving notice, either the patent owner or NDA holder sues for patent infringement, approval of the ANDA or 505(b)(2) NDA is stayed for up to 30 months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, if any of our future small molecule product candidates are approved, competitors could file ANDAs for generic versions of these
products or 505(b)(2) NDAs that reference our products. If there are patents listed for such small molecule drug products in the Orange Book, those ANDAs and 505(b)(2) NDAs would be required to include a certification as to each listed patent
indicating whether the ANDA applicant does or does not intend to challenge the patent. We cannot predict which, if any, patents in our current portfolio or patents we may obtain in the future will be eligible for listing in the Orange Book, how any
generic competitor would address such patents, whether we would sue on any such patents or the outcome of any such suit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be
successful in securing or maintaining proprietary patent protection for products and technologies we develop or license. Moreover, if any of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents that are listed in the Orange Book
are successfully challenged by way of a Paragraph IV certification and subsequent litigation, the affected product could immediately face generic competition and its sales would likely decline rapidly and materially. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any biologic, or large molecule, product candidates for which we intend to seek approval may face
competition sooner than anticipated. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are successful in achieving regulatory approval to commercialize any biologic product
candidate faster than our competitors, such product candidates may face competition from biosimilar products. In the United States, large molecule product candidates are regulated by the FDA as biologic products subject to approval under the BLA
pathway. The Biologics Price Competition and Innovation Act of 2009, or BPCIA, creates an abbreviated pathway for the approval of biosimilar and interchangeable biologic products following the approval of an original BLA. The abbreviated regulatory
pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#147;interchangeable&#148; based on its similarity to an existing brand product. Under the BPCIA, an
application for a biosimilar product cannot be approved by the FDA until 12 years after the original branded product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate
impact, implementation and meaning are subject to uncertainty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, the extent to which a biosimilar product, once approved, will be
substituted for any one of our reference products in a way that is similar to traditional generic substitution for <FONT STYLE="white-space:nowrap">non-biologic</FONT> products is not yet clear, and will depend on a number of marketplace and
regulatory factors that are still developing. In addition, a competitor could decide to forego the biosimilar approval path and submit a full BLA after completing its own preclinical studies and clinical studies. In such cases, any exclusivity to
which we may be eligible under the BPCIA would not prevent the competitor from marketing its product as soon as it is approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If
competitors are able to obtain marketing approval for biosimilars referencing our large molecule product candidates, if approved, such products may become subject to competition from such biosimilars, with the attendant competitive pressure and
potential adverse consequences. Such competitive products may be able to immediately compete with us in each indication for which our product candidates may have received approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our relationships with customers, physicians, and third-party payors are subject, directly or indirectly, to federal and state healthcare fraud and
abuse laws, false claims laws, health information privacy and security laws, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Healthcare providers, physicians and third-party payors in the United States and elsewhere will play a primary role in the recommendation and
prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, principal investigators, consultants, customers and third-party payors subject us to various federal
and state fraud and abuse laws and other healthcare laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These laws may constrain the business or financial arrangements and
relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved. Such laws include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly
and willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the
referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under any U.S. federal healthcare program, such as Medicare and Medicaid. A
person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. federal civil and criminal false claims, including the civil False Claims Act, which can be enforced
through civil whistleblower or qui tam actions, and civil monetary penalties laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment
or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an
obligation to pay money to the U.S. federal government. Pharmaceutical manufacturers can cause false claims to be presented to the U.S. federal government by engaging in impermissible marketing practices, such as the
<FONT STYLE="white-space:nowrap">off-label</FONT> promotion of a product for an indication for which it has not received FDA approval. In addition, the government may assert that a claim including items and services resulting from a violation of the
U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil
liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any
materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the healthcare
fraud statute implemented under HIPAA or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its
implementing regulations, which also imposes certain obligations, including mandatory contractual terms, with respect to safeguarding the privacy and security of individually identifiable health information of covered entities subject to the rule,
such as health plans, healthcare clearinghouses and certain healthcare providers as well as their business associates, independent contractors of a covered entity that perform certain services involving the use or disclosure of individually
identifiable health information on their behalf; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Federal Food Drug or Cosmetic Act, or FDCA, which prohibits, among other things, the adulteration or
misbranding of drugs, biologics and medical devices; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. Physician Payments Sunshine Act and its implementing regulations, which requires certain manufacturers
of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#146;s Health Insurance Program, with specific exceptions, to report annually to the government information related to certain payments
and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their
immediate family members; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws, which may apply
to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that
require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to
healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of
value provided to healthcare professionals and entities; state and local laws requiring the registration of pharmaceutical sales representatives; and state laws governing the privacy and security of health information in certain circumstances, many
of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">similar healthcare laws and regulations in the EU and other jurisdictions, including reporting requirements
detailing interactions with and payments to healthcare providers and laws governing the privacy and security of certain protected information, such as the General Data Protection Regulation, or GDPR, which imposes obligations and restrictions on the
collection and use of personal data relating to individuals located in the EU (including health data). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also be subject to other laws, such federal laws as the U.S. Foreign Corrupt
Practices Act of 1977, as amended, which prohibit, among other things, U.S. companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value
to foreign government officials, employees of public international organizations and foreign government owned or affiliated entities, candidates for foreign political office and foreign political parties or officials thereof, as well as federal
consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ensuring that our internal operations and business arrangements with third parties comply with applicable healthcare laws and regulations will
likely be costly. It is possible that governmental authorities will conclude that our business practices, including our relationships with physicians and other healthcare providers, some of whom are compensated in the form of stock options for
consulting services provided, may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws
or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participating in government-funded healthcare
programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, contractual damages,
reputational harm and the curtailment or restructuring of our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the physicians or other providers or entities with whom we
expect to do business are found not to be in compliance with applicable laws, they may be subject to significant civil, criminal or administrative sanctions, including exclusions from government-funded healthcare programs. Even if resolved in our
favor, litigation or other legal proceedings relating to healthcare laws and regulations may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there
could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our
common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development, manufacturing, sales, marketing or distribution activities. Uncertainties resulting from the
initiation and continuation of litigation or other proceedings relating to applicable healthcare laws and regulations could have an adverse effect on our ability to compete in the marketplace. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Coverage and adequate reimbursement may not be available for our product candidates, which could make it difficult for us to sell profitably, if
approved. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Market acceptance and sales of any product candidates that we commercialize, if approved, will depend in part on the
extent to which reimbursement for these product and related treatments will be available from third-party payors, including government health administration authorities, managed care organizations and other private health insurers. Third-party
payors decide which therapies they will pay for and establish reimbursement levels. While no uniform policy for coverage and reimbursement exists in the United States, third-party payors often rely upon Medicare coverage policy and payment
limitations in setting their own coverage and reimbursement policies. However, decisions regarding the extent of coverage and amount of reimbursement to be provided for any product candidates that we develop will be made on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">payor-by-payor</FONT></FONT> basis. Therefore, one payor&#146;s determination to provide coverage for a product does not assure that other payors will also provide coverage, and adequate
reimbursement, for the product. Additionally, a third-party payor&#146;s decision to provide coverage for a therapy does not imply that an adequate reimbursement rate will be approved. Each payor determines whether or not it will provide coverage
for a therapy, what amount it will pay the manufacturer for the therapy and on what tier of its formulary it will be placed. The position on a payor&#146;s list of covered drugs and biological products, or formulary, generally determines the <FONT
STYLE="white-space:nowrap">co-payment</FONT> that a patient will need to make to obtain the therapy and can strongly influence the adoption of such therapy by patients and physicians. Patients who are prescribed treatments for their conditions and
providers prescribing such services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover a
significant portion of the cost of our products. In addition, because certain of our product candidates are physician-administered, separate reimbursement for the product itself may or may not be available. Instead, the administering physician may
only be reimbursed for providing the treatment or procedure in which our product is used. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third-party payors have attempted to control costs by limiting coverage and the amount of
reimbursement for particular medications. We cannot be sure that coverage and reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Inadequate coverage and
reimbursement may impact the demand for, or the price of, any product for which we obtain marketing approval. If coverage and adequate reimbursement are not available, or are available only at limited levels, we may not be able to successfully
commercialize any product candidates that we develop. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare legislative reform measures may have a negative impact on our business, financial
condition, results of operations and prospects. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States and some foreign jurisdictions, there have been, and we
expect there will continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities and
affect our ability to profitably sell any product candidates for which we obtain marketing approval. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs
and improve the quality of healthcare. For example, in March 2010, the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, was passed, which
substantially changed the way healthcare is financed by both governmental and private payors in the United States. Among the provisions of the ACA, those of greatest importance to the pharmaceutical and biotechnology industries include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an annual, <FONT STYLE="white-space:nowrap">non-deductible</FONT> fee on any entity that manufactures or imports
certain branded prescription drugs and biologic agents, which is apportioned among these entities according to their market share in certain government healthcare programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a Medicare Part D coverage gap discount program, in which manufacturers must agree to offer <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#146;s
outpatient drugs to be covered under Medicare Part D; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to
23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for
drugs that are inhaled, infused, instilled, implanted or injected; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">extension of a manufacturer&#146;s Medicaid rebate liability to covered drugs dispensed to individuals who are
enrolled in Medicaid managed care organizations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid
coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#146;s Medicaid rebate liability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative
clinical effectiveness research, along with funding for such research; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishment of a Center for Medicare Innovation at the Centers for Medicare&nbsp;&amp; Medicaid Services, or
CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There remain judicial and Congressional challenges, as well as efforts by the Trump
administration to repeal or replace certain aspects of the ACA. For example, The Tax Cuts and Jobs Act of 2017, or Tax Act, includes a provision that repealed, effective January&nbsp;1, 2019, the <FONT STYLE="white-space:nowrap">tax-based</FONT>
shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year, which is commonly referred to as the &#147;individual mandate.&#148; Additionally, the 2020 federal
spending package permanently eliminated, effective January&nbsp;1, 2020, the Affordable Care Act&#146;s mandated medical device tax and &#147;Cadillac&#148; tax on high-cost employer-sponsored health coverage and, effective January&nbsp;1, 2021,
also eliminates the health insurer tax. Further, the Bipartisan Budget Act of 2018, or the BBA, among other things, amended the ACA, effective January&nbsp;1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the
&#147;donut hole.&#148; In December 2018, the CMS, published a final rule permitting further collections and payments to and from certain <FONT STYLE="white-space:nowrap">ACA-qualified</FONT> health plans and health insurance issuers under the ACA
adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. On December&nbsp;14, 2018, a U.S. District Court Judge in the Northern District of Texas, or Texas
District Court Judge, ruled that the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the Tax Act, the remaining provisions of the ACA are invalid as well. On December&nbsp;18,
2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the Affordable
Care Act are invalid as well. On March&nbsp;2, 2020, the United States Supreme Court granted the petitions for writs of certiorari to review this case, and has allotted one hour for oral arguments, which are expected to occur in the fall. It is
unclear how such litigation and other efforts to repeal and replace the ACA will impact the ACA. Congress may consider additional legislation to repeal or repeal and replace other elements of the ACA. We continue to evaluate the effect that the ACA
and its possible repeal and replacement have on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other legislative changes have been proposed and adopted in the United
States since the ACA was enacted. These changes include aggregate reductions to Medicare payments to providers of 2% per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013. The Coronavirus Aid, Relief and Economic Security
Act, or CARES Act, which was signed into law in March 2020 and was designed to provide financial support and resources to individuals and businesses affected by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, suspended these
reductions from May&nbsp;1, 2020 through December&nbsp;31, 2020, and extended the sequester through 2030. In addition, the American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several types of providers,
including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional changes that may affect our business include the expansion of new programs such as Medicare payment for performance initiatives for
physicians under the Medicare Access and CHIP Reauthorization Act of 2015, which established a quality payment program, also referred to as the Quality Payment Program. The quality payment program has two tracks, one known as the merit based
incentive payment system for providers in the <FONT STYLE="white-space:nowrap">fee-for</FONT> service Medicare program, and the advanced alternative payment model for providers in specific care models, such as accountable care organizations. In
November 2019, CMS issued a final rule finalizing the changes to the Quality Payment Program. At this time, it is unclear how the introduction of the Medicare Quality Payment Program will impact overall physician reimbursement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, in the United States there has been heightened governmental scrutiny over the
manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug and
biological product pricing, reduce the cost of prescription drugs and biological products under government payor programs and review the relationship between pricing and manufacturer patient programs. At the federal level, the Trump
administration&#146;s budget proposals for fiscal years 2021 includes a $135&nbsp;billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs. On March&nbsp;10, 2020, the Trump administration sent &#147;principles&#148; for drug pricing to
Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> pharmacy expenses, provide an option to cap Medicare Part
D beneficiary monthly <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses, and place limits on pharmaceutical price increases. In addition, the Trump administration previously released a
&#147;Blueprint&#148; to lower drug prices and reduce out of pocket costs of drugs that contained proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to
lower the list price of their products, and reduce the out of pocket costs of drug products paid by consumers. The Department of Health and Human Services has solicited feedback on some of these measures and has implemented others under its existing
authority. For example, in May 2019, CMS issued a final rule to allow Medicare Advantage Plans the option of using step therapy for Part B drugs beginning January&nbsp;1, 2020. This final rule codified a CMS policy change that was effective
January&nbsp;1, 2019. While some of these measures may require additional authorization to become effective, the U.S. Congress and the Trump administration have indicated that they will continue to seek new legislative and/or administrative measures
to control drug and biological product costs. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient
reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition,
regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine which drugs, biological products and suppliers will be included in their healthcare programs. Furthermore, there has been increased
interest by third party payors and governmental authorities in reference pricing systems and publication of discounts and list prices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand
for our current or any future product candidates or additional pricing pressures. For example, it is possible that additional governmental action is taken to address the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. We cannot predict
the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in the United States or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes
in existing or new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our current or any future product candidates we may develop may lose any regulatory approval that may have been obtained and
we may not achieve or sustain profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that these and other healthcare reform measures that may be adopted in the future
may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product, which could have an adverse effect on demand for our product candidates. Any reduction in reimbursement from
Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain
profitability or commercialize our products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to anti-corruption, anti-bribery, anti-money laundering, and similar laws, and <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with such laws can subject us to criminal and/or civil liability and harm our business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167;
201, the U.S. Travel Act and other anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption and anti-bribery laws have been enforced aggressively in recent years and are interpreted broadly to
generally prohibit companies and their employees and third-party intermediaries from authorizing, offering or providing, directly or indirectly, improper payments or benefits to recipients in the public or private sector. We interact with officials
and employees of government agencies and government-affiliated hospitals, universities and other organizations. In addition, we may engage third-party intermediaries to promote our clinical research activities abroad or to obtain necessary permits,
licenses and other regulatory approvals. We can be held liable for the corrupt or other illegal activities of these third-party intermediaries, our employees, representatives, contractors, partners and agents, even if we do not explicitly authorize
such activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we have policies and procedures to address compliance with such laws in the United States, we cannot assure you
that all of our employees and agents will not take actions in violation of our policies and applicable law, for which we may be ultimately held responsible. Detecting, investigating and resolving actual or alleged violations can require a
significant diversion of time, resources and attention from senior management. In addition, noncompliance with anti-corruption, anti-bribery or anti-money laundering laws could subject us to whistleblower complaints, investigations, sanctions,
settlements, prosecution, other enforcement actions, disgorgement of profits, significant fines, damages, other civil and criminal penalties or injunctions, suspension and/or debarment from contracting with certain persons, the loss of export
privileges, reputational harm, adverse media coverage and other collateral consequences. If any subpoenas or investigations are launched, or governmental or other sanctions are imposed, or if we do not prevail in any possible civil or criminal
litigation, our business, financial condition, results of operations and prospects could be materially harmed. In addition, responding to any action will likely result in a materially significant diversion of management&#146;s attention and
resources and significant defense costs and other professional fees. Enforcement actions and sanctions could further harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Dependence on Third Parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We intend to rely on third parties to produce clinical and commercial supplies of our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently manufacturing material for product candidates of three different modalities: mAbs, HCMV-based vaccines and siRNAs. Except for
limited process development and quality control testing capabilities in certain of our facilities, we do not own or operate facilities for product manufacturing, storage and distribution, or testing. We are dependent on third parties to manufacture
the clinical supplies of our current and any future product candidates. We have established relationships with multiple contract development and manufacturing organizations, or CDMOs, that have produced material to support our preclinical, Phase 1
and Phase 2 clinical trials. We have not yet manufactured our product candidates on a commercial scale, and we do not yet have sufficient information to reliably estimate the cost of the commercial manufacturing of our product candidates. Certain of
our product candidates may have to compete with existing and future products, such as the annual flu vaccine or any potential <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccine, that may have a lower price point. The actual cost to manufacture
our product candidates could materially and adversely affect the commercial viability of our product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The facilities used by our contract manufacturers to manufacture our product candidates must
be approved by the FDA pursuant to inspections that will be conducted after we submit our NDA or BLA to the FDA. We do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with
the cGMP requirements. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, we will not be able to secure and/or maintain regulatory
approval for our product candidates. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory
authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to
develop, obtain regulatory approval for or market our product candidates, if approved. Any significant delay in the supply of a product candidate, or the raw material components thereof, for an ongoing clinical trial due to the need to replace a
third-party manufacturer could considerably delay completion of our clinical trials, product testing and potential regulatory approval of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also intend to rely on third-party manufacturers to supply us with sufficient quantities of our product candidates to be used, if approved,
for commercialization. We do not yet have a commercial supply agreement for commercial quantities of our product candidates. If we are not able to meet market demand for any approved product or if we are not able to produce supply at low enough
costs, it would negatively impact our ability to generate revenue, harm our reputation, and could have an adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we currently rely on foreign CDMOs, including a CDMO in China, and will likely continue to rely on foreign CDMOs in the future.
Foreign CDMOs may be subject to trade restrictions and other foreign regulatory requirements which could increase the cost or reduce the supply of material available to us, or delay the procurement of such material. Additionally, the
biopharmaceutical industry in particular in China is strictly regulated by the Chinese government. Changes to Chinese regulations or government policies affecting biopharmaceutical companies are unpredictable and may have a material adverse effect
on our partnerships in China, which could have an adverse effect on our business, financial condition, results of operations and prospects. Evolving changes in China&#146;s economic, political, and social conditions could also negatively impact our
ability to manufacture our product candidates for our planned clinical trials, which could adversely affect our financial condition and cause us to delay our clinical development programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, our reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured product candidates
ourselves, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delay or inability to procure or expand sufficient manufacturing capacity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issues related to <FONT STYLE="white-space:nowrap">scale-up</FONT> of manufacturing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs and validation of new equipment and facilities required for
<FONT STYLE="white-space:nowrap">scale-up;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability of our third-party manufacturers to execute technology transfers, manufacturing procedures and other
logistical support requirements appropriately; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to negotiate manufacturing agreements with third parties under commercially reasonable terms, if at
all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">breach, termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is
costly or damaging to us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reliance on single sources for product components; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lack of qualified backup suppliers for those components that are currently purchased from a sole or single-source
supplier; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lack of ownership to the intellectual property rights to any improvements made by our third-party manufacturers
in the manufacturing process for our product candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disruptions to operations of our third-party manufacturers or suppliers by conditions unrelated to our business
or operations, including the bankruptcy of the manufacturer or supplier; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disruptions caused by <FONT STYLE="white-space:nowrap">man-made&nbsp;or</FONT> natural disasters or public health
pandemics or epidemics, including, for example, the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">carrier disruptions or increased costs that are beyond our control. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot be sure that single source suppliers for our product components will remain in business or that they will not be purchased by one of
our competitors or another company that is not interested in continuing to produce these components for our intended purpose. In addition, the lead time needed to establish a relationship with a new supplier can be lengthy and we may experience
delays in meeting demand in the event we must switch to a new supplier. The time and effort to qualify a new supplier could result in additional costs, diversion of resources or reduced manufacturing yields, any of which would negatively impact our
operating results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, there are a limited number of manufacturers that supply synthetic siRNAs. Alnylam is currently supplying
clinical material for our <FONT STYLE="white-space:nowrap">VIR-2218</FONT> Phase 1/2 clinical trial through its CDMOs. We will assume responsibility for technology transfer and manufacturing ahead of any Phase 3 clinical trials for <FONT
STYLE="white-space:nowrap">VIR-2218.</FONT> Alnylam currently relies on a limited number of CDMOs for our supply of synthetic siRNAs. There are risks inherent in pharmaceutical manufacturing that could affect the ability of Alnylam and
Alnylam&#146;s CDMOs to meet our delivery time requirements or provide adequate amounts of synthetic siRNAs to meet our needs. Included in these risks are potential synthesis and purification failures and/or contamination during the manufacturing
process, as well as other issues with the CDMO&#146;s facility and ability to comply with the applicable manufacturing requirements, including use of the proper raw material components, which could result in unusable product. This would cause delays
in our manufacturing timelines and ultimately delay our clinical trials and potentially put at risk commercial supply, as well as result in additional expense to us. To fulfill our siRNA requirements, we may need to secure alternative suppliers of
synthetic siRNAs and such alternative suppliers are limited and may not be readily available, or we may be unable to enter into agreements with them on reasonable terms and in a timely manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, manufacturers may have little or no experience with viral vector products and therefore may require a significant amount of
support from us in order to implement and maintain the infrastructure and processes required to manufacture our HCMV vector-based product candidates. The challenges to HCMV-based vaccine manufacturing include the large size of the virus, which
precludes terminal sterile filtration, and the attenuation of the engineered human virus, which dramatically reduces high growth yields during manufacturing. To address these challenges, we have made significant internal investments in process
development and <FONT STYLE="white-space:nowrap">scale-up,</FONT> largely funded by grants from the Bill&nbsp;&amp; Melinda Gates Foundation. We have established a cGMP process in support of Phase 1 and Phase 2 clinical trials that has been
successfully transferred and executed at two CDMOs specializing in live vaccine manufacturing (IDT Biologika and Advanced Bioscience Laboratories, Inc.). However, the existing process will require <FONT STYLE="white-space:nowrap">scale-up</FONT> for
later stages of clinical development and commercial supply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these events could lead to clinical trial delays or failure to obtain
regulatory approval or impact our ability to successfully commercialize our current or any future product candidates once approved. Some of these events could be the basis for FDA action, including injunction, request for recall, seizure or total or
partial suspension of production. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business involves the use of hazardous materials and we and our third-party manufacturers and
suppliers must comply with environmental, health and safety laws and regulations, which can be expensive and restrict how we do, or interrupt our, business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development activities and our third-party manufacturers&#146; and suppliers&#146; activities involve the generation,
storage, use and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds and wastes. We and our manufacturers and suppliers are subject to environmental, health and safety laws and
regulations governing, among other matters, the use, manufacture, generation, storage, handling, transportation, discharge and disposal of these hazardous materials and wastes and worker health and safety. In some cases, these hazardous materials
and various wastes resulting from their use are stored at our and our manufacturers&#146; facilities pending their use and disposal. We cannot eliminate the risk of contamination or injury, which could result in an interruption of our
commercialization efforts, research and development efforts and business operations, damages and significant cleanup costs and liabilities under applicable environmental, health and safety laws and regulations. We also cannot guarantee that the
safety procedures utilized by our third-party manufacturers for handling and disposing of these materials and wastes generally comply with the standards prescribed by these laws and regulations. We may be held liable for any resulting damages costs
or liabilities, which could exceed our resources, and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental, health and safety laws and
regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. Failure to comply with these environmental, health and safety laws and
regulations may result in substantial fines, penalties or other sanctions. We do not currently carry hazardous waste insurance coverage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on
third parties to conduct, supervise and monitor our preclinical studies and clinical trials, and if those third parties perform in an unsatisfactory manner, it may harm our business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not currently have the ability to independently conduct any clinical trials. We intend to rely on CROs and clinical trial sites to
ensure the proper and timely conduct of our preclinical studies and clinical trials, and we expect to have limited influence over their actual performance. We rely on CROs to monitor and manage data for our clinical programs, as well as the
execution of future preclinical studies. We expect to control only certain aspects of our CROs&#146; activities. Nevertheless, we will be responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance
with the applicable protocol, legal, regulatory and scientific standards, and our reliance on the CROs does not relieve us of our regulatory responsibilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our CROs are required to comply with the good laboratory practices, or GLPs, and GCPs, which are regulations and guidelines enforced by
the FDA and comparable foreign regulatory authorities in the form of International Conference on Harmonization guidelines for any of our product candidates that are in preclinical and clinical development. The regulatory authorities enforce GCPs
through periodic inspections of trial sponsors, principal investigators and clinical trial sites. Although we rely on CROs to conduct <FONT STYLE="white-space:nowrap">GCP-compliant</FONT> clinical trials, we remain responsible for ensuring that each
of our GLP preclinical studies and clinical trials is conducted in accordance with its investigational plan and protocol and applicable laws and regulations. If we or our CROs fail to comply with GCPs, the clinical data generated in our clinical
trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. Accordingly, if our CROs fail to comply with these
regulations or fail to recruit a sufficient number of subjects, we may be required to repeat clinical trials, which would delay the regulatory approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our reliance on third parties to conduct clinical trials will result in less direct control over the management of data developed through
clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with CROs and other third parties can be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Such
parties may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">have staffing difficulties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fail to comply with contractual obligations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience regulatory compliance issues; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">undergo changes in priorities or become financially distressed. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These factors may adversely affect the willingness or ability of third parties to conduct
our clinical trials and may subject us to unexpected cost increases that are beyond our control. If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines or fail to comply with regulatory
requirements, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reasons, our clinical trials may be extended, delayed or
terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize, any product candidate that we develop. As a result, our financial results and the commercial prospects for any product candidate that we develop
would be harmed, our costs could increase, and our ability to generate revenue could be delayed. While we will have agreements governing their activities, our CROs will not be our employees and we will not control whether or not they devote
sufficient time and resources to our future clinical and preclinical programs. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other product
development activities which could harm our business. We face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CROs, which may reduce our trade secret protection and allow our potential competitors to
access and exploit our proprietary technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our relationship with any of these CROs terminates, we may not be able to enter into
arrangements with alternative CROs or do so on commercially reasonable terms. Switching or adding additional CROs involves substantial cost and requires management time and focus. In addition, there is a natural transition period when a new CRO
commences work. As a result, delays occur, which can negatively impact our ability to meet our desired clinical development timelines. While we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not
encounter challenges or delays in the future or that these delays or challenges will not have a negative impact on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and
receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA. The FDA may conclude that a financial relationship between us and a principal investigator has
created a conflict of interest or otherwise affected interpretation of the trial. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be
jeopardized. This could result in a delay in approval or rejection of our marketing applications by the FDA and may ultimately lead to the denial of marketing approval of our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we
breach our license agreements or any of the other agreements under which we acquired, or will acquire, the intellectual property rights to our product candidates, we could lose the ability to continue the development and commercialization of the
related product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We license a number of technologies to form our antibody platform and T cell platform, and the
technology we use in our siRNA platform is licensed from Alnylam. We have also developed certain product candidates using intellectual property licensed from third parties. A core element of our business strategy includes continuing to acquire or <FONT
STYLE="white-space:nowrap">in-license</FONT> additional technologies or product candidates for the treatment and prevention of serious infectious diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to meet our obligations under these agreements, our licensors may have the right to terminate our licenses. If any of our license
agreements are terminated, and we lose our intellectual property rights under such agreements, this may result in a complete termination of our product development and any commercialization efforts for the product candidates which we are developing
under such agreements. While we would expect to exercise all rights and remedies available to us, including seeking to cure any breach by us, and otherwise seek to preserve our rights under such agreements, we may not be able to do so in a timely
manner, at an acceptable cost or at all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disputes may also arise between us and our licensors regarding intellectual property subject
to a license agreement, including those related to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the license agreement and other issues relating to interpretation of the
relevant agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and the extent to which our technology and processes infringe on intellectual property of the licensor
that is not subject to the license granted to us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right to sublicense patent and other rights to third parties under collaborative development relationships;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our diligence obligations with respect to the use of the licensed technology in relation to our development and
commercialization of our product candidates, and what activities satisfy those diligence obligations; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint
creation or use of intellectual property by our licensors, on the one hand, and us and our sublicensees, on the other hand. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we
are unable to obtain and maintain patent protection for our product candidates and technology, or if the scope of the patent protection obtained is not sufficiently broad or robust, our competitors could develop and commercialize products and
technology similar or identical to ours, and our ability to successfully commercialize our product candidates and technology may be adversely affected. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends, in large part, on our ability to obtain and maintain patent protection in the United States and other countries with
respect to our product candidates and our technology. We and our licensors have sought, and intend to seek, to protect our proprietary position by filing patent applications in the United States and abroad related to our product candidates and our
technology that are important to our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent position of biotechnology and pharmaceutical companies generally is highly
uncertain, involves complex legal and factual questions and has, in recent years, been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our
pending and future patent applications may not result in patents being issued which protect our technology or product candidates or which effectively prevent others from commercializing competitive technologies and product candidates. Because patent
applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we or our licensors were the first to file a patent application relating to any
particular aspect of a product candidate. Furthermore, if third parties have filed such patent applications, an interference proceeding in the United States can be initiated by such third party, or by the U.S. Patent and Trademark Office, or USPTO,
itself, to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent
prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that
we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
or our licensors have not pursued or maintained, and may not pursue or maintain in the future, patent protection for our product candidates in every country or territory in which we may sell our products, if approved. In addition, the laws of some
foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from infringing our patents in all countries outside the
United States, or from selling or importing products that infringe our patents in and into the United States or other jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued and its scope can be
reinterpreted after issuance. Even if the patent applications we license or own do issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us
or otherwise provide us with any competitive advantage. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative products in a <FONT STYLE="white-space:nowrap">non-infringing</FONT> manner.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuance of a patent is not conclusive as to its inventorship, scope, validity or
enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could
limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. Given the amount of time required for the
development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with
sufficient rights to exclude others from commercializing products similar or identical to ours. In addition, if the breadth or strength of protection provided by the patents and patent applications we hold with respect to our product candidates is
threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents may be subject to a reservation of rights by one or
more third parties. For example, the research resulting in certain of our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights and technology was funded in part by the U.S. government. As a result, the government may have
certain rights, or <FONT STYLE="white-space:nowrap">march-in</FONT> rights, to such patent rights and technology. When new technologies are developed with government funding, the government generally obtains certain rights in any resulting patents,
including a nonexclusive license authorizing the government to use the invention for noncommercial purposes. These rights may permit the government to disclose our confidential information to third parties and to exercise <FONT
STYLE="white-space:nowrap">march-in</FONT> rights to use or allow third parties to use our licensed technology. The government can exercise its <FONT STYLE="white-space:nowrap">march-in</FONT> rights if it determines that action is necessary because
we fail to achieve practical application of the government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, our
rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in the United States. Any exercise by the government of such rights could harm our competitive position, business, financial
condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining our patent rights depends on compliance with various procedural, document
submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other
similar provisions during the patent application process. In addition, periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or patent applications will have to be paid to the USPTO and various
government patent agencies outside the United States over the lifetime of our owned and licensed patents and/or applications and any patent rights we may own or license in the future. We rely on our service providers or our licensors to pay these
fees. The USPTO and various <FONT STYLE="white-space:nowrap">non-U.S.</FONT> government patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. We
employ reputable law firms and other professionals to help us comply, and we are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. Noncompliance events
that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, nonpayment of fees and failure to properly legalize and submit formal
documents. If we or our licensors fail to maintain the patents and patent applications covering our product candidates or technologies, we may not be able to use such patents and patent applications or stop a competitor from marketing products that
are the same as or similar to our product candidates, which would have an adverse effect on our business. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are
situations, however, in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be
able to enter the market and this circumstance could harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if we fail to apply for applicable patent term
extensions or adjustments, we will have a more limited time during which we can enforce our granted patent rights. In addition, if we are responsible for patent prosecution and maintenance of patent rights
<FONT STYLE="white-space:nowrap">in-licensed</FONT> to us, any of the foregoing could expose us to liability to the applicable patent owner. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent terms may be inadequate to protect our competitive position on our product candidates for an
adequate amount of time. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally
20 years after its first effective filing date. Although various extensions may be available, the life of a patent and the protection it affords is limited. In addition, although upon issuance in the United States a patent&#146;s life can be
increased based on certain delays caused by the USPTO, this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. If we do not have sufficient patent life to protect our products, our
business and results of operations could be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given the amount of time required for the development, testing and
regulatory review of our product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. We expect to seek extensions of patent terms in the United States and, if available, in other
countries where we have or will obtain patent rights. In the United States, the Hatch-Waxman Act permits a patent term extension of up to five years beyond the normal expiration of the patent, provided that the patent is not enforceable for more
than 14 years from the date of drug approval, which is limited to the approved indication (or any additional indications approved during the period of extension). Furthermore, only one patent per approved product can be extended and only those
claims covering the approved product, a method for using it or a method for manufacturing it may be extended. However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other
countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors may be able to take
advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or
otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a negative impact on the success of our business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends, in part, upon our ability and the ability of others with whom we may collaborate to develop, manufacture,
market and sell our current and any future product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the proprietary rights and intellectual property of third parties. The biotechnology and
pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual property rights. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties,
exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of
the patent rights of others. We may in the future become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our current and any future product candidates and technology,
including interference proceedings, post grant review and inter partes review before the USPTO. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their
merit. There is a risk that third parties may choose to engage in litigation with us to enforce or to otherwise assert their patent rights against us. Even if we believe such claims are without merit, a court of competent jurisdiction could hold
that these third-party patents are valid, enforceable and infringed, which could have a negative impact on our ability to commercialize our current and any future product candidates. In order to successfully challenge the validity of any such U.S.
patent in federal court, we would need to overcome a presumption of validity. As this is a high burden and requires us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of
competent jurisdiction would invalidate the claims of any such U.S. patent. Moreover, given the vast number of patents in our field of technology, we cannot be certain that we do not infringe existing patents or that we will not infringe patents
that may be granted in the future. While we may decide to initiate proceedings to challenge the validity of these or other patents in the future, we may be unsuccessful, and courts or patent offices in the United States and abroad could uphold the
validity of any such patent. Furthermore, because patent applications can take many years to issue and may be confidential for 18 months or more after filing, and because pending patent claims can be revised before issuance, there may be
applications now pending which may later result in issued patents that may be infringed by the manufacture, use or sale of our product candidates. Regardless of when filed, we may fail to identify relevant third-party patents or patent applications,
or we may incorrectly conclude that a third-party patent is invalid or not infringed by our product candidates or activities. If a patent holder believes that our product candidate or technology platform infringes its patent, the patent holder may
sue us even if we have received patent protection for our technology. Moreover, we may face patent infringement claims from nonpracticing entities that have no relevant product revenue and against whom our own patent portfolio may thus have no
deterrent effect. If a patent infringement suit were threatened or brought against us, we could be forced to stop or delay research, development, manufacturing or sales of the product or product candidate that is the subject of the actual or
threatened suit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are found to infringe a third party&#146;s valid and enforceable intellectual property rights, we could be
required to obtain a license from such third party to continue developing, manufacturing and marketing our product candidate(s) and technology. Under any such license, we would most likely be required to pay various types of fees, milestones,
royalties or other amounts. Moreover, we may not be able to obtain any required license on commercially reasonable terms or at all, and if such an instance arises, our ability to commercialize our product candidates may be impaired or delayed, which
could in turn significantly harm our business. Parties making claims against us may also seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The licensing or acquisition of third-party intellectual property rights is a competitive
area, and more established companies may also pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to
their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or
acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain
the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have an adverse effect on our business, financial condition, results of operations and prospects.
Furthermore, even if we were able to obtain a license, it could be nonexclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty
payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product candidate. We may also have to redesign our products, which may not be commercially or technically
feasible or require substantial time and expense. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#146; fees, if we are found to have willfully infringed a patent or other intellectual property
right. We may be required to indemnify collaborators or contractors against such claims. A finding of infringement could prevent us from manufacturing and commercializing our current or any future product candidates or force us to cease some or all
of our business operations, which could harm our business. Even if we are successful in defending against such claims, litigation can be expensive and time-consuming and would divert management&#146;s attention from our core business. Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could
also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of our common
stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative
impact on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims asserting that our employees,
consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or
pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or <FONT STYLE="white-space:nowrap">know-how</FONT> of others
in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#146;s current or former employer.
Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending
against such claims, litigation could result in substantial costs and be a distraction to management. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may in the future
be subject to claims by our former employees or consultants asserting an ownership right in our patents or patent applications, as a result of the work they performed on our behalf. For example, we may have inventorship disputes arise from
conflicting obligations of consultants or others who are involved in developing our product candidates. Although it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property
to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own, and we cannot be certain
that our agreements with such parties will be upheld in the face of a potential challenge or that they will not be breached, for which we may not have an adequate remedy. The assignment of intellectual property rights may not be self-executing or
the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be involved in lawsuits to protect or enforce our patents, the patents of our licensors or our
other intellectual property rights, which could be expensive, time-consuming and unsuccessful. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may infringe,
misappropriate or otherwise violate our patents, the patents of our licensors or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file legal claims, which can be expensive and time-consuming
and are likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid or is unenforceable, or may
refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our owned or licensed
patents at risk of being invalidated or interpreted narrowly and could put our owned or licensed patent applications at risk of not issuing. The initiation of a claim against a third party might also cause the third party to bring counterclaims
against us, such as claims asserting that our patent rights are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge
could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, <FONT STYLE="white-space:nowrap">non-enablement</FONT> or lack of statutory subject matter. Grounds for an unenforceability assertion
could be an allegation that someone connected with prosecution of the patent withheld relevant material information from the USPTO, or made a materially misleading statement, during prosecution. Third parties may also raise similar validity claims
before the USPTO in post-grant proceedings such as ex parte reexaminations, inter partes review, post-grant review, or oppositions or similar proceedings outside the United States, in parallel with litigation or even outside the context of
litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We cannot be certain that there is or will be no invalidating prior art, of which we and the patent examiner were unaware during prosecution. For
the patents and patent applications that we have licensed, we may have limited or no right to participate in the defense of any licensed patents against challenge by a third party. If a defendant were to prevail on a legal assertion of invalidity or
unenforceability, we would lose at least part, and perhaps all, of any future patent protection on our current or future product candidates. Such a loss of patent protection could harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries
where the laws may not protect those rights as fully as in the United States. Our business could be harmed if in litigation the prevailing party does not offer us a license, or if the license offered as a result is not on commercially reasonable
terms. Any litigation or other proceedings to enforce our intellectual property rights may fail and, even if successful, may result in substantial costs and distract our management and other employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that
some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts
or investors perceive these results to be negative, it could have an adverse effect on the price of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not have
sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial
resources and more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating or from successfully challenging our intellectual
property rights. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have an adverse effect on our ability to compete in the marketplace. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the
value of patents in general, thereby impairing our ability to protect our current and any future product candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in
either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Assuming that other
requirements for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the
patent. After March 2013, under the Leahy-Smith America Invents Act, or the America Invents Act, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first
inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. The America Invents Act also includes a number of significant changes that affect
the way patent applications are prosecuted and also may affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by
USPTO-administered post-grant proceedings, including post-grant review, inter partes review and derivation proceedings. However, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of
our patent applications and the enforcement or defense of our issued patents, all of which could have an adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection
available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty
with respect to the value of patents, once obtained. Depending on actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain
new patents or to enforce patents that we own, have licensed or might obtain in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions, changes in the governmental bodies that enforce them or changes in how
the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we own or have licensed or that we may obtain in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to protect our intellectual property rights throughout the world, which could negatively impact our business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Filing, prosecuting and defending patents covering our current and any future product candidates and technology platforms in all countries
throughout the world would be prohibitively expensive. Competitors may use our technologies in jurisdictions where we or our licensors have not obtained patent protection to develop their own products and, further, may export otherwise infringing
products to territories where we may obtain patent protection but where patent enforcement is not as strong as that in the United States. These products may compete with our products in jurisdictions where we do not have any issued or licensed
patents, and any future patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The
legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make
it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our intellectual property and proprietary rights in
foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of
not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce
our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many countries have compulsory licensing laws under which a patent owner may be compelled to
grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish
the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of
operations and prospects may be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to protect the confidentiality of our trade secrets, our business and
competitive position would be harmed. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to seeking patent and trademark protection for our product candidates, we also
rely on trade secrets, including unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> technology and other proprietary information, to maintain our competitive position. Because we rely on third parties to help us discover, develop and
manufacture our current and any future product candidates, or if we collaborate with third parties for the development, manufacturing or commercialization of our current or any future product candidates, we must, at times, share trade secrets with
them. We may also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development partnerships or similar agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer
agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of
these parties to use or disclose our confidential information, including our trade secrets. We also enter into invention or patent assignment agreements with our employees, advisors and consultants. Despite our efforts to protect our trade secrets,
the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others or are disclosed or used in violation of
these agreements. Moreover, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our confidential information or proprietary technology and processes. Monitoring unauthorized uses and
disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. If any of the collaborators, scientific advisors, employees, contractors and consultants who are parties to these
agreements breaches or violates the terms of any of these agreements, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets as a result. Moreover, if confidential information that is licensed or
disclosed to us by our partners, collaborators or others is inadvertently disclosed or subject to a breach or violation, we may be exposed to liability to the owner of that confidential information. Enforcing a claim that a third-party illegally or
unlawfully obtained and is using our trade secrets, like patent litigation, is expensive and time-consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our competitors may independently develop knowledge, methods and <FONT STYLE="white-space:nowrap">know-how</FONT> equivalent to
our trade secrets. Competitors could purchase our products and replicate some or all of the competitive advantages we derive from our development efforts for technologies on which we do not have patent protection. If any of our trade secrets were to
be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. Given that our proprietary position is
based, in part, on our <FONT STYLE="white-space:nowrap">know-how</FONT> and trade secrets, a competitor&#146;s discovery of our trade secrets or other unauthorized use or disclosure could have an adverse effect on our business, financial condition,
results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also seek to preserve the integrity and confidentiality of our data and other confidential
information by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be
breached, and detecting the disclosure or misappropriation of confidential information and enforcing a claim that a party illegally disclosed or misappropriated confidential information is difficult, expensive and time-consuming, and the outcome is
unpredictable. Further, we may not be able to obtain adequate remedies for any breach. In addition, our confidential information may otherwise become known or be independently discovered by competitors, in which case we would have no right to
prevent them, or those to whom they communicate it, from using that technology or information to compete with us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any trademarks we may obtain may be infringed or successfully challenged, resulting in harm to our
business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to rely on trademarks as one means to distinguish any of our product candidates that are approved for
marketing from the products of our competitors. We have not yet selected trademarks for our product candidates and have not yet begun the process of applying to register trademarks for our current or any future product candidates. Once we select
trademarks and apply to register them, our trademark applications may not be approved. Third parties may oppose our trademark applications or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully
challenged, we could be forced to rebrand our products, which could result in loss of brand recognition and could require us to devote resources to advertising and marketing new brands. Our competitors may infringe our trademarks, and we may not
have adequate resources to enforce our trademarks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, any proprietary name we propose to use with our current or any other
product candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of the
potential for confusion with other product names. If the FDA objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable proprietary product name that
would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual
property rights do not necessarily address all potential threats to our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future protection afforded by our
intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business. The following examples are illustrative: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may be able to make compounds or formulations that are similar to our product candidates but that are not
covered by the claims of any patents, should they issue, that we own or license; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may be able to develop technologies that are similar to our technology platforms but that are not covered
by the claims of any patents, should they issue, that we own or license; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or our licensors might not have been the first to make the inventions covered by the issued patents or pending
patent applications that we own or license; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or our licensors might not have been the first to file patent applications covering certain of our inventions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without
infringing our intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that our pending patent applications will not lead to issued patents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issued patents that we own or license may not provide us with any competitive advantages, or may be held invalid
or unenforceable as a result of legal challenges; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors might conduct research and development activities in the United States and other countries that
provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights, and then use the information learned from such activities to develop competitive
products for sale in our major commercial markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not develop additional proprietary technologies that are patentable; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patents of others may have an adverse effect on our business. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The exercise by the Bill&nbsp;&amp; Melinda Gates Foundation of its licenses to certain of our
intellectual property and its development and commercialization of products that we are also developing and commercializing could have an adverse impact on our market position. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into a letter agreement with the Bill&nbsp;&amp; Melinda Gates Foundation, or the Gates Agreement, in December 2016 in connection
with the Bill&nbsp;&amp; Melinda Gates Foundation&#146;s investment in us through the purchase of $20.0&nbsp;million of shares of our convertible preferred stock. We are obligated to use the proceeds of the Bill&nbsp;&amp; Melinda Gates
Foundation&#146;s investment in furtherance of its charitable purposes to (i)&nbsp;conduct our programs to develop products to treat or prevent infectious disease caused by HIV and TB, respectively, with at least 50% of the funds to be used for such
programs, and (ii)&nbsp;develop our HCMV-based vaccine technology platform in a manner reasonably expected to result in the generation of products for the treatment or prevention of other specified infectious diseases, in each case for use in
specified developing countries. We agreed to use reasonable efforts to achieve specified research and development milestones with respect to our HIV program and TB program and, if requested by the Bill&nbsp;&amp; Melinda Gates Foundation, to work
with the Bill&nbsp;&amp; Melinda Gates Foundation on an additional mutually agreeable infectious disease program. Additionally, we agreed to specified global access commitments including a commitment to provide any products developed using the
proceeds of the Bill&nbsp;&amp; Melinda Gates Foundation&#146;s investment at an affordable price to the people most in need within the specified developing countries, not to exceed a specified percentage over our fully burdened manufacturing and
sales costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to comply with (i)&nbsp;our obligations to use the proceeds of the Bill&nbsp;&amp; Melinda Gates
Foundation&#146;s investment for the purposes described in the paragraph above and to not use such proceeds for specified prohibited uses, (ii)&nbsp;specified reporting requirements or (iii)&nbsp;specified applicable laws, or if we materially breach
our specified global access commitments (any such failure or material breach, a Specified Default), we will be obligated to redeem or arrange for a third party to purchase all of our stock purchased by the Bill&nbsp;&amp; Melinda Gates Foundation
under the Gates Agreement, at the Bill&nbsp;&amp; Melinda Gates Foundation&#146;s request, at a price equal to the greater of (1)&nbsp;the original purchase price plus 5% compounding interest or (2)&nbsp;the fair market value as determined by an
independent third-party, which amount may increase in the event of certain underwritten public offerings of our common stock or a sale of our company or all of our material assets relating to the Gates Agreement. Additionally, if a Specified Default
occurs or if we are unable or unwilling to continue the HIV program, TB program or, if applicable, the mutually agreed additional program (except for scientific or technical reasons), or if we institute bankruptcy or insolvency proceedings, then the
Bill&nbsp;&amp; Melinda Gates Foundation will have the right to exercise a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> fully-paid license (with the right to sublicense) under our intellectual property to the extent necessary to use, make
and sell products arising from such programs, in each case solely to the extent necessary to benefit people in the developing countries in furtherance of the Bill&nbsp;&amp; Melinda Gates Foundation&#146;s charitable purpose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exercise by the Bill&nbsp;&amp; Melinda Gates Foundation of any of its <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses to
certain of our intellectual property (or its right to obtain such licenses), and its development and commercialization of product candidates and products that we are also developing and commercializing, could have an adverse impact on our market
position. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Business Operations, Employee Matters and Managing Growth </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are highly dependent on our key personnel, and if we are not able to retain these members of our management team or recruit and retain additional
management, clinical and scientific personnel, our business will be harmed. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are highly dependent on our management, scientific
and medical personnel, including our Chief Executive Officer, Dr.&nbsp;Scangos. Our key personnel may currently terminate their employment with us at any time. The loss of the services of any of these persons could impede the achievement of our
research, development and commercialization objectives. Additionally, we do not currently maintain &#147;key person&#148; life insurance on the lives of our executives or any of our employees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recruiting and retaining other senior executives, qualified scientific and clinical
personnel and, if we progress the development of any of our product candidates, commercialization, manufacturing and sales and marketing personnel, will be critical to our success. The loss of the services of our executive officers or other key
employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be
difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize our product
candidates. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for
similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to
assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are
unable to continue to attract and retain high-quality personnel, our ability to pursue our growth strategy will be limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future
performance will also depend, in part, on our ability to successfully integrate newly hired executive officers into our management team and our ability to develop an effective working relationship among senior management. Our failure to integrate
these individuals and create effective working relationships among them and other members of management could result in inefficiencies in the development and commercialization of our product candidates, harming future regulatory approvals, sales of
our product candidates and our results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have in the past and may in the future acquire or invest in other companies or
technologies, which could divert our management&#146;s attention, result in dilution to our stockholders and otherwise disrupt our operations and adversely affect our operating results. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have in the past and may in the future seek to acquire or invest in additional businesses and/or technologies that we believe complement or
expand our product candidates, enhance our technical capabilities or otherwise offer growth opportunities in the United States and internationally. The pursuit of potential acquisitions and investments may divert the attention of management and
cause us to incur various expenses in identifying, investigating and pursuing suitable acquisitions, whether or not they are consummated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, we acquired TomegaVax, Inc., or TomegaVax, in September 2016, Humabs BioMed SA, or Humabs, in August 2017, Agenovir Corporation,
or Agenovir, in January 2018 and Statera Health, LLC, or Statera, in February 2018. Realizing the benefits of these acquisitions will depend upon the successful integration of the acquired technology into our existing and future product candidates.
Furthermore, we may not be able to integrate the acquired personnel, operations and technologies successfully, or effectively manage the combined business following the acquisition. We also may not realize the anticipated benefits from any acquired
business. The risks we face in connection with acquisitions and investments, whether or not consummated, include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unanticipated costs or liabilities associated with the acquisition; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversion of management&#146;s attention from other business concerns; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse effects to our existing strategic collaborations as a result of the acquisition; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assimilation of operations, intellectual property and products of an acquired company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential loss of key employees;</P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulty integrating the accounting systems, operations and personnel of the acquired business;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the assumption of additional indebtedness or contingent or unknown liabilities, or adverse tax consequences or
unfavorable accounting treatment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">claims and disputes by stockholders and third parties, including intellectual property claims and disputes;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks and uncertainties associated with the other party to such a transaction, including the prospects of that
party and their existing products or product candidates and regulatory approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increased operating expenses and cash requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">use of resources that are needed in other parts of our business; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">use of substantial portions of our available cash to consummate the acquisition. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A significant portion of the purchase price of companies we acquire may be allocated to acquired goodwill and other intangible assets, which
must be assessed for impairment at least annually. If our acquisitions do not yield expected returns, we may in the future be required to take charges to our operating results based on this impairment assessment process, which could adversely affect
our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our acquisitions of TomegaVax, Humabs and Agenovir
included the following future contingent payments: up to $30.0&nbsp;million in milestone payments related to the TomegaVax acquisition, up to $240.0&nbsp;million in milestones payments related to the Humabs acquisition, and up to $135.0&nbsp;million
in milestones related to the Agenovir acquisition. The milestone payments related to the TomegaVax acquisition are dependent on the per share price of our common stock. We may in the future be required to make these payments, which could adversely
affect our financial condition. For example, as a result of the achievement of a certain development milestone achieved in June 2020, we paid an aggregate of $10.0&nbsp;million to Humabs securityholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Acquisitions could also result in dilutive issuances of equity securities or the incurrence of debt, which could adversely affect our
operating results. In addition, if an acquired business fails to meet our expectations, our business, financial condition, results of operations and prospects may suffer. We cannot assure you that we will be successful in integrating the businesses
or technologies we may acquire. The failure to successfully integrate these businesses could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2020, we had 237 full-time employees. As the clinical development of our product candidates progresses, we also expect to
experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of research, development, regulatory affairs and, if any of our product candidates receives marketing approval, sales, marketing
and distribution. In addition, we also expect to hire additional personnel in order to operate as a public company. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems,
expand our facilities, and continue to recruit and train additional qualified personnel. In addition, we must effectively integrate, develop and motivate a growing number of new employees, and maintain the beneficial aspects of our corporate
culture. The expansion of our operations may lead to significant costs and may divert our management and business development resources. We may not be able to effectively manage the expansion of our operations or recruit and train additional
qualified personnel. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Business disruptions
could seriously harm our future revenue and financial condition and increase our costs and expenses. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations, and those of
our CDMO, CROs and other contractors and consultants, could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, public health pandemics or
epidemics (including, for example, the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic), and other natural <FONT STYLE="white-space:nowrap">or&nbsp;man-made&nbsp;disasters</FONT> or business interruptions, for which we are
predominantly self-insured. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to develop our product candidates could be disrupted if our operations or those
of our suppliers are affected by <FONT STYLE="white-space:nowrap">man-made&nbsp;or</FONT> natural disasters or other business interruptions. Our corporate headquarters are located in California near major earthquake faults and fire zones. The
ultimate impact on us, our significant suppliers and our general infrastructure of being located near major earthquake faults and fire zones and being consolidated in certain geographical areas is unknown, but our operations and financial condition
could suffer in the event of a major earthquake, fire or other natural disaster. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business could be materially adversely affected by the effects
of health pandemics or epidemics, including the current outbreak of <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and future outbreaks of the disease, in regions where we or third parties on which we rely have significant manufacturing
facilities, concentrations of clinical trial sites or other business operations, or materially affect our operations globally, including at our headquarters in the San Francisco Bay Area, which is currently subject to a state executive order and a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">shelter-in-place</FONT></FONT> order, and at our clinical trial sites, as well as the business or operations of our manufacturers, CROs or other third parties with whom we conduct business.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business could be materially adversely affected by the effects of health pandemics or epidemics, including the current
outbreak of <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and future outbreaks of the disease, which was declared by the World Health Organization as a global pandemic, and is resulting in travel and other restrictions to reduce the
spread of the disease, including a California executive order, a San Francisco Bay Area and several other state and local orders across the country, which, among other things, direct individuals to shelter at their places of residence, direct
businesses and governmental agencies to cease <FONT STYLE="white-space:nowrap">non-essential</FONT> operations at physical locations, prohibit certain <FONT STYLE="white-space:nowrap">non-essential</FONT> gatherings, and order cessation of <FONT
STYLE="white-space:nowrap">non-essential</FONT> travel. The San Francisco Bay Area <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">shelter-in-place</FONT></FONT> order took effect in March 2020, has been amended, and has no current
expiration date. Similarly, the March 2020 California executive order will continue for an indefinite period of time. In addition, our Humabs BioMed S.A. subsidiary headquartered in Bellinzona, Switzerland has employees who reside in Italy and who
are affected by the national quarantine imposed by the Italian government to slow the spread of <FONT STYLE="white-space:nowrap">COVID-19.</FONT> As a result of these recent developments, we have implemented work-from-home policies for most of our
employees. The effects of the state executive order, a local <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">shelter-in-place</FONT></FONT> order, government-imposed quarantines and our work-from-home policies may negatively impact
productivity, disrupt our business and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the
ordinary course. These and similar, and perhaps more severe, disruptions in our operations could negatively impact our business, operating results and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Quarantines, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">shelter-in-place</FONT></FONT> and similar government orders,
or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, related to <FONT STYLE="white-space:nowrap">COVID-19</FONT> or other infectious diseases could impact personnel at third-party
manufacturing facilities in the United States and other countries, or the availability or cost of materials, which would disrupt our supply chain. In particular, some of our CDMOs that we use to supply our early stage product candidates are located
in China, where the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak was first reported and where there have been government-imposed quarantines. While many of these materials may be obtained by more than one supplier, including suppliers
outside of China, port closures and other restrictions resulting from the coronavirus outbreak in the region may disrupt our supply chain or limit our ability to obtain sufficient materials for our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our clinical trials have been affected by the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. Site initiation
and patient enrollment has been and may be further delayed due to prioritization of hospital resources toward the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, and some patients may not be able or willing to comply with clinical trial
protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, our ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to <FONT
STYLE="white-space:nowrap">COVID-19,</FONT> has been delayed or disrupted, which has adversely impacted our clinical trial operations. As previously disclosed, clinical trials for our <FONT STYLE="white-space:nowrap">VIR-3434,</FONT> <FONT
STYLE="white-space:nowrap">VIR-1111</FONT> and <FONT STYLE="white-space:nowrap">VIR-</FONT> 2482 product candidates have been delayed due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. Further delays to our trials may occur. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The spread of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> which has caused a broad
impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, may be difficult to assess or predict, it is currently
resulting in significant disruption of global financial markets. This disruption, if sustained or recurrent, could make it more difficult for us to access capital, which could in the future negatively affect our liquidity. In addition, a recession
or market correction resulting from the spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> could materially affect our business and the value of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The global pandemic of <FONT STYLE="white-space:nowrap">COVID-19</FONT> continues to rapidly evolve. The ultimate impact of the ongoing <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic or a similar health pandemic or epidemic is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials,
healthcare systems or the global economy as a whole. These effects could have a material impact on our operations, and we will continue to monitor the <FONT STYLE="white-space:nowrap">COVID-19</FONT> situation closely. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our internal computer systems, or those of our collaborators, service providers or other contractors or consultants, may fail or suffer security
breaches, which could result in a significant disruption of our product development programs and our ability to operate our business effectively, and adversely affect our business, financial condition, results of operations and prospects.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our internal computer and information technology systems, cloud-based computing services and those of our current and any future
collaborators, service providers and other contractors or consultants are potentially vulnerable to malware, computer viruses, data corruption, cyber-based attacks, natural disasters, public health pandemics or epidemics (including, for example, the
ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic), terrorism, war and telecommunication and electrical failures that may result in damage to or the interruption or impairment of key business processes, or the loss or corruption of
confidential information, including intellectual property, proprietary business information and personal information. We have in the past experienced security breaches of our information technology systems. Any significant system failure, accident
or security breach could have a material adverse effect on our business, financial condition and results of operations. The costs to us to mitigate network security problems, bugs, viruses, worms, malicious software programs and security
vulnerabilities could be significant, and while we have implemented security measures to protect our data security and information technology systems, our efforts to address these problems may not be successful, and these problems could result in
unexpected interruptions, delays, cessation of service and other harm to our business and our competitive position. If such an event were to occur and cause interruptions in our operations, it could result in a disruption of our development programs
and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in
our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our internal computer
and information technology systems, cloud-based computing services and those of our current and any future collaborators, service providers and other contractors or consultants are potentially vulnerable to data security breaches, whether by
employees, contractors, consultants, malware, phishing attacks or other cyber-attacks, that may expose confidential information, intellectual property, proprietary business information or personal information to unauthorized persons. For example, we
have experienced phishing attacks in the past and we may be a target of phishing attacks or other cyber-attacks in the future. In addition, our software systems include cloud-based applications that are hosted by third-party service providers with
security and information technology systems subject to similar risks. If a data security breach affects our systems, corrupts our data or results in the unauthorized disclosure or release of personally identifiable information, our reputation could
be materially damaged. In addition, such a breach may require notification to governmental agencies, supervisory bodies, credit reporting agencies, the media or individuals pursuant to various federal, state and foreign data protection, privacy and
security laws, regulations and guidelines, if applicable. These may include state breach notification laws, and the GDPR. Accordingly, a data security breach or privacy violation that leads to unauthorized access to, disclosure or modification of
personal information (including protected health information), that prevents access to personal information or materially compromises the privacy, security, or confidentiality of the personal information, could result in fines, increased costs or
loss of revenue and we could incur liability, our competitive position could be harmed and the further development and commercialization of our product candidates could be delayed. Furthermore, federal, state and international laws and regulations,
such as the GDPR, can expose us to enforcement actions and investigations by regulatory authorities, and potentially result in regulatory penalties and significant legal liability, if our information technology security efforts fail. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We receive, process, store and use personal information and other data, which subjects us to
governmental regulation and other legal obligations, liability and risks related to privacy, security, and data protection, and our actual or perceived failure to comply with such obligations could harm our business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We receive, process, store and use personal information and other data about our patients, employees, partners and others. We must comply with
numerous foreign and domestic laws and regulations regarding privacy and the storing, sharing, use, processing, disclosure, security, and protection of personal information and other data, such as information that we collect about patients and
healthcare providers in connection with clinical trials in the United States and abroad. We strive to comply with all applicable requirements and obligations; however new laws, policies, codes of conduct and legal obligations may arise, continue to
evolve, be interpreted and applied in a manner that is inconsistent from one jurisdiction to another and conflict with one another. Any failure or perceived failure by us or third parties working on our behalf to comply with applicable laws and
regulations, any privacy and data security obligations pursuant to contract, our stated privacy or security policies or obligations to third parties may result in governmental enforcement actions (including fines, penalties, judgments, settlements,
imprisonment of company officials and public censure), civil claims, litigation, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, operations and financial performance. With substantial
uncertainty over the interpretation and application of these laws, regulations and other obligations, we may face challenges in addressing their requirements and making necessary changes to our policies and practices, and may incur significant costs
and expenses in our efforts to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The global data protection landscape is rapidly evolving, and we expect that there will continue to
be new and proposed laws, regulations and industry standards concerning privacy, data protection and information security, and we cannot yet determine the impact that such future laws, regulations and standards may have on our business. For example,
in May 2018 the GDPR went into effect in the European Union. The GDPR imposes stringent data protection requirements for processing the information of EU subjects, including clinical trial data, and to date, has increased compliance burdens on us,
including by mandating burdensome documentation requirements and granting certain rights to individuals to control how we collect, use, disclose, retain and process information about them. The processing of sensitive personal data, such as physical
health condition, may impose heightened compliance burdens under the GDPR and is a topic of active interest among foreign regulators. The GDPR also provides for more robust regulatory enforcement and greater penalties for noncompliance than previous
data protection laws, including fines of up to &#128;20&nbsp;million or 4% of global annual revenue of any noncompliant company for the preceding financial year, whichever is higher. Further, Brexit has created uncertainty with regard to the
regulation of data protection in the United Kingdom, including with respect to whether laws or regulations will apply to us consistent with the GDPR in the future and how data transfers to and from the United Kingdom will be regulated. The type of
challenges we face in Europe will likely also arise in other jurisdictions that adopt laws similar in construction to the GDPR or regulatory frameworks of equivalent complexity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, various states, such as California and Massachusetts, have implemented similar
privacy laws and regulations that impose restrictive requirements regulating the use and disclosure of health information and other personally identifiable information. These laws and regulations are not necessarily preempted by HIPAA, particularly
if a state affords greater protection to individuals than HIPAA. Where state laws are more protective, we have to comply with the stricter provisions. In addition to fines and penalties imposed upon violators, some of these state laws also afford
private rights of action to individuals who believe their personal information has been misused. For example, California recently enacted legislation, the California Consumer Privacy Act, or CCPA, that will, among other things, require covered
companies to provide new disclosures to California consumers, and afford such consumers new abilities to <FONT STYLE="white-space:nowrap">opt-out</FONT> of certain sales of personal information, that became effective on January&nbsp;1, 2020. The
CCPA was amended several times throughout 2018 and 2019, and it is unclear whether further modifications will be made to this legislation or how it will be interpreted. In addition, the CCPA requires covered companies to provide new disclosures to
consumers in California, and affords some consumers new data protection rights, including the ability to <FONT STYLE="white-space:nowrap">opt-out</FONT> of the sale of their personal information. The GDPR, CCPA and many other laws and regulations
relating to privacy and data protection are still being tested in courts, and they are subject to new and differing interpretations by courts and regulatory officials. Additionally, the interplay of federal and state laws may be subject to varying
interpretations by courts and government agencies, creating complex compliance issues for us and data we receive, use and share, potentially exposing us to additional expense, adverse publicity and liability. We are working to comply with the GDPR,
CCPA and other privacy and data protection laws and regulations that apply to us, and we anticipate needing to devote significant additional resources to complying with these laws and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is possible that the GDPR, CCPA or other laws and regulations relating to privacy and data protection may be interpreted and applied in a
manner that is inconsistent from jurisdiction to jurisdiction or inconsistent with our current policies and practices and compliance with such laws and regulations could require us to change our business practices and compliance procedures in a
manner adverse to our business. We cannot guarantee that we are in compliance with all such applicable data protection laws and regulations and we cannot be sure how these regulations will be interpreted, enforced or applied to our operations.
Furthermore, other jurisdictions outside the European Union are similarly introducing or enhancing privacy and data security laws, rules, and regulations, which could increase our compliance costs and the risks associated with noncompliance. It is
possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices and our efforts to comply with the evolving data protection rules may be unsuccessful. We cannot guarantee that we or our vendors may be in
compliance with all applicable international laws and regulations as they are enforced now or as they evolve. For example, our privacy policies may be insufficient to protect any personal information we collect, or may not comply with applicable
laws. Our <FONT STYLE="white-space:nowrap">non-compliance</FONT> could result in government-imposed fines or orders requiring that we change our practices, which could adversely affect our business. In addition to the risks associated with
enforcement activities and potential contractual liabilities, our ongoing efforts to comply with evolving laws and regulations at the federal and state level may be costly and require ongoing modifications to our policies, procedures and systems. In
addition, if we are unable to properly protect the privacy and security of protected health information, we could be found to have breached our contracts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our actual or perceived failure to adequately comply with applicable laws and regulations relating to privacy and data protection, or to
protect personal data and other data we process or maintain, could result in regulatory enforcement actions against us, including fines, imprisonment of company officials and public censure, claims for damages by affected individuals, other lawsuits
or reputational and damage, all of which could materially affect our business, financial condition, results of operations and growth prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees, principal investigators, consultants and commercial partners may engage in misconduct
or other improper activities, including noncompliance with regulatory standards and requirements and insider trading. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are
exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and commercial partners. Misconduct by these parties could include intentional failures, reckless and/or negligent conduct or unauthorized
activities that violates (i)&nbsp;the laws and regulations of FDA and other regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities, (ii)&nbsp;manufacturing standards,
(iii)&nbsp;federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations in the United States and abroad and (iv)&nbsp;laws that require the true, complete and accurate reporting of financial information or
data. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and
regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct also could involve the improper use of individually
identifiable information, including, without limitation, information obtained in the course of clinical trials, creating fraudulent data in our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trials or illegal
misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to
detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or
regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us and we are not successful in defending ourselves or
asserting our rights, those actions could result in significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participating in government-funded healthcare programs, such as Medicare and
Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, contractual damages, reputational harm and the
curtailment or restructuring of our operations, any of which could have a negative impact on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent changes and possible future changes in tax laws or regulations could adversely affect our business and financial condition. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;22, 2017, President Trump signed into law a comprehensive tax reform bill, or the Tax Act, which significantly revised the
Internal Revenue Code of 1986, as amended, or the Code. Future guidance from the U.S. Internal Revenue Service and other tax authorities with respect to the Tax Act may affect us, and certain aspects of the Tax Act could be repealed or modified in
future legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to our U.S. operations, the taxation of foreign earnings, and the deductibility of expenses under the Tax Act or future tax reform legislation
could have a material impact on the value of our deferred tax assets, could result in significant <FONT STYLE="white-space:nowrap">one-time</FONT> charges in the current or future taxable years, and could increase our future U.S. tax expense. The
foregoing items, as well as any other future changes in tax laws, could have a material adverse effect on our business, cash flow, financial condition, or results of operations. In addition, it is uncertain if and to what extent various states will
conform to the Tax Act or any newly enacted federal tax legislation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;27, 2020, President Trump signed into law the
Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, which provides temporary relief from certain aspects of the Tax Act that had imposed limitations on the utilization of certain losses, interest expense deductions, and minimum tax
credits. We are currently in the process of assessing the <FONT STYLE="white-space:nowrap">tax-related</FONT> provisions of the CARES Act and its potential impact on us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to use our net operating losses, or NOLs, to offset future taxable income may be subject
to certain limitations. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred substantial losses since inception and do not expect to become profitable in the near
future, if ever. As of December&nbsp;31, 2019, we had net operating loss carryforwards of $241.6&nbsp;million for federal tax purposes and $118.8&nbsp;million for state tax purposes. If not utilized, federal carryforwards arising in tax years ending
prior to 2018 will begin expiring in 2034 and state carryforwards will begin expiring in 2031. Our ability to use our federal and state net operating losses to offset potential future taxable income is dependent upon our generation of future taxable
income before any expiration dates of the net operating losses, and we cannot predict with certainty when, or whether, we will generate sufficient taxable income to use all of our net operating losses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, under Sections 382 and 383 of the Code, a corporation that undergoes an &#147;ownership change&#148; (generally defined as a
greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over rolling a three-year period) is subject to limitations on its ability to utilize its <FONT STYLE="white-space:nowrap">pre-change</FONT> NOLs to
offset future taxable income. We may have experienced ownership changes in the past or as a result of the IPO and may experience ownership changes as a result of future offerings and/or subsequent changes in our stock ownership (some of which shifts
are outside our control). In addition, Agenovir has experienced at least one ownership change in the past resulting in a limitation under Section&nbsp;382 of the Code, which has been accounted for in calculating our available NOL carryforwards. As a
result, if, and to the extent that we earn net taxable income, our ability to use our <FONT STYLE="white-space:nowrap">pre-change</FONT> NOLs to offset such taxable income may be subject to limitations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Tax Act and the CARES Act includes, among other things, changes to U.S. federal tax rates and the rules governing NOL carryforwards. For
example, NOLs arising in tax years ending after December&nbsp;31, 2017 can be carried forward indefinitely, but the deductibility of such federal NOLs may be limited to 80% of current year taxable income for tax years beginning on or after
January&nbsp;1, 2021. Deferred tax assets for NOLs will need to be measured at the applicable tax rate in effect when the NOL is expected to be utilized. The changes in the carryforward periods, as well as the new limitation on use of NOLs may
impact our ability to utilize our NOLs to offset taxable income in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Ownership of Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our financial condition and results of operations may fluctuate from quarter to quarter and year to year, which makes them difficult to predict.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our financial condition and results of operations to fluctuate from quarter to quarter and year to year due to a
variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The market price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common
stock. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market price of our common stock is likely to be volatile. The stock market in general and the market for
biopharmaceutical and pharmaceutical companies in particular, has experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic, for example, has negatively affected the stock market and investor sentiment and has resulted in significant volatility. As a result of this volatility, you may not be able to sell your common stock at or above the price you paid for your
shares. In addition to the factors discussed in this &#147;Risk Factors&#148; section and elsewhere in this Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> the market price for our common stock may be influenced by the following:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the commencement, enrollment or results of our planned or future preclinical studies or clinical trials of our
product candidates or those of our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory or legal developments in the United States and other countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of competitive products or technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments or disputes concerning patent applications, issued patents or other proprietary rights;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the level of expenses related to our product candidates or clinical development programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of our efforts to discover, develop, acquire or <FONT STYLE="white-space:nowrap">in-license</FONT>
additional product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by
securities analysts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to obtain or delays in obtaining adequate supply for any approved product or inability to do so at
acceptable prices; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant lawsuits, including patent or stockholder litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">variations in our financial results or those of companies that are perceived to be similar to us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the structure of healthcare payment systems, including coverage and adequate reimbursement for any
approved product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">market conditions in the pharmaceutical and biotechnology sectors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic, political, and market conditions and overall fluctuations in the financial markets in the
United States and abroad; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">investors&#146; general perception of us and our business. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These and other market and industry factors may cause the market price and demand for our common stock to fluctuate substantially, regardless
of our actual operating performance, which may limit or prevent investors from selling their shares at or above the price paid for the shares and may otherwise negatively affect the liquidity of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some companies that have experienced volatility in the trading price of their shares have been the subject of securities class action
litigation. Any lawsuit to which we are a party, with or without merit, may result in an unfavorable judgment. We also may decide to settle lawsuits on unfavorable terms. Any such negative outcome could result in payments of substantial damages or
fines, damage to our reputation or adverse changes to our business practices. Defending against litigation is costly and time-consuming, and could divert our management&#146;s attention and our resources. Furthermore, during the course of
litigation, there could be negative public announcements of the results of hearings, motions or other interim proceedings or developments, which could have a negative effect on the market price of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A public market may not be sustained, or be liquid enough for you to sell your shares quickly or at market price. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the IPO, there had not been a public market for our common stock. If an active trading market for our common stock is not sustained
following the IPO, you may not be able to sell your shares quickly or at the market price. An inactive market may also impair our ability to raise capital to continue to fund operations by selling shares of our common stock and may impair our
ability to acquire other companies or technologies by using our common stock as consideration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentration of ownership of our common stock among
our existing executive officers, directors and principal stockholders may prevent new investors from influencing significant corporate decisions. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our executive officers, directors and stockholders who own more than 5% of our outstanding common stock beneficially own a significant
percentage of our outstanding common stock. If these persons acted together, they may be able to significantly influence all matters requiring stockholder approval, including the election and removal of directors and approval of any merger,
consolidation or sale of all or substantially all of our assets. The concentration of voting power and transfer restrictions could delay or prevent an acquisition of our company on terms that other stockholders may desire or result in the management
of our company in ways with which other stockholders disagree. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If research analysts do not publish research or reports, or publish unfavorable research or reports,
about us, our business or our market, our stock price and trading volume could decline. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our common stock
will be influenced by the research and reports that industry or financial analysts publish about us or our business. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual
property or our stock performance, or if the clinical trials and operating results fail to meet the expectations of analysts, our stock could decline. If analysts cease coverage of us or fail to publish reports on us regularly, we could lose
visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because we do not anticipate paying
any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should not rely on an investment in our common stock to provide dividend income. We have never declared or paid cash dividends on our
capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital
appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an &#147;emerging growth
company,&#148; and the reduced disclosure requirements applicable to emerging growth companies may make our common stock less attractive to investors. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company,&#148; or EGC, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and we
intend to take advantage of some of the exemptions from reporting requirements that are applicable to other public companies that are not EGCs, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with the auditor attestation requirements in the assessment of our internal control
over financial reporting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight
Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure obligations regarding executive compensation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to hold a nonbinding advisory vote on executive compensation and stockholder approval of any
golden parachute payments not previously approved. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may take advantage of some or all of these reporting exemptions
until we are no longer an EGC. We will remain an EGC until the earlier of (i)&nbsp;December 31, 2024, (ii)&nbsp;the last day of the fiscal year in which we have total annual gross revenue of at least $1.07&nbsp;billion, (iii)&nbsp;the date on which
we first qualify as a large accelerated filer under the rules of the U.S. Securities and Exchange Commission, or the SEC, and (iv)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in
<FONT STYLE="white-space:nowrap">non-convertible</FONT> debt during the prior three-year period. We cannot predict whether investors will find our common stock less attractive because we will rely on these exemptions. If some investors find our
common stock less attractive as a result, there may be a less active trading market for our common stock and our share price may be more volatile. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under Section&nbsp;107(b) of the JOBS Act, EGCs can delay adopting new or revised accounting standards until such time as those
standards apply to private companies. We have elected to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will not be subject to the same requirements to adopt new or revised accounting standards as other
public companies that are not EGCs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>As a public company, we are now subject to more stringent federal and state law requirements.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, we are now subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, or the
Exchange Act, the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, the Dodd&#150;Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, the listing requirements of The Nasdaq Stock Market LLC, or Nasdaq, and other
applicable securities rules and regulations. Despite reforms made possible by the JOBS Act, compliance with these rules and regulations will nonetheless increase our legal and financial compliance costs, make some activities more difficult,
time-consuming or costly and increase demand on our systems and resources, particularly after we are no longer an EGC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of
disclosure of information in this Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and in filings required of a public company, our business and financial condition will become more visible, which we believe may result in
threatened or actual litigation, including by competitors and other third parties. If such claims are successful, our business, results of operations, financial condition and prospects could be harmed, and even if the claims do not result in
litigation or are resolved in our favor, these claims, and the time and resources necessary to resolve them, could divert the resources of our management and adversely affect our brand and reputation, business, results of operations, financial
condition and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also expect that as a public company, the associated rules and regulations will make it more expensive for us
to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain adequate coverage. These factors could also make it more difficult for us to attract and retain
qualified members of our board of directors, particularly to serve on our audit committee and compensation committee, and qualified executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also be subject to more stringent state law requirements. For example, on September&nbsp;30, 2018, then California Governor Jerry Brown
signed into law Senator Bill 826, which generally requires public companies with principal executive offices in California to have a minimum number of females on the company&#146;s board of directors. Each public company with principal executive
offices in California is required to have at least one female on its board of directors, and by December&nbsp;31, 2021, will be required to have at least two females on its board of directors if the company has at least five directors, and at least
three females on its board of directors if the company has at least six directors. The new law does not provide a transition period for newly listed companies. We are currently compliant with the requirements, but there are no assurances that we
will be compliant in the future. If we fail to comply with this new law, we could be fined by the California Secretary of State, with a $100,000 fine for the first violation and a $300,000 for each subsequent violation, and our reputation may be
adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will incur significant increased costs as a result of operating as a public company, and our management will be required to
devote substantial time to new compliance initiatives. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, we have incurred and we will continue to incur
significant legal, accounting, investor relations and other expenses that we did not incur as a private company, particularly after we are no longer an EGC. In addition, the Sarbanes-Oxley Act and rules subsequently implemented by the SEC and Nasdaq
have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Stockholder activism, the current political environment and the current
high level of U.S. government intervention and regulatory reform may also lead to substantial new regulations and disclosure obligations, which may in turn lead to additional compliance costs and impact the manner in which we operate our business in
ways we do not currently anticipate. Our management and other personnel will need to devote a substantial amount of time to comply with these requirements. Moreover, these requirements will increase our legal and financial compliance costs and will
make some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance. We cannot predict or estimate the
amount or timing of additional costs we may incur to respond to these requirements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to maintain proper and effective internal control over financial reporting, our ability to
produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act, or Section&nbsp;404, we will be required to furnish a report by our management on our
internal control over financial reporting, including an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. However, while we remain an EGC, we will not be required to include
an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. The rules governing the standards that must be met for management to assess our internal control over financial reporting
are complex and require significant documentation, testing and possible remediation. To comply with the Sarbanes-Oxley Act, the requirements of being a reporting company under the Exchange Act and any complex accounting rules in the future, we may
need to upgrade our information technology systems; implement additional financial and management controls, reporting systems and procedures; and hire additional accounting and finance staff. We are currently in the process of hiring additional
accounting and finance staff as we grow our business. If we are unable to hire the additional accounting and finance staff necessary to comply with these requirements, we may need to retain additional outside consultants. If we or, if required, our
auditors, are unable to conclude that our internal control over financial reporting is effective, investors may lose confidence in our financial reporting and the trading price of our common stock may decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot assure you that there will not be material weaknesses in our internal control over financial reporting in the future. Our previous
acquisitions and strategic transactions and resulting international operations have increased the complexity of our accounting, and additional acquisitions and transactions and further geographic expansion will likely increase this complexity and
the related accounting challenges. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude
that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines that we have a material weakness in our internal control over financial reporting, investors may lose confidence in
the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material
weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our reported financial results may be adversely affected by changes in accounting principles generally accepted in the United States. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally accepted accounting principles in the United States are subject to interpretation by the Financial Accounting Standards Board, or
FASB, or the SEC, and various bodies formed to promulgate and interpret appropriate accounting principles. A change in these principles or interpretations could have a significant effect on our reported financial results, may retroactively affect
previously reported results, could cause unexpected financial reporting fluctuations and may require us to make costly changes to our operational processes and accounting systems. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more
difficult and may prevent attempts by our stockholders to replace or remove our current management. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions in our corporate
charter and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These
provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for
appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of
directors. Among other things, these provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish a classified board of directors such that not all members of the board are elected at one time;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allow the authorized number of our directors to be changed only by resolution of our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limit the manner in which stockholders can remove directors from the board; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and
nominations to our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by
our stockholders by written consent; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prohibit our stockholders from calling a special meeting of our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to
institute a stockholder rights plan, or <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;poison pill,&#148; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been
approved by our board of directors; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require the approval of the holders of at least 66<SUP STYLE="font-size:85%; vertical-align:top">2</SUP>/<SUB
STYLE="font-size:85%; vertical-align:bottom">3</SUB>% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporation
Law, or DGCL, which prohibits a person who owns 15% or more of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired 15% or more of our outstanding
voting stock, unless the merger or combination is approved in a prescribed manner. These provisions could discourage potential acquisition proposals and could delay or prevent a change in control transaction. They could also have the effect of
discouraging others from making tender offers for our common stock, including transactions that may be in your best interests. These provisions may also prevent changes in our management or limit the price that investors are willing to pay for our
stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive
forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware (or, if and only if the
Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District
of Delaware) will be the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any derivative action or proceeding brought on our behalf; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action or proceeding asserting a claim of breach of a fiduciary duty owed by any of our current or former
directors, officers or other employees to us or our stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action or proceeding asserting a claim against us or any of our current or former directors, officers or
other employees, arising out of or pursuant to any provision of the DGCL, our certificate of incorporation or our bylaws; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action or proceeding to interpret, apply, enforce or determine the validity of our certificate of
incorporation or our bylaws; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action asserting a claim against us or any of our directors, officers or other employees governed by the
internal affairs doctrine. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This provision would not apply to suits brought to enforce a duty or liability created by
the Exchange Act or any other claim for which the U.S. federal courts have exclusive jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our amended and restated certificate of incorporation provides that the federal
district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, or the Securities Act, unless we consent in writing to the selection of an
alternative forum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These exclusive-forum provisions may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it
finds favorable for disputes with us or our directors, officers or other employees, which may discourage these types of lawsuits. Furthermore, the enforceability of similar choice of forum provisions in other companies&#146; certificates of
incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find the exclusive-forum provision contained in our amended and
restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g939163g12i79.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g939163g12i79.jpg
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M-3:T(C%S='5VLK4802,D41DS0D-286+_Q  ; 0$  P$! 0$
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M'#XXX?''#XXX?''#XXX?''#XXX?''#XXX?''#XXX?''#XXX?''#XXYTM3O\
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MXX?''#XXX?''#XXX?''#XXX?''#XXX?''#XXYTM3O\HJW_;@/_UD7Y^59_\
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MSH-H_-9LM'G5D(G59 LYF?R0$!=2RJ*("\RZC?,1PK 'W,NK32DU<&DFHP5
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MQ'3?9G++\2Q<^D3XDF:8]KU3+PDC@*Y:;2[/G&W=1=9KZ+(D/8LK1+,OI]I
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M=I2%8L[EDU0W&,<]<G$4Q0"$6!_E$F 2*2(/#;1D(#YF-XNDAGR/<>._=;"
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MD;L1<+(&K)[$V)4*H4,CZ;LZSWB9CRP-#I7M[D:\>3$SU"0 ,\=#@G.ZE/\
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M=T5UNG5PEP>&J\5KB1$94L[ /*/<<5A3AXP9N)F<B_*#(@\$&56BY3TQR:K
MO*C8]JSO+QRF/@8D--P\],"%'4ADS&Z6<XTIG&1+@3:H2DQ:4WC7O2A/84VK
MJ5?8()/;:_>O/15E7/%\;HPDC_%;./2G-I]5<A\4=*W68'FJ3WK:WTO3E-A=
MN0[5P]$S%M2&2/LP2$M)XM9$)MQ[POOQ4LFMQA("$JW=\O74]!BGQ7F 00.^
M440'T3+NR^P"%,><3F.1WDH1<79;Y')'DB^P1OIC!G/Y IT##1Y7_P WO=^^
MFRGG@&P^EK:K[4WX32;I9B-:"J9B$&>Q#=E'5J<:+X=ZE>A_/ED7$C:<QPF
M+@:]>6.FW#?\_37?/BUR,HXRME5GV^GRNYDN."]7H59CY(4 ] :"@ 'WKE^0
MD,9<AEQI4ZYSQ44-B%F)A@HZ5F?R?R23RT7GSUNJPX4^JO1-VUQ'N)?OVR*
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M]=H\EKYJ$ UP&<NI& "UG_:%]-N96T9Q9%'E?(QYM-6!4^1P'F*.@/79T:=
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M+I,'M2@**20 H9T0\?#CY<L-9H_;/0/TAN TQ$T5GR33M0CJB$.WHDDJK,/
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MDYW9R(SDLFTP1IEJ,;  L=!%WU[-L0!:OB\D6S(P!]L+N](M$^LN/E2UV[N
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M%V;3BN/51,R+PSW GL(R+-'Z:]+TC.^$E;7E)'9\DRQF1"#*JS%.]J "?S9
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M_P!RVQQXV-)A4$$BUY9#_(C=(B 36OPH^VGL?K\O?OUU<FJF1!7]C&L$]?\
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M)QIM:8DU<.[UR&561/N'\HFKZ#A00 2X 5G</1E!4OIF#6OET9"B)* 9U=_
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M +S\_0<7^&Q_[B/_ &UYS@*?XD1_YZ7_ *CI\_48_P!5+^[3_2.? T_K*?\
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M0<@2P2V*!@I&T4;/T&\2>"<TG-<*0IY2U7H7G0N[[)>2U1#H *HZU8%454]
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MZ!2%Q65H@$^BLWD.Q_+?!VWO\D[/OG/N:ELAR06R59:DC\AJ)4]?_3\D77Z
M>@-<3:3X)J!,C)@/NWW2YH5>,0YL3:L=;,)$:S$,00YLSKI'NIC(@>(?PML?
MVCP& S=#0L<:ACBW*#DB.@RH]$_I\9A%[W><W#SD]6,E96[H>J]>W1].@<L
MP5M;4$7/GV<NW2*4HI1ZI("I5EZL.Y)Z]E^+%>I*DC>B>73EQN4V+)A]\;9X
MRX_:-VQKG\NV>7?GMRZ8UV__ *=LZ;Y^F?\ ZS_7YN_/,7XY6N3Y52N*%3:
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M%6M3$G2/ ;PERITOB/XS)_;G#Y2ILR1SCZ\].TJ1TUVZ[Z<>AK"-6 #4C.C
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M6I$[9':Z*33-;6UKET'IO-%NFJK[=<9F5IRMJ>3COZ67I*1VZ1=;)V$,:V>
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MTVVZ;YQG;?;.V<YSJ "@*!H*  /Y #0'OW^/Y\S$EB6)V6))/\R3LGUZ_/\
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M%2&6:$K-35[MT !!)+*'9AS%EU:JXDO+]Q1)N:."6)M6S#J68;<K-)+V).P
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M>V\+QB,=AP;#%0&B05C_ &,:R^RT[,D A;ZE&DR !X8XZR9Z)[_9G)>#K1T
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M>VBJ$AB#U8 @>RI ]@\XL;.C425&FG[SJC%%(Z[!8#0([+L;V 0?P>12!?\
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MR3.W$//'B"<R+,ZQX,KIRM\LNK-Y9=5049O(G59L&*T8]M+-E5F5R0K!6()
M)%?BKM5\=.S.9JO1MM12%::C6RX+*"HVP) (V1S60KWI,C8/]DX^VZWFV?\
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M&^?,?TI_@\?_ !/_ (J<][Z!_$7_ +D?ZUY(O2_]W3O^,=_\!/S+_13\Y_\
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MN,B]0-@FHHG7JQ<@&9*@D\&%4[4 ,[459LM4\141:[MV/HCQE&#=E" D.-D
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M; .B-$;_ $(_0C]1^AYE(T2-@Z)&P=@Z.M@_J#^A_4<V'SO.<L9YN_S*P?\
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M-  ';=#10B NX[*&UL$R.#5BS3\80^9Y+2TQ1I1=U=C[5=($8LYZ(=$C^08
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MS\9\A92C=/-Y->)GF"R^'OUV@H ?5JY:JJ-X3YYP,$IY!XPI#J'\7CV:*CD
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MD@1>JZD-:!TMU\[SD]I'J:X]&#5+EEQX"*H79>Q)W1BYVQ-#V[$=CJ07X?\
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MQ4@LZKK9_&R.PQ5?'QRN/BTM6ET89-ZR=BC(%6:+D1[$;((",VR!^2!S>GK
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M+3#$(3^/971/K\\8ORSE?#XXX?''+&>;O\RL'_0]/]?&^?,?TI_@\?\ Q/\
MXJ<][Z!_$7_N1_K7DB]+_P!W3O\ C'?_  $_,O\ 13\Y_P#9C?YWY?\ T@_&
M)_;?_*7.>-^7:F^=*C<KD?>G?"VG11V>L:+V'1I90N?-#5A8!1)9B:,#PY;
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M3 5E:M(J$JCW[R[]BV/Z=9LTV6;%BS$H61%<$2;Z;19ERS K.=6+2=8]*%-
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MNM;7N6'7G1OYZ7/.YTM3O\HJW_;@/_UD7Y^59_\ '9O^+R?^\_/T'%_AL?\
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M#0541550/P%'$ L^':Q6I:*/_G%QGZMJQE$-U84.RNT0G4J(<6)?Z]+W&0]
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MZ9@.I8:/7:_@G<XY31G20E&B496?R*Y)Z?NJ2E$VH.V"G8[?+\@:L<NB.H
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M,'K@3%AQ=@VJ":A;3-1NXN+!BF8^/-VH.Z-7ZIXB2Q=KQS[B6."20?+,]9*
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M4G[<&HB;[NB:UOLP77;>M[(_/4Z_GHZ_!Y-9T?71';>]=59M]=;UH'>MC?\
M+8W^1RK#AYO\]^@[4D^A'$HDVBHQJBCU3^U\Y<4@LQH(EL.MS!)*- 9@UA%
M)B,9XC6=++Q)"]/BC(L@WSG<]>,>-E?%Q\BQR7*53P"/7T5"J[NQ+JVBK!M.
MA'4@ ML>AJ3)R,>0QT#R?S&N]$.245% 5EV&4KM'4A@2=:/ODEDUWXVL$GM>
M^T*EF?*O-7<D7P>P@9:E%+(W2/A.EM&PTM_#B)Q(Z[0<*1!DC3"JITYC\ Y
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M8*PZH@9"M!KV01%L='_GOP]I*3_P[ _!Y!K78'L[E7#H=_@@U6[K^-?UO6C
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MO5/0(8X3)/IR1?U#T;S@)*I!"U[Z?#>M;&4T]AE#P"^,BS!Q>LFDF_MG,O\
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M^?E6?_'9O^+R?^\_/T'%_AL?^XC_ -M><X"G^)$?^>E_ZCI\_48_U4O[M/\
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M11/KB7F?C/Z;C]<3MM=M-IN,_D^N)>VFVVF9./\ \V==MM<[_3.<9NT/Y?\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g939163g28p24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g939163g28p24.jpg
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MX$*;#H")HV/!M2FP\C:Z$$I"]O"J=S_^'-V%G.<Y[24W.<_QSG.LS?ISG_\
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MPYKUL5_GZ?2;_P#;Z[3?^*1+_P @.Y^DO1/_ -7&D/\ PAK_ &KM?G/TJ?\
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M1KA(0_$9C.760AV=;W+A)D,)4VF!'>ZF0CVVG>D+3\N6W<=2&/!-LO\ 8KY
MA[+L\_UEJL%OLDAV-(@1W&);TENUQUM0;@FW1V'U)=5/?9ZZ.Y\UM0]C*]08
M.\*9>]9.;+U=O:169]FK<&Z2]?V6$4H]LE6RISA5MAA;(W'98?($()D;) S&
MB<27A<>0-G0XDUKZI>]+R;DYI^=;KL+5=]/)EMQ)3D!%RBN,W"$B%-;>A+D1
M2I2DMM.,.HDMJ96C"DNMK6VKY=9=2Q[<W?8-PM1NEIOZHCDN*W.7;I3;T"8N
M9#<9FH8DA*4J<=;?:5'6EU"P4EIQMMQ.=[1=Q[1VE$@X5HJ@JNSA&UMR[0=E
M!2,MZ!*5MB/KN!% M#9;&7F&JD-UY$B,%9)(A.-*(2),S$9]#BI.#2.AXFD'
MY#D2:]*;?LUBM"4/M(2X@695S<7)4ZA6U2IKMS6M3*&FFV TE"-R2 C8U9K6
M7JUF.B7$9C.,W>^78K8<6IM9O*;8VF.&EI*DIAM6Q"$O+=<<?ZU2W-J@2N>:
MM[VYTI10 S6FHH0?9416FXMGO1;85LLM9L@K2.V8&X:Q]3UP6;=8K)PM8PXF
M%8B(VT/!LB&B3%;K-:D&9TI7.N_1Y]/7"2[=;VX_:EB^KB6YBVPXDN*]J"S.
MV29UET9(5+CLQ7WUQ6W8B7P\IM4J7*2PVD;]IU_]!6^.U:[,VQ=$&R)E7!ZY
M3)462S8KPU>XFRV/ IBR'I3#")3K4LL%E+J8L2*I]Q9R.Q>_+5JIMVUM3].Q
M:+KZS:FL.M@H1V^3[.2KI.Z]A _8>YVM\W(K@M1I)2P"45T8"S &-AP.(>'"
M1.7%>>FX;7T<*ASH%TG7Q=QN46\QKI(D"W-Q&Y34#33^F8$-+"93P8ZF,\93
MLCK'2](ZS#32%I2WFN?2&F7!G6N%946^VRK/)M;$<W!R6[&=G:D8U+.EJD*B
MLE\.R&1%:CEMI+$<(RZZM*E.770_I%@5UVQ<\;-K(?7^N]R;>WKL78!"9-M5
MNB0Z_NK1'^#I6AJ15!,*U08^6(<=^+>@$,H6#29;<G%.,18+T*;P;CT828%F
M@?1,M^YW.QV33UKMK:$0X2UR;#J+Z<9N0,QYR&XL*6I*[?(6TR^A!3VUA;B7
M&^Y;^DJ/.O$T76(S;[9>KUJ"Y7%Q;DN8A$:^Z>-D>MQ$1E$MM)2A!1<(R'7F
M%+"^Q/H;+;FK'=K;>L=@[*U5C1Y#+E3U#HG6&JQI@9BV1H+I:F+,SWI5?F70
M>"N4N'"=+L1&3!P%79\^;"DSV0@J([$BM^PT#9;M;+5>>\#8$V]ZBNUX=8=[
M&IP,3@PVE$E$!R1!0XX&%+4Q'D2FVFW$-JD/+2M9\GKN\6JXW2T?0+F8=FT_
M:K0V^UVQ+:GH)?<4N,N<W'G+;0IY*$O2(\5QQ:%N)CLH*$"V-A_246S8NX:[
MM<EK$ +:!:'VWJ-ZI!CCT,63MV\*W=AFR]MOR,!<J:/V:P71ZR3A28KC3N!0
M\7DGZ$JG<XULZ*X=KLDFSM7:0\J1J*RWI,U^.E;S4+3\J [:K*E)D<8T2- 3
M%;>*P4]<Z]U63U==BY=*$VYWJ+>';5&:$?3UXLRH;#ZD,O3;]%GM72\J4&/=
MDRI,XRG&@@A09;9+O#K*P5T^D.N>Q*M?M;W.HO'M4VW46HJ-7*'.NQ&1$UKL
M72U3KE<JFW:5)D"'XXN<0DA)LVV56,,C#K/!-2!)0@\N+%))V(/1E!MDRW76
M#-3'O$*]WNXRKBW;VDKNMLOTR5*F66>E+Z5.MM)D-MPYBW5NQ'&$O,M)"UM'
M6G=)$VY0[C:YT-4FSS++9;?&M[D]U2+7<[%#C18=Z@*4RI++CJF%N3(B&D-R
MVWU,O.J+;;H]E'^D";CU7;,/<>HD[/V+M\9"I]@VM4;@$T?88NKAT5/LM:#X
M-!UIF%! EBKLTA<9 Q8Z;=(BAP(^Y*$#$1Y%+AT;%4VRN6.]&TVNR.N38UFF
MP9%_BKN[JSNNKKEQNP<<DLLAMJ"ET.MP%AR1&"'G2I.2!TBA,.\MWNS"ZW.]
M--PI-WAS&+#(1:6D#;:FVK=:^K;CO/%QV<IDM.3T%J/)*V6@E=:[;[3:]V)U
MSU?H"LZ,F:Z;U@Q DQC@O:LX@"LMO>:PW<=AVFD)IPF,;NUM1Z8B#)(W,76
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MVQF Q,:DW*)-*W75-K1$#L15XMJ<-KPS?&+?!C2E@@H:CD;'=^$VBS])]<)
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MOO!X+LA]IJ>!-5^5C"T\-'1C+84]+B:G+-VF+U.B?-<LL=^/(AZKD19<]AJ
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M7\/'_LM2Y ZAN(0XC3/7=2'$)6A7AOT3CTI7C"DY]&==XSCTXSC/HSC&<?\
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MVT)0A.,)0E*<8QCS1)42I1*E*)*E$DDDG)))XDD\23Q)KT@ 2 E("4I "4@
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MCVC2*)5M47^56[+LO;^LB.Q"ZJ:)KZ"^FUVL19Y%?@NW)5D+CXUGJA" [.<
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MNX(><8,124O0F5OA25[63D3T4S3*F1%7F$ASM4:!9MT:6%7:?*L(U&U%=;*
MY:UH@+9;?[4E1:F/H8VJ1EX5Y/\ H]-EOZXJ-DI%D$7_ &6=B:(*']-AAA*
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M-4[(HI6][EOE(L=^#4U^M6$?%-U$+@'7%*=NI>,^*?68!NCHTZ)-<DQ_*O\
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MW/1[<ZB$MF:M3/9Y";@VZ]$[,X'"F2IQMAY:T,=8M@-K$A+1215BYZP1976
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M<Q'3=)RX<9Q+*D%U(???#393H,]);K C2&[)%%U*-+QKI<.V22BXP=)RH$J
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M1XTMEU5NEMF9,7UDFX-Q'8L?KT-QY2UL.L_/;J'V^M_4*R7P_6:T$N#5WIJ
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MXMPSG7O=Y%*U"!UV2U &LMII^F=_:%J&PE6\X'6)UYV :M<LXB;58L20++V
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MG._Y.1\S\4IX&&/Q.=_R<CYGXI3P,,?B<[_DY'S/Q2G@88_$YW_)R/F?BE/
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M-:O8M0_1+MZ4Y.;@-2X,(N.2'VUN/7%F:_$++:E!;S3C<"3^6;"FPI*4[LJ
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MDDD_>?&MH# P/ <!7^?[])O_ -OKM-_XI$O_ " [GZ2=$_\ U<:0_P#"&O\
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MU3:1 R%6G]<Q->T7MI+[,R[0!+2+%$/3;B2AOLTV/6YM>%B(TAIPXJS+P[B
MC.>B^\-R7H;$ZVJLB)=UO$1]UR6FZ+N=PT:C2C<22PF*N,W":6E4Y<IN2Z\M
M*A'[(-O6' .DNT.1F9;\*XIO2XEKL\MEEN(JV(MMOUBO52Y<=Y4E$AR:ZA28
M*8KD9IE"@9':^(;KN._2;B;'&+BC)#=Q4"=D?2#,F Q*? F#2@/LW5F@NB Y
M >_<G(<N!K2<X1?)CGVUP:HQ,>53&R[C[K7*QNB9Z*MAYAJP,R(R>C53+[3;
MJ'69&DY9?U"\TZF"E:'+JV&DLNI(<F*;2)Q8"4FID=*;4I+S+SM^=CR%=) ?
M8=<;6T\QJN&&-/LNM*G%"V[6X75.M*!;AI<48(>*E"K$[B[CUY9NI6QGX>VX
M1DQN(QU!GU#40S;.OK[5Z UK?6=C#W,;KRFU6R$;C0:\/<;$H/JV)3-;39!>
M0,"10I1T0\8F<O0UCN<36EL2NRN,,V1C6S<Z].V:YVZ7<C=+M%?@NW.=,BM0
M;C*<!>,86R==6T,)>?7(9#Z6$=/6M[MLO1]S4B\(>>O3VBW(5F:O%MN$2W)M
MEJE,36K;!B2G9UNC-$,B2;G!M:U/J:CH8>4RI]S3.H=SJ[7>DECZ_2JN=D;J
M;:N6M]?;(C^[\ Z[U_VG:Z-?]ETV6IPA@FLN3M5-G1Q^6A;T1L'=;*SB9#=>
M<;F>[FZ%E2M?1=2HF1TV$J@W2Y6I76=HE:DL\.X6VU3D -=4&&8<YM3@4\E9
MD08JMBPE)1XF%K>-&T)*TXJ)(5?0)ULMUS26Q'C:<NTRWW*Z05Y<ZTO.S(*T
MMX:4@1Y\M/6(*BES9\E]*73@9267HNN9A]LKOC1VPK!7-FTR@%A1F@:YZS4G
M2]I"PB4F;9B=0N<RT5B08JEEK+<2<.'?4)D@HVXX0KKWDFNB&=):0Q<;HW&+
M.G=06R-*M,^Y,O,7*Z:KGWV(^XTEN*S-@(ARTL3(LLK;==ZQM+) ;E)]4]TL
MPF'EOV^V+DAZ_P!@N,F+=8-N>9?MUKTK!L4MA#JURW84YR7%4_#E1$H<::ZM
M:G02Y&5JX/[ =7#^Z2>-NZLLFP-&D=S6?:Q;9$P0Z]VYNPPFX3+C*%=+ [M^
M/0G@LHW-BQ;83&M1SY,9&E3!I,60G-MP?7.Z:U?&L+7T+>(EMU W8HEG9M;;
MP3HN ZT&F7;C C)LJKBF0AAM:X;3I5&:=6AMUIUILESR;>HM)R+ZZ+S:95QT
M^[?)=X>N:V2K64]ITNO-6^=)-Z3;E,+?<0B8ZTE$EUI*W&G677 &[[KW;WJ1
M#W'MG>)LKV.D;,,U^M5;0MR&::TU$B:""C@OV?E)HVO,;F:K(>?6*[''576$
MOW@6Q4X$>18%LRK3(9(P_.R=$ZS<L=FT_':TPBTL294S44%V^7Q:]22'9':4
M&X7,V)4I]N7*4[,NS?5,]M=4F,%(AI4TOT4;6>CF[W>;^^]J95T?C18FGIK5
MCLB$:=8;8[,OL%M^G!%9<B14M0[2OK'A#;2N24KF*2ZC6C4O:6D4/6^MZ3;@
M%RORJ%W,UWV">AS9L>*/+:UI%:E!7JFT4]\/$!9^7(?P[%B1X+@6.TX\XHAZ
MWI8=]7>M(3[C=+K/A28-M%RT+<]-I<;0M;K-UN$M$A,Q3/4):>C(2G"UJ<#Z
MR$CJL>\GRMFU9 M]KMD";'FW'Z/UM;-1*;6XE#;UKM\5QA4-+O7*<9D+4O*$
M);+" 5'K,^Z93V>[=T#;>X.O>Q PVX[*5IUU,NVV+:M8IE#,;+BXVX<V5 J$
MZFT,O::F*!@!1ARJ-E&9C\ZP8D321,?&Q]7B)TM(Z*N5ELFIK6^["M7TX"B%
M&L\N=<6;4OZ%CVIR:W.N#$.:](DO,"86E(2B,4H::=7[SAW-5ZRMUYO.G+DP
MU-NALI*YDF\1(-O>NB?IJ1=&X3D&WO3(;,>.R^8G7)<4Y)W..NM(&U%;,;+^
MDATS>MP5&:4K>SKCHPZ-[!5O=M?-AH0:\SZ1OV4&(N56JSR6W=C8(NT(_6:W
M;P4]^Q5  JTBU3 5-IT>=-9?\I:NBV^V^R36V95I@:@C.Z:E6"2Q(<D6]NX:
M<0^T)DQMJS6SJA<8\N5"D-HBSI/8WNKDSIRD-J3ZBZ=)MDGWN&X[&NLW3\AO
M4D6^QGV&V)[L#4:V73#B..WFYETVZ1%C38SBI4*.9C17'A04N+"O$$^DZIT^
MB;CCV^K6<5=;EL'?=M""Z\#CF:5::UMO6XG6M1H5TPO9=.'#!>MJ\%@5Z!)+
M4+;+*JNTU% BZR:CX,OY)'1-.:N-B7"EQ'X$&VZ<A2'I4A3$^'*LUT>NDVY0
M,6J:Z\]=)+[DEQ+-RLRA+4I<EV6PKJ$XV.E2&Y;[TF9%ELSIMRU%-CLQHZ'X
M$N+>;4S:H=NG W6$TTS;(S#<9I3UNO">R)"([45](>5)=-=OZ5M[?%N);<L,
MG/4"M=9]75^R:TVAL"M5^6S8-'TC6=B%MZMHTVQ$E6$_==T:E9&H@TJ%-,S*
MW;Y$^PQAWK.-Q=2^Z(G633L)JRQD]]I>J[O(B76TVR5);5&U!<+K&>-XN#<9
MH1HT"QWE3I<GN(91*A):BJ=PDJW+'K2#>=0S';S)4=%Q=+6F/*M5VN46,M,B
MP0+5*:%H@.273)D3[[9DM!N"VM]R-.4[)0UDA&B.ENXLK7V_-I;ZV!K\9L^Q
M[@7:DV*7*.V&O%J]B_65DS<R%1)@B$";!($Q.256]7ZXPA=<+$PN7VH)"6AS
MZ)?M#HN>F[1IRVW)ZTQ;((9BH1'C269)MT53$%N:S(;<;<:9?ZJ9^8HB4PR^
M$EQI!'SZQZU7;=17;4-QMK-UE7HS!)6N1)C/1OI*4E^<["=CNMK;=>9+T3\]
M.8K[K&Y+;BPJ>P.W&IO'GMWL*2UW9<=?-WV';PS8>M8DB-*MI[76VQIB =<=
M]Y'G1L:U2C,Z+??=T>PX!AK-':'AIS8B#!]7G.:*O/U=673+5TBG4M@C61ZV
M75:5(A1KG97F'(X'51PZN&AAM=NZU4;M#\11<D-EYQS/11K*SGI!O.I';;*[
MN7Z3>6KE:T*2N9(MEX:>;?4>MD%I,Q;SB+CU29/9V):0VPX&6VR-OIWTKFM;
M'?*Y:BVM[57W;75MS9W:<!0!\@DG9]YI56U-0+U21HF\T>=/CTO5E$#U^9!9
MNFN2DG-OOC8\U%<E,D)GB6^ARZQ;=*AL72'*$.98OH"/(=<0T;3;Y\R\W*WW
M!UZW3VVU3KO<7Y*'# N;*.Q6XN,+#9:1[)SI=MDJX1ICULEQE3(=\^G)$=MM
M;J;M<($2S6ZX0&F;A <=3!M%O8CK;$ZV/*,VXAJ0A2TNN=0KZ4/4L7.W77JM
M>6"!V_.7*M%F*A"DKV>.3U_KNDX]<VT+1NL9!&)<DUYXY-('5[W:EP;59V)@
MN79)CUHG2]T1WI?T*$R[<IN/;1!E,JFN(%H=.I)5_5*LSQL+SCQ")28[;<<:
M>*'(<12'416TPVZL]*UG1],E46X!R1<3.BO)AMJ-U;[N1K"F+>6A?6VV@5QE
M2'''SJ!*VY<I*VEREJEN0F3])!K$E6^K8)-=V12YO6%?6TB,/4T)39#U[+T'
M4X_6>T9%Z"GK-)!6&4(4&%2=.G)D+WBP 6=KLMFG2#:SL3?3T6W9J5J^3VFU
M3T:M&J6G8TZ1.2FWL7&\N7:T(M\B/$1(C(>Z]Y-[CH<ZI4D1Y*%3DQQ'7I+Z
M3K6[&TE'$6Y07-*'2[K4F$Q"6JX/6ZSMVN[*GL2)2H\E;'4LJLDA;?6IC&1&
M6(*Y!D-ZN]GNQ>J=U=@M2;&J,K;%3!4\!20UOMT-DC"M;9&OVTP:E6#5%#M.
MZ-I1]?H%"Y\)-=K#&W' 7VCA2SC2 &2DF.GUVD]+WFPZ:O5KFHLTV1.D3WX4
M)Q33D,M283,=$:\7&'8;0JY%YYM9DRU642.S.(CJ[3U*5GR>J]2VB^ZCL]SA
M+N\./"C0&)LQ =;F!V-,??7)M%OEWR[IMH9:=0(T1-Y5'[4VN0GL_7+2,]W*
M[E4_L3NS5.]*'7[C6"%%5E,W75H^SSM.'O@-AE+8&-UJ;7G8F7"6PFB&;%L]
MB56QN47R4:G0"9R"1C^[]?0NA9VF+!>=/7&3!EM7$?D[I$,E,YU,FV,PGX\M
MN2E82U;5-]FM*D2G<VY##;C,=QI76;&MM;0M2WZT:@M\:;$<@$[[9+$8PFE1
M[D],8?BKC*1EVY)<[3=DKC-$7%<AQMZ0V\GJO1WO[<ZS[/XKTJFBKY-.8V9M
M;910_LH'3@Q2HA-DYJLD9I&JR:B7+N66A48J'/%15@L*A!29+LDQQ( :Z]/>
MG5Z.]%7;27:D3GK<W'^B;/:F8UJD3GV9LBU]L2[?YB)K#"8EQN#+\=EZ-&ZY
MI"(C8,ET!M+=ND'6-KU7V9<%JX+?^E+Q<W9%SCPF'H4>Z&(MJQ1%PGGC*M]O
M>9D/,R9/4NK7*61':4IU3FW!GZ4#3#EC'6Y@1O6VIF]E-1[Z<US;V*@Q2M0B
MZ=JJ]:[-T_44Q%O.^W>KI*R!;-0B,JL56!*4"$PR8@+(#>\3'BF.B2_"*["4
M_IZ$6]*WK3@ND)4TS[V].O%ON<>=>D=BC[4RFHK\2XM(ES'$"0\XT\^E_J6/
M9/\ 2M8S*:FI8U!,"]4V74)MDU,),"RLP;1<+:_"LRQ-D!2HSTIB5;G51(;:
M^SLH=987'ZQ_ 4KZ1S4M/-U0-*L6_;V!K6JRE',[;V32:W9]H;&DE-QM[2BB
M;,&%;TJEI"@:;&0L91C-;["1RPHP\\5FBYXI3%?B[-PZ+KU.CS'T1=.6Z3+O
M#-P8LMKGR8MHM:&;$JSK?B/O:>F1'Y,Y1#MP8E::6R\PE++;S;P5)7K0>DRS
MPI$-A<G4-PC1;0[;W[S=8,:7=[FIV]B[(8E,LW^'+8C04[FH#\74B7F7E*><
M9<:VQD8 G](EI=>C]EZXK5,V77IQTCV6A@ QA:KW!MP7?5Y59Q%CV'=3VSV$
M+O5-&NM07BY_5^U#I$C7JH3@W$7(A3'9&RST8WY.H+5=)4ZU26X[6E7),AC%
MN<A2-.P.R/Q;; CVA1^CISJ2XEB/=K1'::E3&7(+R5H"==WI)L9L-TMD6#=(
MSDAS5+<=A\FX-S6-13S+9E7.=(NJ0;A!:*6R](M5VDNNQH;K<YE3:R:4[X]P
M=9=I*_0$5F/L>;= ELN-DL5@M@Y5+"*@6<;6X[8]NBB=L[(H\^W.$0\B58-@
M5"N:AA'(;8F$N@L_5$.Q^]T=:(NVD)-R,M5K;@/PX,6+&A.B>_UD1V4HNFXO
M6:U7!N$&GD(C6V=)O3D=9>6+DK>0KA](.M+5JR/;NRIN;DYB9-E2I,QLP8Y;
ME-14AH6YF\72 Y-+C"UR;E"C65N0@,MFVIV H^:W/JM?+Z<4IQ2G%*<4IQ2G
M%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*_TU:=_\HU;_NX#_P#3(O/RAG?Z
M;,_[U(_VRZ_4Z#_H4/\ [K'_ -BBI'S5K:IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ
M2O@'V9ZT=2[=OK:-DNW6NHVRUF+1)F';).V#O,7+,3EL1TKF/CZYM,,#BN+0
MA"<M#1<*-CU<92PE659S](M/2YTAV.W1+3:]0JBV^ R&(D<6NRO=4TDDA'6R
M+<Z\O!43N<<6KCQ/A7SFZ]$W1_>[C+NUSL':9\YTORG_ *4O+/6ND!)7U4>X
M-,HR$CW6VT)X>%47X1>D7PDT?S0[&_K-SH?7CTI>:5<GT_\ A5<_ZD>C'RS_
M !B_?BE/"+TB^$FC^:'8W]9N/KQZ4O-*N3Z?_"J?4CT8^6?XQ?OQ2GA%Z1?"
M31_-#L;^LW'UX]*7FE7)]/\ X53ZD>C'RS_&+]^*4\(O2+X2:/YH=C?UFX^O
M'I2\TJY/I_\ "J?4CT8^6?XQ?OQ2GA%Z1?"31_-#L;^LW'UX]*7FE7)]/_A5
M/J1Z,?+/\8OWXI3PB](OA)H_FAV-_6;CZ\>E+S2KD^G_ ,*I]2/1CY9_C%^_
M%*>$7I%\)-'\T.QOZS<?7CTI>:5<GT_^%4^I'HQ\L_QB_?BE/"+TB^$FC^:'
M8W]9N/KQZ4O-*N3Z?_"J?4CT8^6?XQ?OQ2GA%Z1?"31_-#L;^LW'UX]*7FE7
M)]/_ (53ZD>C'RS_ !B_?BE/"+TB^$FC^:'8W]9N/KQZ4O-*N3Z?_"J?4CT8
M^6?XQ?OQ2GA%Z1?"31_-#L;^LW'UX]*7FE7)]/\ X53ZD>C'RS_&+]^*4\(O
M2+X2:/YH=C?UFX^O'I2\TJY/I_\ "J?4CT8^6?XQ?OQ2GA%Z1?"31_-#L;^L
MW'UX]*7FE7)]/_A5/J1Z,?+/\8OWXI3PB](OA)H_FAV-_6;CZ\>E+S2KD^G_
M ,*I]2/1CY9_C%^_%*>$7I%\)-'\T.QOZS<?7CTI>:5<GT_^%4^I'HQ\L_QB
M_?BE/"+TB^$FC^:'8W]9N/KQZ4O-*N3Z?_"J?4CT8^6?XQ?OQ2GA%Z1?"31_
M-#L;^LW'UX]*7FE7)]/_ (53ZD>C'RS_ !B_?BE/"+TB^$FC^:'8W]9N/KQZ
M4O-*N3Z?_"J?4CT8^6?XQ?OQ2GA%Z1?"31_-#L;^LW'UX]*7FE7)]/\ X53Z
MD>C'RS_&+]^*4\(O2+X2:/YH=C?UFX^O'I2\TJY/I_\ "J?4CT8^6?XQ?OQ2
MGA%Z1?"31_-#L;^LW'UX]*7FE7)]/_A5/J1Z,?+/\8OWXI3PB](OA)H_FAV-
M_6;CZ\>E+S2KD^G_ ,*I]2/1CY9_C%^_%*>$7I%\)-'\T.QOZS<?7CTI>:5<
MGT_^%4^I'HQ\L_QB_?BE/"+TB^$FC^:'8W]9N/KQZ4O-*N3Z?_"J?4CT8^6?
MXQ?OQ2GA%Z1?"31_-#L;^LW'UX]*7FE7)]/_ (53ZD>C'RS_ !B_?BE>2?U5
MZ)BH<@B3ZKZ\&CXC>7I4Z?MGL/#AQFL9QC+LB3(W2VPRWC.<8RMQ:4XSG&,Y
M_CQ]>/2EYI5R?3_X53ZD>C#RU_&+]^*5'DZ#^CH4,<-)Z_::4&9E(A.ED[SW
MKD8U,=1EQN(Y/QO+,5$IQM*EHCJ=PZM&,J2C*<9SR?KPZ4_#O0O/R^AM/_A-
M1]271AX]VACY_3-^_%*Y9Z__ $=F [EBSUZT[BOM2<PW#O\ CCO?W.W+PE*L
MQ5D_\<OJ29.$J2KV"G\.^A2<^IZ,X]+Z\.E/P[T+S\OH;3_X33ZDNC#Q[M#'
MS^F;]^*5F8W5SH9-&(-0^KNMI8=R.Y+06C;=["/C%Q&L+4[*1/:W6N*J.VE"
M\N/8=RVC"%Y4K&$Y]$?7CTI>:5<FT_\ A53]2/1AY:_C%^_%*P;N@_HZ(\N+
M ?Z_::9G3FX3T*$[O3>K<N8T20VZ.=BQU[S2](;GM/-.0ELH6F4AUM;&7$K3
MG,_7ATI^:%\FL'X34?4ET8>6AQ\/^6;]^*5EF>LW0.0U$?C]9=7OLSR#PF \
MSN/L"ZU-*Q_K69 R(XC=JD22#&(4S+T)G*Y+7U25Z[:?8.^I'UX]*7FE7)M/
M_A53]2/1AY:_C%^_%*R_A%Z1?"31_-#L;^LW'UX]*7FE7)]/_A5/J1Z,?+/\
M8OWXI3PB](OA)H_FAV-_6;CZ\>E+S2KD^G_PJGU(]&/EG^,7[\4IX1>D7PDT
M?S0[&_K-Q]>/2EYI5R?3_P"%4^I'HQ\L_P 8OWXI7D>ZJ=%(\J'!D=5M>,32
M'UCZA#>VSV':E3OJC>'I7U..O=*79/U9I279'L4+]BWG"W/53G&>/KQZ4O-*
MN3:?_"J?4CT8>6?XQ?OQ2C'53HI)DS8<;JMKR1+&N,M$8K&V>P[LF [)CMRX
M[<UAO=*G8KC\5UJ2RA]+:G8[C;R,*;6E67UX]*7FE7)]/_A5/J1Z,/+/\8OW
MXI7K\(O2+X2:/YH=C?UFX^O'I2\TJY/I_P#"J?4CT8^6?XQ?OQ2GA%Z1?"31
M_-#L;^LW'UX]*7FE7)]/_A5/J1Z,?+/\8OWXI3PB](OA)H_FAV-_6;CZ\>E+
MS2KD^G_PJGU(]&/EG^,7[\4IX1>D7PDT?S0[&_K-Q]>/2EYI5R?3_P"%4^I'
MHQ\L_P 8OWXI3PB](OA)H_FAV-_6;CZ\>E+S2KD^G_PJGU(]&/EG^,7[\4IX
M1>D7PDT?S0[&_K-Q]>/2EYI5R?3_ .%4^I'HQ\L_QB_?BE/"+TB^$FC^:'8W
M]9N/KQZ4O-*N3Z?_  JGU(]&/EG^,7[\4IX1>D7PDT?S0[&_K-Q]>/2EYI5R
M?3_X53ZD>C'RS_&+]^*4\(O2+X2:/YH=C?UFX^O'I2\TJY/I_P#"J?4CT8^6
M?XQ?OQ2GA%Z1?"31_-#L;^LW'UX]*7FE7)]/_A5/J1Z,?+/\8OWXI3PB](OA
M)H_FAV-_6;CZ\>E+S2KD^G_PJGU(]&/EG^,7[\4IX1>D7PDT?S0[&_K-Q]>/
M2EYI5R?3_P"%4^I'HQ\L_P 8OWXI3PB](OA)H_FAV-_6;CZ\>E+S2KD^G_PJ
MGU(]&/EG^,7[\4IX1>D7PDT?S0[&_K-Q]>/2EYI5R?3_ .%4^I'HQ\L_QB_?
MBE/"+TB^$FC^:'8W]9N/KQZ4O-*N3Z?_  JGU(]&/EG^,7[\4IX1>D7PDT?S
M0[&_K-Q]>/2EYI5R?3_X53ZD>C'RS_&+]^*4\(O2+X2:/YH=C?UFX^O'I2\T
MJY/I_P#"J?4CT8^6?XQ?OQ2GA%Z1?"31_-#L;^LW'UX]*7FE7)]/_A5/J1Z,
M?+/\8OWXI3PB](OA)H_FAV-_6;CZ\>E+S2KD^G_PJGU(]&/EG^,7[\4IX1>D
M7PDT?S0[&_K-Q]>/2EYI5R?3_P"%4^I'HQ\L_P 8OWXI3PB](OA)H_FAV-_6
M;CZ\>E+S2KD^G_PJGU(]&/EG^,7[\4IX1>D7PDT?S0[&_K-Q]>/2EYI5R?3_
M .%4^I'HQ\L_QB_?BE/"+TB^$FC^:'8W]9N/KQZ4O-*N3Z?_  JGU(]&/EG^
M,7[\4IX1>D7PDT?S0[&_K-Q]>/2EYI5R?3_X53ZD>C'RS_&+]^*4\(O2+X2:
M/YH=C?UFX^O'I2\TJY/I_P#"J?4CT8^6?XQ?OQ2GA%Z1?"31_-#L;^LW'UX]
M*7FE7)]/_A5/J1Z,?+/\8OWXI3PB](OA)H_FAV-_6;CZ\>E+S2KD^G_PJGU(
M]&/EG^,7[\4K^E\.TRP(%L1VDL1V1T%IAE*G%I99;C-(::2MU;CJTMH2E&%.
MN+<5C'I6M2LY5GY2M:G%K<6=RW%*6M6 ,J42I1P  ,DDX  'P%?4T(2VA#:!
MM0VA*$)R3A* $I&223@ #)))^))K(\K5Z<4IQ2G%*<4IQ2G%*<4IQ2G%*<4K
MXO;]_P#K+L/_ +PO_P#]+'%*J#BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE
M.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE57N\(5L>IKV"!PGB)8F"?BP(+&$9
M>DOJ=94EIO"U(1ZV<)5G_B4G'\,_QY(X$?K%0>(/ZC5'WW3!L4,R;'S"UHL1
MF_:\)FEUBL5@<L<$J+9E#<D57)*70LR<Q@F\M]PNN8B8O,9AUM,=K*%6"AQ^
M VD ')R3_P ?V"JE)\?$[@3C X#Y9..'_P":]LD#8\*U]:'*O<K,.JDR\PR8
MH[6*1!LL:?81@IL';8=7!.BZ\6CB%QY(W_EK:*):FR'4(<2VZO,#XC(&<?/'
MWC/$C/ _*ASP."<9\<9\.! ! ./Z?E63K #;2=;F!J M5 QR4F_N20DNNH$G
MB DM'RH0_!'5L_*!A#9&2]/>GQI;Q%#;K\='_+PA>%,C<#Q/AQS_ .F2/Z*G
M!*?@.!X8Q^KX\/[:\.K]7VR-9LEBSTVNPH%.TQ$7 ?"5HDR<EU^IHB&AZYA,
M>0(#5#Y;.84AT3)@N^N_[1#JW&F'&Y400,<>*OGPR<_VU"003GAP3\N.!C^R
MH17=5[*KQ6@/C8#_ +G(['M5SL4*<XES-6L<3%_#AS*&O:YQ[ILH,T$5,99P
MZIJ2*8=]5"I[B<02"#\\ #^S(_8<_P",5(!!'RR2?[<?T@C^BK.TU V)&LD1
M=M1L1$1% 1'-JMIEL@)D;%P7B*L<L0PW/E^S&OQ4P\U_V;; UB&@BV+8CK=(
M9D#CX8\>&,YQ]_ #_?\ ?09^.?#CG!&?Z3C^P?=4.+ >P/VH)#!Y*Q8J_O\
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M(KCZ$Y+@20$I2H^Z"5>YG:2H852E*/Y( @J:"2I0"5)5)0RH\$%0))4D')
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M4:9%;%"%2-DI=-3V:[G["C<M/:  AY4?<M+;8+J3[Q.]\'JQE/O)"U\3^3X
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MRFO3C1.45K30&VF8+069(S9FI4Y<)L+9,1!]T.G=_FZEJ+1]P/-+=PC#IWX
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MHSGU4^GT8UW4%MQQLG);6M!/S*5%.?VXK.VOK&T+QC>A*\?+<D'']M?L_6M
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M!!X$) (.!6,U0+TD>H9=K5@$,[KRQK^SQ1IBODAX*S1JW5 >LV4M-&X$5NQ
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MM2C]VM)]:IZYK\@G83YA3DA^61G94Z#KZU@A:U+"@XG!.0IM/!0 X#8E/#
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M;4[$)*5-+2IPAQ<=;9)!XD2&W$()2#P+86A/^JG=M.$^&0QU)=0I* 4(>;6
M",@=2XVM0"E#B%E"CCB<%0W*\?H $F$"(400*AWZ\4G"X$PD E2X,^2#GRHK
M3\P1(G"WY0R:^-D+<A/2QTF1!DN,J>B/NL+;<5H$ $@$* ) 4 0" >! (! /
MC@@'Y@&MT$D D;20"4Y!P2.(R.!QX9' _"LIR*FG%*<4IQ2G%*<4IQ2G%*<4
MIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G
M%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4
MIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G
M%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4
MIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G
4%*<4IQ2G%*<4IQ2G%*<4IQ2O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g939163g34b40.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g939163g34b40.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X68B:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC
M871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET
M;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/F<S-&(T,#PO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @
M(" @(#QD8SID97-C<FEP=&EO;CX*(" @(" @(" @(" @/')D9CI!;'0^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M<F5P86ER(CY&:6QE
M($YA;64Z(" @(" @(" @(" @(" @9S,T8C0P+F%I)B-X03M5<V5R;F%M93H@
M(" @(" @(" @(" @($1E;'1A)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @
M(" P,BU*=6PM,C R," Q,SHP.#HQ,R8C>$$[15-4(%1I;64Z(" @(" @(" @
M(" @(" P,BU*=6PM,C R," P,SHS.#HQ,R8C>$$[4V-R:7!T(%9E<G-I;VXZ
M(" @(" @(" @,BXV)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q-BXP
M+C F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @07)T=V]R:R8C>$$[)B-X
M03OB@*(@,B!R87-T97(@:6UA9V5S(&AA=F4@82!R97-O;'5T:6]N(&)E;&]W
M(#(V-2XF(WA!.R8C>$$[XH"B(#<@0TU92R!B;&%C:R!O8FIE8W1S(&-H86YG
M960@=&\@9W)A>7-C86QE+B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S
M(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @("!!
M<FEA;"U)=&%L:6--5"8C>$$[(" @(" @(" @($%R:6%L+4)O;&1-5"8C>$$[
M(" @(" @(" @($%R:6%L350F(WA!.R @(" @(" @("!#86UB<FEA)B-X03LF
M(WA!.U1H92!F;VQL;W=I;F<@8V]L;W)S(&%R92!P<F5S96YT(&EN('1H92!D
M;V-U;65N=#HF(WA!.R @(" @(" @("!#35E+)B-X03L@(" @(" @(" @0FQA
M8VLF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!I=&5M<R!H879E(&)E96X@9FQA
M9V=E9"!F;W(@0U,Z)B-X03LF(WA!.T5M8F5D9&5D(&EM86=E(&ES(&QO=R!R
M97,F(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+28C>$$[1FEL92!.86UE.B @(" @(" @(" @(" @(&<S-&(T
M,"YA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @("!R<C8P-C(Q,R8C>$$[
M3&]C86P@5&EM93H@(" @(" @(" @(" @,#(M2G5L+3(P,C @,C,Z,C Z-# F
M(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,#,M2G5L+3(P,C @,#(Z,C Z
M-# F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N-B8C>$$[26QL=7-T
M<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @
M(" @(" @($%R='=O<FLF(WA!.R8C>$$[XH"B(#(@<F%S=&5R(&EM86=E<R!H
M879E(&$@<F5S;VQU=&EO;B!B96QO=R R-C4N)B-X03LF(WA!.U1H92!F;VQL
M;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[
M(" @(" @(" @($%R:6%L+4ET86QI8TU4)B-X03L@(" @(" @(" @07)I86PM
M0F]L9$U4)B-X03L@(" @(" @(" @07)I86Q-5"8C>$$[(" @(" @(" @($-A
M;6)R:6$F(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!C;VQO<G,@87)E('!R97-E
M;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @($--64LF(WA!.R @
M(" @(" @("!";&%C:R8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&ET96US(&AA
M=F4@8F5E;B!F;&%G9V5D(&9O<B!#4SHF(WA!.R8C>$$[16UB961D960@:6UA
M9V4@:7,@;&]W(')E<R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03L\+W)D9CIL:3X*(" @(" @(" @
M(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.F1E<V-R:7!T:6]N/@H@(" @
M(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R
M9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!'26UG
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R]I;6<O(CX*(" @(" @
M(" @/'AM<#I-971A9&%T841A=&4^,C R,"TP-RTP,E0R,SHR,#HU-RTP-SHP
M,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @(" @/'AM<#I-;V1I9GE$871E
M/C(P,C M,#<M,#)4,C,Z,C Z-3<M,#<Z,# \+WAM<#I-;V1I9GE$871E/@H@
M(" @(" @(" \>&UP.D-R96%T941A=&4^,C R,"TP-RTP,E0R,SHR,#HU-RTP
M-SHP,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z0W)E871O<E1O
M;VP^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO>&UP.D-R96%T
M;W)4;V]L/@H@(" @(" @(" \>&UP.E1H=6UB;F%I;',^"B @(" @(" @(" @
M(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z=VED
M=&@^,C4V/"]X;7!'26UG.G=I9'1H/@H@(" @(" @(" @(" @(" @(" \>&UP
M1TEM9SIH96EG:'0^.38\+WAM<$=);6<Z:&5I9VAT/@H@(" @(" @(" @(" @
M(" @(" \>&UP1TEM9SIF;W)M870^2E!%1SPO>&UP1TEM9SIF;W)M870^"B @
M(" @(" @(" @(" @(" @(#QX;7!'26UG.FEM86=E/B\Y:B\T04%14VM:2E)G
M04)!9T5!4T%"24%!1"\W44%S54=H=F1'.7IA1SEW241-=4U!0311:VQ.02LP
M04%!04%!0D%!4T%!04%!14$F(WA!.T%10DE!04%!05%!0B\K-$%$:T9K8C)*
M;$%'5$%!04%!068O8D%)44%"9U%%0D%514)G549"9VM'0E%92D-W9T="9V=,
M1$%O2T-W;TLF(WA!.T1"04U$07=-1$%W441!-%!%03A/1$)-5$9"451%>'=B
M1WAS8TAX.&9(>#AF2'@X9DAW14A"=V-.1$$P645"05E':%521E)O9DAX.&8F
M(WA!.TAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF2'@X9B\X04%%46=!64%%04%W15(F(WA!.T%!25)!
M44U2068O14%A24%!04%(05%%0D%114%!04%!04%!04%!449!=TE'05%!2$-!
M:TM#=T5!06=)1$%114)!445!04%!04%!04$F(WA!.T%104-!=U%&0F=C24-1
M;TQ%04%#05%-1$%G44-"9V-$0D%)1T%N34)!9TU20D%!1DE227A15D5'13)%
M:6-9155-<$=H0GA7>%%I4$(F(WA!.U5T2&A->%II.$-2>6=V16Q1>E)4:W%+
M>5DS4$-.55%N:S9/>DYH9%5:2%1$,'5)24IO34I#:&=::$I21E)Q4S!6=$Y6
M2T)R>30O4$4F(WA!.S%/5#!:6%=&;&%7,7AD6&PY5UHR:'!A;71S8E<U=EDS
M4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\K0VLU4U9L<&59;5HF
M(WA!.W%B;DHR96XU2VIP2U=M<#9I<'%Q=7-R839V;U)!04E#05%)1$)1545"
M45E%0T%-1&)114%!:$5$0D-%4TU514954DYH26=:>&=:17DF(WA!.V]B2'=&
M34A2-%-.0T962FEC=D5Z2D121&=H85-5>5=I63=,0T(S4%-.94I%9WAD56MW
M9TI#:&=:2FI:1D=I9&MD1E4S.'%/>G=Y9W F(WA!.S K4'IH2E-K=$U45350
M4FQD65=6<&)81C%E6#%2;%IM9&]A5W!R8D<Q=6(R4C%D;F0T95AP-V9(,2MF
M,T]%:%EA2&E);4MI-'E.:F\F(WA!.RM$;$I75VPU:5IM<'5C;EHV9FMQ3VMP
M86%N<4MM<7$V>71R<2MV+V%!07=$05%!0T5135)!1#A!-V1&*V%B=F17<T(X
M<S9U;VQ9<&,F(WA!.WE',U!'3G1G=D5M;DU%;G%E3S-J,'EF0C5S94I6,#<X
M,$ER>3930B],,G-W3$Y)<5%Y=&%K<GAC<4]4,%!W,#4W,')T:5E+2DTR>40F
M(WA!.THU:C4R=C=38E<S;75,3%A98FTQ<EHR9'IO-G-80S%%:GE.<V=!971&
M;S=62%5$3$EH:$IJ=',Q>&)Y47)-,VTQ;'4O4VQD5EIP3UHF(WA!.VQQ4#-V
M=TE+<7$O1G8R03EX3#5)*V(R:E1B-6(O5#=E.5=+5T)B;4Y:5FAN6&A+9V-6
M-'5T5%)H,T=5;'-3:GHP.&@X=5A&<6QH3G$F(WA!.U Q+R]!15)O8F-G4TE*
M45(V<6MQ-$)J*S!+:G)42E(U;TQY:E5.4W-6=5 Y-B]/5FQB5S1%:S!926IJ
M=&]U2D-/;W%W0VMX<V\S03@F(WA!.T]L1%E"-VUS+T9'5TYW63EA,#18:F5B
M-W=X6$U$4W=4+W9B55951D,R=S5J:U%'1D(Q4%=M-#9D13EE<C)R2VUX0S9R
M3&91-EIE5%<F(WA!.T51=4PV3T-2-U-":E%34W%H36%%,5A:;6]/=45+5T=F
M-'$O3D-*-#1P9DM58S=23WDS37-6,&EP2W9)<6AH-45L3WI(;E@V36Q1-S(F
M(WA!.TYN=5I&-6$Q;GI"<5)U:')':'1O,V]L4%%,6$-806TU8W563T-R>#0X
M4C$X8VE116=L6#AW,U=V5S%R03)I,FMD-6-.3W%Z>'ET>$,F(WA!.W=C5UHR
M0G%V>&)!1#-/27!3>'DO.#$O;4EK35)S+THU85EY=7-Q=F5235!446=!<5%%
M*S-8878S2$I#23<P16YU5DY/.'HK9G)M*W,F(WA!.S=E-SAQ+U4T2G!Y3&TW
M835J:T551E-194,Y5S0P1F$Y93-B16=D-F=N=5I,<F,R<7=A5F-3-E1!;'IQ
M2W%0<3!-:&]J35-".%<V-U4F(WA!.S,V-45-:7A33'ID*UDP8DY"8RM41$Q)
M:%E'94<Y:5=*-DU10V]:5TY/4&EF;WE80T\Y:EHW;5<V6%!Q53!->F%H071V
M2W,X>5)+:F,F(WA!.V<P2WE%4E X,E-H>4I:26)Z2&1E64QE>FAB43=73S=U
M;FU66E5M3D972&EX9'9T2G9S04XK*TER<6=S96<X,V5F,S12>2M4<$EM4$(F
M(WA!.UI*=G)C3$)72V=S-&I&3U-Q5'-/9%0T:DIC23<P5V4U;&5K>E@P*VPR
M:S)O4D-#*VMH4C=M0F5I4TUO3$M+:SE$-S5%<VMQ.#)A;#4F(WA!.W1S4F%V
M-68P>4Q5=V5B6&MC:BMM=U93;U99,DI!-4YY4%5(<&A!2%9"=$LR.#$K9EI9
M<FA9=DM,,C!Q3$PV16MT>D9+<&%/;D%&1DTF(WA!.UHK3W!'>F)E*T=H,V]S
M.7I-;VDW4F]:1C1/44,V,7)1,#-&8V=Y66XU:#$W>C-:,S%Z1'!/9W)Q14%+
M:3%M36EX<E0P,6-S-4PQ8FLF(WA!.R].3TE58V%"<6UT36M!1TI*46QV-78X
M07I&26(Q=DIB13AJ>#0S<U,P54)E=%$Q86MT5"]!1$](:$AE=&YU5%AY>G(O
M04IR,4<V94PF(WA!.U=03')A4D%Q37E81%A-8S-*=5,X531)=&$X5S-.93,S
M06=D-E%3>4,U:&%A,FQH5U)O5VM2:U=63FU1<TMC;'(S2%5:1DQW93%5>5(F
M(WA!.TEL,T(U='0T25%S9'9#=%I3:7EO45564VM0=V5N1U%X2&HP,T]89DIQ
M*V%V2$]X=&]M=7)R>G8V,&-*4U0P-'5#-VML=TMU4E1P.7<F(WA!.W@K4R].
M-U9P1G5L='!6;&)O6D-K345586U956QO<4%$;5 U='0O9DMI,G$S,5,Q+S-Y
M;B]!04DO<&=6,S%3,2\S>6XO04%)+W!I<G8F(WA!.W%L<B]!3#54+V=2+U1&
M56HX,&%W*VE1>'E7,FAY-F]:03%&=&M"-'-P5V=E:7-2>4).1%1T:V=,45-K
M,7@U,VYH2TMV;&UA859O-#,F(WA!.VMG4DI055%U0GE&1V=#;F=4,41B:6A(
M-UA%.$M,6E9P16M.+W!D<F5Y5TET6DQI2EI(='!&2$I#=W%63W<V9DQ);&MI
M+W%L<B]V;% F(WA!.RM"2#E-0W--;3@K4E=P94LV.'(V:6)H5V]N,6$Q33!,
M2V$X5T5J3$=D,494.$<R5#1F3FIA2W-V3U9L95AT=F%2*UA.5&AA9599;6PF
M(WA!.W5,3EDT;S8W;&YF:S%!0B]40G=P=&Q0,5,Q+S-Y;B]!:BMM4E-X-WI*
M-6A':S-K3FQA841C86YC4W%*5V5'2VM+4C%92&Q,>&(T+V@F(WA!.RMZ5'9K
M9TQ14S,U5C$X834V=W5.0G5.2V%&5EE#-VE+:&EZ3W)+<$MQ4&@T02\W3$5I
M;$)T-#DU=3@X95EX-6DQ*U,S=GI93F]D,$DF(WA!.W)'>&I725%Y4DQ+65=,
M;S-X4TUF:&)O4C$V0VUD0G Y2&HT23-'*TEB;C17-E10<3AN1D]J6$%D9WE,
M.#!V3G5R5U!L<GET<59K<U8F(WA!.W!C87!!6C=Q35)+44=A2THK241":4M&
M>FU*;W1(:FYK;D=7-&E82C%E<6Y#15I$67EE82\X<DLX,B\X04Q42"]!36E9
M+W=$;6Y.;"\F(WA!.TIE1'4K,'5U+VQ03#5F2C,O2WEV3G8X07DP>"\X:5DO
M*V%C9C5,=V0S,FQF-51Y*UAY6$@X>F9.-4%"=5DV3# O8WAF4"M82"M3.$@F
M(WA!.V0Y<%@K53AV;#AL=B]+>79.=CA!>3!X+SAI62\K86-F-4QW9#,R;&8U
M5'DK6'ED+WES<GIB+WDP>"\X04EM4"]!2G!X+VMV0C-F858F(WA!.R]L4$PU
M9DIC+W=#6G9M.3-::F-X,5EK;6M-43-0*WAX+VMV0C-F858O;%!,-69*:UAK
M5'IR-6@Q6%=0<60U14QU0C%*859%5E!2<"LF(WA!.S!A04%G.5 Q6F<V+U$T
M<V-/2T]X*SEZ9$1R8VU39$574'5E:U)Q=DYD:#%'85(R-C8T4D)024%O<'IB
M=#<T<7 X5CA":7%0,%-/3G0F(WA!.U5G1$M#0U1514%J-TIX5FMD-5!"8GI'
M1U!46DQM5#!M:U524DIW6F=#5FDY4GEI0C-#3E-R0E(K,'DX:S5414Q&,RM0
M>"M.:7=--DXF(WA!.V9J-2]$.%=&<3-%4U<Y=DID865695(T-%HO4FI-<5)Y
M=7AJ3D]34GET1TI!0C9N<&=C4TA.1C5&4E1+,38S3F<O=T)5.4\P6FQU,C0F
M(WA!.V=M25)T1T1#6F<P<V-V0U).9T9P>#5":4%13C9.3&%7*V-.5G,Y0G-R
M5R]L34U&=CE9.4MB;$8V:&8Q27!"1T9#,#93.%=B8V9#1'8F(WA!.VI%5W!.
M34%T+W=!,3<Q6795=3 P<'5A<#9-9'9B,U1-6%EG;$1Z-#%O:VE5-#%R6&%V
M869!>#1L8V5F=DYG:W0P93 P:#%U66\U234F(WA!.TDW93=P5U8S:$%)8FEY
M.%IO-D=O+T4T3T5,6EID-4$Q9E4Y8W-B<3<Q4S)S;VUI;59,8U=I=#EK>$I,
M5FDO24AA455+;6XV.&I)57DF(WA!.T)2;'8K65AK,C1U27)A2%4T,VYN2W)#
M9U=3<G,W;4Y66#1D>5A&2UDX2E=W>4A)<&1I<D=T9CA!33)R85IE9E9R8E)R
M<E5"5&U*;VDF(WA!.T]"5#1E-%)V:7)Z*T4O>3%R.%%Y44-#571L+TU$56MI
M=4I).4-U-2]1;5-%3$AZ<5$W4T1M43!+:V-F4S,V.69L53A+3%I:63-5;# F
M(WA!.W-X84ME,CE'6C112FQ64S11,#E22U9Q:F9S;DES:U1W8BMC+V@O5$%Q
M4W(U>3AQ;$A:.5EG:$UB1DAJ;F196D%Y:W%2-F-G4BMO.$TF(WA!.U!#55=R
M4BM:+TQC<W-554]S,G-S<S="25DT-3186C)*;T%Q<5-4:E)7,# T3B]/9G<O
M<&=39V17,7)3=$IH175O,W$R>6M%;T=)3',F(WA!.T9)0C1)05=A:%ED0C-W
M9U=T<4]L*UI.0S%7-6QT=$\Q0F)M94%&<%DP-F="=4YD,4@W5S)*0D-,95,K
M8W90.$%P=CA!:6)5;FHP4T,F(WA!.SAT3DIN4S(Q37I3=$A*8TUJ1U!L-E-F
M=6Y61U1H5U)8,G T,'IE86)2>3A-96]G>49J>2](:S9R4')">%-Q3FE03FM0
M-6TK9$Y,<SDF(WA!.T@P1%5N<V9R.79Q:V)4,C9Y.$9:1EI),T9D;D932$9C
M=W1,;S54;$M);'=M3&LV:E9X:$5327-3964O.')1,% O<5@T+W=$9VLO-6\F
M(WA!.WI/+VMV2B]0*R\X05<T9CAP-"\U<G8X06QA1V@O=T15=G@O.$5N+TY'
M4#A!2F54*V8Y+S8Q+VQ02"].6'0K85=H1D5595AO=U9"0E F(WA!.TM097!R
M+TIJ+TIE5"MF.$%F*W1F-51X+WI6;B]!0W1$42\X07%8-"\K0U0O04IO>"]K
M=DHO4#A!=B]7=CAP-"\U<G8K5F]A2"]W0E,F(WA!.R](+W=39CA!3D=0.&PU
M4#4O=T(O-C$O;%!(+TY8>2]M;&]4>74T.'92<4=9:TQY:C)Q83 O=3AF-4QY
M9GHO=B]!1G(O04-N:B]M<'HF(WA!.S55."]A2G%D*V)&3$9D3VUL2#=Q;$-S
M:$9F:$I53%$K1UEM<C=0>5DT.%8X441K-F)847E3-%%/17,Q:DDU<G0S1V%X
M,D,V-% K:U,F(WA!.S=F='0K=D963V\X3592*V@W-G)B9V)B;F-F-G X8U9:
M9U%2,6,P-E8K2')7;FAI<7DS;6AU8F5+-71R9U17.'E,2D1.1U9D2%)X5E<F
M(WA!.U9G0T-#1%5%65-+5E4T3B]/9G<O<&=61&%J4%I7;&TY>F9Z3$AA4E5-
M:VMO6&=T4T%#86IB8SEC259+;R].6&LQ,W!(<6QQ>DPV9W$F(WA!.W)2.4EL
M3'E%1VQ/2W%L4V5N5'A'1VEI=S!N;6IY8F(R56MK3V\R-'1B555L4T%+,W!Q
M0W!9=$A'<%I657E$:V%556YE;4Y&8D-,,&(F(WA!.UAD13%)=$1P;'IZ34MQ
M>E$K;3!25E1S<#1U:4=M06=R8F]F2UAL:4,T:75)9$QT634T4W!H:U=*455+
M16Q3=3)X0EDT,E9P3G-#6%DF(WA!.W%X4'I**UAM;F$W<6DV;%!03D1C<491
M96Y*44)61$-I:FIS8717=FIK:$MK14EF+T%*5F9P:E-2>79E6&AN:E-+3DI&
M;4,X5FE6;$LF(WA!.VA1;$%R.&AY2"M30C!R53AA3T9K=6QA9F-7154P8C-5
M,39:6FYM16QY+TIL1"\W<E=I9T)6-T1):W-K8E=4*U5F968V6493830X;2LF
M(WA!.U9R:50Q6CE&<W!*3G9J84I#9FA"02]:-U9W.%)2459,8GER-61T8FA,
M;3(P:7IH=4DR-7AY<$5I<W)!535!:&%G,'AS<E-A,6LO;$@F(WA!.S-N*VU"
M2T-V.48P>E5:27!B*WAT-W%314523DUO8W%'24IP>54P,U59459P,6QO=6PR
M16YQ5U9H8E<P;D5P>FE256)I>$1&87%O,DHF(WA!.T%/3G)4>5AZ6&\S:TYV
M3D=O=W1C6$U3-FQ*6%8O<393>5)R2D=W:VTT<TA59D-2>F%S8VY%+V1L,&4S
M4$1Q2C--978T+U$V=DYJ=S@F(WA!.UI'+W$U.# Y+TUN4W9*,'5J-D1B-FA)
M67)#,VI:3DXY1FY91TU*1T)U<7158U%T36I(=$DT4UI8.6)F<4UE27A!;GDV
M34(O=SDK5C,F(WA!.R],5% O=T%L=BMA37,O,%%N*V-0:S1N9S98.%<W+T0S
M-5AF.'1-+R]!0U<O-6]X+S!1;BMC4&MV9S98.%=U8GDY*U9F0D].>E!Y;V4F
M(WA!.V8Y.3%R="MX-%DO-DE4+T](>5AW9$PK3%A7,VQB.',W;61)26)I67EY
M1VE!=$EO2CA+<V]'1U!B.&EA16@X:W@P*VQK84@V53(O-58F(WA!.UHU4R]K
M;B\U1TA-:BM68S-L.&Y)+VLS1#-F87%82#55*U59-VE734I04DA:4BLY4%%'
M;FAJ+TMU8GDK4R]W06TT93<W561O9FMV>2\F(WA!.V]T=S%Z6E).-C=$:4I*
M1'I+:G9X<C!R,WEJ4')C;55623=.,DA363A:=4DS5#9/;DYF;4UX2$I86$90
M<D5V.$%R="MV1E908GAX5D@F(WA!.S9(+W@Q8F5M-7%E=3,W2GA6:W0S<$9J
M951'5S=T:VY:;VUT,E-2;6%.;UI!4DI',%HK06\O3#0Q26\Q1G)8:71*:5I!
M;V9J.&9J;5<F(WA!.T)G0V(O2'DK4#-D=V)M,'4R;31'4T]R>'ER4$A+2DA%
M:75R;'A35#=F2#1M57)8:G=*4VY%:UI(:5I5,'5L44PY57%P:TYI,T\R85<F
M(WA!.U)P6%9H0UE/4FMK1%--,W!S=TQ&<6UP<6-0171.-G-.4&)4<'AQ<3(U
M,#AR4S1&>58Y27)59F(U:FHQ.&-!4U=+2DXK5F=V5%IX5VPF(WA!.V=B<T-:
M9E)J=&U,071&5UI">&DK,EDK<2]A4%1*97!J<W-J=79Y<%IN5DQA=T1Z4GDS
M56DK9W=:;V\O,S!J<U!40DDO8SAV96=P6&(F(WA!.T@Q3'-M+VQQ.3AM9G52
M;TLR-FDY.50P,F=2:'E-6#(P3$9">%ED941%2'9406(V<$9*+SE::CA(+W=#
M4F(O.$%.3U)3-S9Z2#10.$$F(WA!.SAI,R]!3V%C5F0Y6FHX2"]!3U)B+W=$
M3D]+<$@U;SAT-F0U:6AJ:75:-WDR0T)L2G1G>6,Q8W%3<C%29V0P1DUK1%-#
M3%-I5#AU3DDF(WA!.V531FAF-F=Q=VE&5E%,.$I%1D%N3#DS.7!1=$9B<5!F
M1'AO<&Q7;5)1869P,7)923 X<5=K36-#4WEO-U--23%#9W51;W%X<'9K4WDF
M(WA!.T-**W-X*T0O05!)="]W1&UN07)$2G9Y.7136%<Q,7I73$LS:V)M.7)B
M35DT95)Q5V]I>&=$:WAQ8VYX365&1E=8:S%B83ET-VU46'0F(WA!.V%U;'0U
M5FQ7,W5*6DAI8FHP5C$T1&M+-S1/2DY-<"MS>"M$+T%0270O=T1M;DEP4V)Z
M1&]C5W0K:W(V:'%&;$9'<G!*1EIL-&QL5U,F(WA!.V=94U51.'1H465'14=K
M14LS;#-3-$Y%,#<V:W1Z9#-G.5(U9E9U5F0R<35Q44M+2T-U.5!'=4I.<4=(
M6&9L2%AO2F14=$Q#-&Y.;'$F(WA!.V-K:W%Y;%<O9&5Q>$Q,>5EH,#5B2S56
M2#5$3F9,5'I&9TA9=4EC16A90C),=E!V;%IR=E)T0S K0V-G86)%651*2D<V
M.'=Q4F]$4VXF(WA!.RM2:S@R;$UO>$%0,'!Z86)J:4EG.&U%+SAQ*W90*U=T
M4"M!9BMM63,X;GDW=S0S.&YN=F0O=T%Q*W90*U=T4"M!9CA!<&HO2CAU.$PF
M(WA!.R]*-3<Q>F9L,V5+:4XY8E0T=U-09V9S865'4#AN>3=W=CAN;G985R\U
M9GEI6D109$%W9S%C26IC:5!!5D='4%HU=F,W2FHR9G9U5V$F(WA!.W!W4D92
M95A&44%+:&EA1&)C;F,U<W=+9&U%4F532V)Y8S!0.30O-THO;5!T:%92-6IW
M4#-(*VU+='AU=DYD:C%(62\P>%9F8U-,.5DF(WA!.VPR4#(R+UI0:CAS5E4K
M63A$.7@O<&EQ3S!/5E)Q='531S9N;W)(.6LK07A6;5 Q;5!W9B]!2D9V+W=!
M,#1Q-S9Z2#10+W=!:3,O-7 F(WA!.WA6,S%M4'=F+VM7+R].3TMR2C)T3&E*
M;UHT5$Q#*WIX=D5Z2U(W9W)1-'%W:3@P5'I(9&%U-6TP<E)P3DUL=35$2DLQ
M=DUB9U=J=78F(WA!.RM25#%8579Y4'9T5$HR1TY&3&XX<V5B;%<P361J<#!C
M,&-5<U8P,$58=W5K<&)M<6UA,VM91G<W.'8R4U0Y:T-O2C1G=$9L+VQR4TDF
M(WA!.S=/,FAN=C=A2#E-.'!J3F,R,759;%!R4U9R<W%I<%)5-64T>4)+445G
M2&TO.#!5=4%8.&U#5S-736AW=#-%:G1,>2LR<$IE:6-F,F4F(WA!.TI.9C)S
M;'=J=EDR935(:GI6-39E1VXK14AH=4=J66IL95)/<7E"6E-G86=7;TIJ5'8K
M,3=B=$1V5%HW;54V8DYD>C9F8E18:T@Q83<F(WA!.VMI4G)I,W%'.4]1<4,V
M,4))3D0W-4%S:W(X,%<O;3971U X07<U9%<Y=DM1>7DO5U9R43%5<7EF0R]3
M:D$Q1T56,5%B4U<V=&9Z55 F(WA!.W!,8C-D;T%O:$9X25-H6FU&4%5A3E1$
M44)U-G0P4#)45&)*96Q'-TQ.2UA51C R,5A55T0S-&E4-C!Y,&]:2V9&4V=!
M-BM!1U),2F8F(WA!.V9I.$YJ8T-Y6E9V5$4T=&UK*W=*94HT1G5U,TML8T-S
M4DHO3G5*>&)Q3DUU25EI1RMU14]S<W%+,650045)2&1243="9#EI36XV5T\F
M(WA!.S=O;B]!1&8U8VYJ,&-*-F]F9U=N-65M,U9#44MF04<V.61V9D@P<G5Z
M6$E-:VTX=S9N-6AS+U-44G1)+U-B4W$O3U)P,&A32G1H2'DF(WA!.T1B<T-4
M=E-L0FA!0T-R95AB-U=B,U1V5S%E=T=N6&9Q3V]G1&@V;T0X3&)6;V5X*U9E
M:'A+:#58<F-6>$YQ5W(S5W!X6%@V6G1*-68F(WA!.W%,>%1-:UA#=$ET*U W
M<%EG4%57<$A/=6%F24-35$LK269J-U!T9&)-16MK,WA$;'8K2U1,.'DW<EAX
M;TAL<51N8U)8<VM*83E%9DHF(WA!.T<Y57AX1G595VQ0:7)T;#)Q;$U2:E8S
M,5HV<54K0TY89E=N;G8Q-WI.+WDP6'8X07=C=CEC=W503#-Y*S%W=5!,,WDK
M,3,Q-WI.+WDF(WA!.S!8=B]!06-V.6-E4$PS>2LQ95!,,WDK,7,S+VUI9T)U
M3#)G*WHX8W8T8C0X95AV;#EQ.&58=FPY<7196'9M<S-K26AL=7!*0W<T<$DF
M(WA!.S!J268Y64UA57E52C5B1D5S<V,X,T5+=#982#9N<'(V9T%K;T]96&-C
M<6(P<C)Z9&DV,V0P151E+W=#.6LO.$%X:V8O04EK8U5Q3TLF(WA!.W1X+V)8
M-6I&5CEX+W923"]!2S=F<GA65'A62#9&+W@Q<F8U;B]I2G=Q>E!&6%EQ-T95
M1')53W)486),1G!--E<Q*S514E1Y04UQ1&TF(WA!.W9-,$E913A/5DYU=45+
M5U!Y4B]M871N2#95;&<Y.$Q:56U,.'9186(Q:41):6A6:U9H1'5A<U9,9$%+
M8FY::G5S6E!Z5FMH0F0Y36DF(WA!.VLU:'!%='I)<#E)231+23AQ5$1M5S1N
M:WDP2&=25W(V5C-2;6E1964Q,6QN,64T=#,P>C!14%-I<%@Q=4LX:79W2S-(
M;%=L5SAA.5(F(WA!.U).2D9S9RMR4BM,+T%027@O=T1M<DEP9#E7:CA8+S5'
M4"]Z5FER=G$P9FDO+TEX+RMA<U93,U=D83!$4E56.55V1&%Q>7,V8S-L4$DF
M(WA!.TM11S1H4V$P-41965%#545O1U1Z=#5.:FQH:6LQ1C!E-%9(9W%,:T)L
M:T-L4T13;C=9<C1D.%!#5G-*-6$O5DQQ,FEU8F52-4E*,%<F(WA!.U-*>$I*
M4FMC8VQ/-3=G-49+6"M98CDY2G-6=31R4V4K068X06924E-Y0C%I5D=D,T@R
M9U-!;7=*04HR<4U)1F],1S1V>DXP=5905U0F(WA!.U)D8F$R-'A-<S9W<U90
M<D%&44M3,% R9TYJ5W4Q36QW231L8V9M1%DX3V8V1C%Q:&TK<F]O:&-U>FA#
M-V9$-FQ!0E-N6'(R,D]00W8F(WA!.T5Y5%)R;&13,#)+.6$S=4Q4,6DO1S-N
M9#%L0W$U5E-Y,3),2T$Q4&9);&LW53E2,%13,$0V:F9*84MY=39E=$]53$--
M5F9G0S%7-&<F(WA!.S<P>$%282]48GI3=%1T=G)/;C-0,6U!3S!::VIL8V=/
M:&]Y;F9R:5%L9S)P96)B:6)5-3=Z5#E-=')N5#E+95-/5SEU3&YJ379O+V$F
M(WA!.TMN;%=-4V9::C)0235R-39G;59G06E0-"]S8TM78S-906]+=FYV>E)A
M5V5L-DYF>'=3>7AA:D<P,&%T2W=+<552>%=V3',K5S5T54DF(WA!.U)"<C9M
M>DQQ4D-)3F,R1VHX=V)A;W):4T%D>4I39C1:4B]+03=N2"]!2E%(8WEQ>FYT
M8GDR:G5B9'DX36=Q<F-M*UAJ,GI/:$U31F@F(WA!.WHT4T5H635)>5=*9E%G
M,V)O,S=49GI(,WEB2E(Y3F9&=BM#8BMU2W4Y3F9&=BM#8BMU2W$Q-45V,7EF
M9'8W>"\R;2]M4'9I<6HV82LF(WA!.TQF.$%"3B]81E8P8V$X,3-B<5 R;2]R
M:7$V-&I8-GA,=3,R,B]A8G@K94MQ9G!R-'0O=U1F,7A62#9(17 Q5S-"3&14
M,%IH*WEF030F(WA!.W%Z2#9T2#1V+W=!:D@O-7%X5FDY-S5W9VEV5$1A5V,Q
M>F)X>7EW5%A:=5!445-1-U-+<6QI>#154$MO1D%/6#)D.#%/<3=43U V66,F
M(WA!.U%',T]U6'HO045F3&0R=4QS>FEJ8W!C36E!44M*,E!,>3,R-RLW;G-Y
M3S!%1C%A=S--6FM#5&]S:4%Y4%=J:FM++T8W-7-C1U5:25(F(WA!.VU/56=$
M.#-7-4E'16I%.'=A5F9Q,&9I+R])>"\K87-T64U2=69/53A&,V91;E)R>#1,
M5G!5:'9%:VQE2U9O6$-S:#1+>DEX<65/>$@F(WA!.W8Q<$QH4F%8,T@U<6%:
M67)'3E,P<E592FYA4W-58DTU5DDQ53AJ>6%-,7$Y2U4W2&9B1'=)-&U7*UAT
M5',Y83!Y4%5R9%I9-#-E4D(F(WA!.T9*25,V;4M2:RM)2WI,=GAR,7E*1DI#
M8EE%=7A6>#9E4'1I<4$Q0W=S3E)2578X0516=3!1:V]S>5)3058V,#5-8TE+
M;U(O3&9L-E$F(WA!.WAL=$5H2FEB;D@K-FA&1TE513=(<5%G2'EX<V]P36]A
M45%X=W<R<E)W>$M%:FI8,'=Q<6]O1D%$8D%$06Q:95)*95=K.7!C5S!J,CDF
M(WA!.WA',%5Y8VM&5613<D-O8T5B2$972WDO;&0U4&MU;G52<# X8G-3-F]K
M,45346UV<4MV3VQA.6HX4'1K*TUS945,62]Y<3AL;S-0.$$F(WA!.U)L=UI/
M4W5:1&-V57-U.61P859*<50X>FIX;&5%37DY850O9D0O96XO3E=16DE/+S!Z
M5$Y194]3*S!T3' T9C=P<&MH8W)U1'-72C@F(WA!.TU.<78P*WES.4YT+W$Q
M:' T=%E+;'93:45A3%4Y5%%.:5-R1'17.')E5T1Q,7A(2F1X,F)A:7=E-7-:
M2DEH23=U>&%Q2UIL2%5K<GDF(WA!.U)Q2'!T45IG>G=1-&IV5CE(16YH:&17
M3C%4>C$U9C!U-G-.2W1*;S5)3&5Y5F\W6E$V1#11<4M"56QQ,$-J3&-U;FA)
M04AO,EI-15HF(WA!.T%!.&=X0E!*9FPW;79X4W9U4&A-:6(K,C(K56I262LY
M<$=I>'-K:E99;S%J:FDT4F]!<7%T04%",D<K6F]!06]/64)7=U8U5V(P65 F
M(WA!.V=04G9$*UDK*T9+;'E0.$%)9G<O<FER=5(O:U T9C%X5E=V2&(V-5 X
M0D@W>#ET=C5J-S1Q;SAJ+TEF=R]R:7)C8DYZ6#1$,4AH+U@F(WA!.T96.7=Z
M9E=*9F=0,C(X4$@U-'%P.&HO269W+W)I<4\P3C)'<3(U16)(8S=$:B]+9D4T
M<7I(,7!0.3A0.39F.$%.5TMS6#%J4DY.:S$F(WA!.U<Q;&PQ0S0P-DQK>FI4
M;UIO3&1*;DUN<4TQ5DMY16QY4W@U5G%A9V=K,3$R<GA994EC8RM$>31U1S-A
M86)6-5)J:T)!5%!,:4E-:4(F(WA!.U96,V-U5S-Z1$HP:TM)<4IB3W%+0495
M96U!04YG04]78D-)04<S2C%H3C@R+U=K+S-W+S-P+WI6:%%X1RLO3%!Y=F0S
M9C%T<E,W:6XF(WA!.UHS959K=4LK;UI&65!Y-74Y3U)F:U-T1%A*8UI9.$MO
M;C5C95=)-#19-&)/-VAJ=#)K:V=73S5:945K=$]49RMP6&QT,7@T>6YH0V0F
M(WA!.S9(<$9J;W1M3$Q4-U-31S,U;#9&;&%H86<W<V%!04%!1'1G2G111TI3
M5U@U>FMU178W0E9$4#9B555S5D)B:E5'1VTO360O,F0K=5,F(WA!.SE+3C!:
M4$8K8D9F.4AK,#A%;VY,,4A,9T9);$I#.%E9>GEK;59U6D]W5FAX04ER:C96
M,U0O=T%U4F59-#1B:V$U3$A,3#8S*VI'2V@F(WA!.TAP0D9&4U934'$O23!P
M=&M46%))569.1VAA>'%S36%A6G)%=6MU07EY=$=V3&U'2VM(6FQ+;&5054AV
M:413:TI*9"M34$YC:C(W>&4F(WA!.UHW:%!30W!-;TUY:5)55D%#9C-P;S%6
M67-W*S$T8FLU3&E(8VEM5S968EA.<G!T<F)8535U8FE'2D5M;DY36&-#:&)C
M:SEF13%Y2EHF(WA!.TE$>F)O,S96,&%72D))8FTS1#-&;7-40TYZ8TI'-&EO
M-4AW14UW25ED1&E$4T-(;5 V0R]-4T-D-'!%,7579%)'2DQY3%5X-E)J:2LF
M(WA!.T9N4E-J37AF-&TT5DIQ4G-C<W--2TMR1G!8-6AS2V95=&-61W5&:V5B
M.4MW:59O:7!653-8:T](24U2,')8=T=.:$\W,5A2=$U84SDF(WA!.TYI<VQN
M;'5F5$QS,7A/,T]6,FMC=7I-,V-L;4]6:W,P2#5H,'9Z0F8K:VUL-G@K:6]G
M<G)C0EE%;&0K9$%#<G-F9TMI=$MD.%%19W$F(WA!.S-L,U0Y5W-.3SE$5DY1
M3W!84'%/+W="64M"2TMX<44V;6]'.4LO3'1I4V]E6C9P;T=P2F4V=VPS<&-6
M.7%6>$Y/*VY88F\U2E=B66LF(WA!.V=':C!3;G!H43-":G93;6%I94TR8D9N
M<"M0=3=N6%-X1S57050P+T@S278X>61#,7%F45!,9'-):E!D,G-"4S=)64@Y
M-$DT;%DQ2C,F(WA!.W%Y;DQD5&AN2TU10EI$4%4T6GEH141C:&=#954O35A)
M571'53%&1S5)2V4O6$U-85A*,T]%3DIK-VYP1VYW,U5.;$1&9'DK=F-);T4F
M(WA!.VMO1DMN+U!V;35X9VE)0DYL,TU!4D5!-VQ(4R\S14AY8B]I4GEX;7!9
M1F1I<71E+S<R5"]!4$=2+W=$:5)X5E)X5G50-V$O35EQ=G4F(WA!.U Y-DIF
M.61V,31Q<#1Q:CE#+S0V,78X04TO.$%%5&A6;65+<T$Q6'DW<6DV=V]H,'1T
M4FQU6G!:<&16:V5#2EDP;&MQ<U),0U=2:$,F(WA!.VI!0V\O6C9-=G=$4C9Z
M47EK845E2WIU9'8R;6@K3$=Z,$]N,750=WIC*T-G04EE;S-1,U!196\O9GI"
M.51/8DLR1G):=U=W8FU)23 F(WA!.VHU;F%V0E%T9G=Z8C1-47@T-'=(.$E!
M*U1O8W,K3U)L,VTP4')7;C-/;V%B3%HR.3-*67EY;% Y2VEQ2D966%9M0VM&
M4T-Y9W)7=F8F(WA!.TQG=TM14#5:.#1I>$5-6&U-:3A7,5<S1C8P6$QK-&XU
M;5)O:7AJ-65J.$%:84XQ2DHR;V)(8WAO<E8X<BMC-4%N,79Z33!S9V1'37,F
M(WA!.U5)9TM+;VMQ1E-.9VIC=6%F,V=99D0P>'-D>6%+=C5D.',K63E0,5$S
M5V]A-4IF,C-P;5 V=3-Q54Q556,O:F1L0DI"3W<R-V14:5,F(WA!.T9!6E)K
M575X5GA&4E1&5U K6B]-,FDK5S19-612*W-L6E99>"MK6&9K54MG<CEO04@T
M<3<T44Q15%-64R]M4#5A:DU1.4\W8WEX<$LF(WA!.T%S:5954%%C5T)M0E9G
M5V]2+U564$%6=&LR;%A.;G%E;3(R;U=X;45&,4=S<UED,U9G1T9A34]2,W=&
M2T8X=S,W-E19<F1X5VLY.$$F(WA!.R]W0RMI:6QK1')%<4TW=5!T06M"3F=3
M051T55EG5V=S8FDO33-3-54Y6DY&,71R8FI%>7IR0WA5*W-!5D%P3%$O84$R
M3F$W57E806HF(WA!.VE6>"M93FIW-2]O6%=Q1V(V=6EI1GDW3T5,=#A0<55!
M1DMD979B630X2SA42DY'=58Q3%19<C%R931T4%=,.&)E9#-754MR;%9,3%@F
M(WA!.UES;T15.3AI5U-".'EE6B],+VPQ65)Q33 S<C-)63(Q=D<P:E-38TMC
M<69%1D@R:#EO:D5!;$).2UAL+WID-68Q-CEL<S="<FXQ66LF(WA!.V%3<VAK
M4E=26#E-;$1Y3F%.:$U31D)91C5H+TYZ5G)45G1:5%1R4T)T4#!+-%,R=5DW
M:#=O>GEN,4=I9&MA3G944E$V,"M0>$A5-UHF(WA!.W1S4%IS5$=0151C>&93
M;E=:9&9)1UA#0E5$=6IV>DHX.')P;6@K6'15=')6<&\Y6&E--G!*331+2S!C
M8F=F=&8W.'EJ5&%$>$IY:50F(WA!.UA#,V%N5V5(0TUG3#1M04PK8C S26-T
M34A'=3E*,W)4+V=C>E0R35 U,S)/1T\Q+S90,G923DQV8E15=%!G=G)9=C9&
M=W9*3U):5T@F(WA!.UEG:799:DY*;'AM16I%.'<W9DA-5&E*1&M5=VQI6#!)
M3C(V3BLP,SAX.3AG>E5F5%AX8B]!24IV-C1Q-S Q.%<O=T-#8BMU2W$Q-44F
M(WA!.W8Q>69D=C=X+W="<'8U:C<T<6\K;79I,R]"3B]81E8P8V$X,3-B<5 R
M;2]R:7$V-&I8-GA,=3,R,B]A8G@K94MQ9G!R-'0O=U1F,7@F(WA!.U9(-DA%
M<#%7,T),9%0P6F@K>69!-'%Y;39N,#(P5FUU<FM12VMC:S=M5V1K<$9&5#%*
M1%9H.$-C:'EB;TLW-%%#545U:&TP*U9)1T4F(WA!.W)X=&-Q<E%X4W9,1DME
M86QW1$9)5FM6=4M-4W!7;V]A:EDT,'1Q:VXQ2T]32T]38W!*335J:%)P;41/
M-%%Y1E9"8F,X1DQ52%E%-# F(WA!.VQD2F)$,#(Y3FU%;$1W3%-3158W5F\S
M5$%R>D184$]N;791<%AS6C=V5%=V3%I)5VU38S-Z>6XQ;E9A.&]22$8K,W14
M3$)%1F=3578F(WA!.VDO37IZ0D4S1S4Q2%1%9$)2+U97+T-H479,;$IX04ED
M+VA)03(S<%%';4AG0SA4,&9Y<S)R,W1U*W!A:DEN,6$W-%1A8D1#,&<T5S<F
M(WA!.T%S:&LU35-86E-P8F5N=&Q:6D)/=E=K+S-W+S-P+WI69U,W,7!0.$%F
M1"]E;B].5TMU.6%4+V9$+V5N+T%$5FER5%--=V\Q=35(=C8F(WA!.V8O3E=+
M<D-S6DI*<WE3,4]2<$AV>"MZ6#1U,4YS5EAR27EQ1E<S9%9554%(<&=!1"]:
M67%P6&M36&QP4&%81G1).79C4G1&36Y*0E8F(WA!.TA5<7=Q2$)'>'A6:7-V
M-5AE5#5,<#=K86101S=%=7%*3E)%:TIR-FER>G!7=EDO1#=:4&I,2&A#,E X
M04MR>5=J8R\P6F-'5&MR;5$F(WA!.S-,,4Q,=EAA5VQ386LO330X6EAH1$UV
M5VLO,W<O=T(V9C@Q6D)K=%IU8D)M=%=:;')X2CE-:U8V,"M,1E=X27DO6G1N
M2'DY4"]M<D8F(WA!.UAM+VU(>5HK6'1X<F0W3&535#(Q>F9U<E@X351P=TQ%
M.'9T9D9W-4Y2;7%F9F)#9F%'1T5J2$M58FHW.79E>$A9-7E!>45456MY.#DF
M(WA!.V584$PR;V%F<%9R95=0.$%O=&MR2EI*-FA25E1I:6=,-F-G<4]+:G)L
M:TYD3$5425-!-'9D=CA!3FA04U)Y1&A-8G(S<U%8>40U2D0F(WA!.T%J5'=3
M1%5!>GEN.$1*;&XX<UI$=#1G+S),6"]!0U9J1R]!9G1:2V=#27%*2'A24496
M5C1G041904%(35EM,TI6-5=B,%E09U!2=D0F(WA!.RM9*RM+<5A)+W=!:"]$
M*W5+=35(*U$O:"]81E9A.&1V<FLO=T5F=D@R,B]M4'9I<6IY4#AH+T0K=4MT
M>',S3F9G4%5E2#EC5E@S1$XF(WA!.SE9;"M!+V)B=SAF;FEQ;GE0.&@O1"MU
M2V\W43-987)B:U)S5%9T:'@O;%!I8U9:5E,R:W544#A!5D$Y>D5657DP:4QQ
M5E9U235C<6DF(WA!.VEZ3E0R62M/4S1J5EAT*U R351J1C)2=B]B*W,O83 X
M3G)*2#E897E$4G))='@V4D5206M%=G),2G@U9F$Y5F594#A!3G8Q=U=Y<# F
M(WA!.TYR8E%*1$A"6D=+2S)O3&5*4%1627=Q96UO4E$S1E%%*T5!1$=Y:6QD
M<%I3<$%H:U5K8DXK-S(O-&)!;&=V.$%H3#AW3U1/9DU)36HF(WA!.S!K950V
M;&)+>E-R2'A8;59C8S!6-DUQ='1486UW>69%3S5J4E)6,S55.#!84#90:V96
M-798=$A5>BMN2$A$2$MQ=DED-#!F:CEH,%4F(WA!.VEL1'@Y.&5)3%-A*U9.
M2S%Z4S0W:$Y4=35B.'I/<E)!:VQ9;$$S5E1*3$DQ3C9F4EAC:S1#56A!*U@Y
M03%N5'13:75R+W=!,%-A:F(F(WA!.W)'>7E7<FUI=$I5.$<S6G9S<DEW4&I2
M9D1%:V1Y9TUQ*W0R=BLO:R\T268Q>4M89E<W6"]!2#AN+T)$*W5+<V8X>F%4
M<4=Q=6XV4#@F(WA!.W=T<&-:5D9M4U T:65$:S%5<3A:57-R37)F-T4O<S5)
M1D)#2&TP3%=*4%9).#!32GI!0T)A1&I215AS+V-Q>F94.#AB2&-T36<P+S F
M(WA!.TQ3,%-"-S0S3'%73'IZ3T-Z1FU,2#5!5F]",D=!<&)V-45N<V)I0S-V
M170U-5EN4TLT0D)-8G-P0W5"558T;F9!<D5$;UAN94YX1&(F(WA!.RMB-#)S
M;VE(:$5S56)43GAB:W-C:W4W53)!3#%*3SE2:S=(8WAO='AA2#4X5G54*V,T
M9C<P4RMN.59I2VEU-W!Y3%9++T51;SEH:EDF(WA!.S=L;SDW3F9R9'(O=C50
M.$%G:"]824UK<S%I,VUU-4EP<DQ60EIY=U)Z0TU"=5-.3$EO5D=K5&M&8TIU
M84U$=BM*0T50-6-T3E9S6DPF(WA!.W585TYD5%9:3&=P-E%#3$%K45%T<W%+
M>D1C35!U>$I52D)Q1VQA:4QV54DT:$A,2&1Y>7EX3TI11DEL2%)T=C)A+W1%
M6GEM9G,O4'@F(WA!.S5!0EEN2U)'+W=$3S<O9#5U.7AA<D9W>$I.8TE!*U,W
M>F1P,'(V5F\Y<DA.2$Y*85)M3U9G=W!52V<R.79H>DDW4C=,>35C3T]%84HF
M(WA!.V=.+VM'<E-A,TA$2D]2,D5I>&(Y0S-V*U(O=U=A8B]1+W%F-E!Z9&@O
M2W5(>BM39C(V;4]&1654,4=554QN=FYA86)&2T=-4FME26<F(WA!.V,S;DTP
M>$M:249!.4542S9E:D-/47%!,60O.$%+3UAT86IY6'A'2W4U3#1J1E9A.&1$
M9'IK34-$23%$6"]+3TMQ4$IF15EQ=5)L-7(F(WA!.W5/;WA69&-/:&YK25E%
M1FTW*RM+<69*9D59<6HY1&MJ6%991UIG;T)A<$I!2#)4:7))-VEY,%<U36AM
M8T]*6EE,:#%->F-F5G185U,F(WA!.T9G;V%I.%AJ56UN,G%F1EA"5$]/5U$U
M968R.#!N=$Y$97EU;SE39W5R95A6<%I&9W9*<'!*0D5U;DQ/,&E7.$5337-3
M3D9'5E970T$F(WA!.TU14W<K235%4F(U6GA)8THK;G!Y*W%U6C8W<"MZ5V8Q
M9UA#,TE%9U0P*TIL4' X95%9;C K451L=#EQ;&9O>61/4'AB56@Y6FE';V$F
M(WA!.UI,6G=A;#E3;6Q+9C960S%(54LV<R]':D%J:V]+.61Q-%%X2U-T;R]M
M2F1)3G1&-7!(-E(K<G!!3#$T-'E/4WI--U-&3U9/5%).-F0F(WA!.V5U,6$Q
M=S)/-49&45A1=DY-9U0V,S5S5U=13VI'5TM.64-I<4I+:%5J8TDS3&UN.31'
M2'<Y36)(8VEI<BM89$4Q;E0Y54XQ<4AM3#8F(WA!.R]B96U9+W$W33E#,49(
M4#0U1U5%:T4W1&)T,4]*25-!+W=$+S)1/3T\+WAM<$=);6<Z:6UA9V4^"B @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^
M"B @(" @(" @(#PO>&UP.E1H=6UB;F%I;',^"B @(" @(#PO<F1F.D1E<V-R
M:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@
M(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B"B @(" @
M(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B/@H@(" @(" @(" \>&UP34TZ26YS
M=&%N8V5)1#YX;7 N:6ED.D1!1#)#135!1C5"0T5!,3$Y-SA$14(W1C)#-# V
M.30Q/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ1&]C=6UE
M;G1)1#YX;7 N9&ED.D1!1#)#135!1C5"0T5!,3$Y-SA$14(W1C)#-# V.30Q
M/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$
M;V-U;65N=$E$/G5U:60Z-40R,#@Y,C0Y,T)&1$(Q,3DQ-$$X-3DP1#,Q-3 X
M0S@\+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-
M.E)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+WAM<$U-.E)E;F1I=&EO;D-L87-S
M/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N
M:6ED.D0Y1#)#135!1C5"0T5!,3$Y-SA$14(W1C)#-# V.30Q/"]S=%)E9CII
M;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N
M9&ED.D0Y1#)#135!1C5"0T5!,3$Y-SA$14(W1C)#-# V.30Q/"]S=%)E9CID
M;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N
M=$E$/G5U:60Z-40R,#@Y,C0Y,T)&1$(Q,3DQ-$$X-3DP1#,Q-3 X0S@\+W-T
M4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.G)E
M;F1I=&EO;D-L87-S/F1E9F%U;'0\+W-T4F5F.G)E;F1I=&EO;D-L87-S/@H@
M(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" @(" \>&UP34TZ
M2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z1D,U
M048U1$0S,4)#14$Q,3E#049%-T9%.3(R.40P144\+W-T179T.FEN<W1A;F-E
M240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C M,#<M,#)4
M,3(Z,S$Z,S4K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R($-3-B H
M5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D1!1#)#135!1C5"0T5!,3$Y
M-SA$14(W1C)#-# V.30Q/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#(P+3 W+3 R5#(S.C(P.C4W+3 W.C P
M/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V
M=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA
M;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI
M<W1O<GD^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SII;&QU
M<W1R871O<CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]I;&QU<W1R871O<B\Q+C O
M(CX*(" @(" @(" @/&EL;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/E!R:6YT
M/"]I;&QU<W1R871O<CI3=&%R='5P4')O9FEL93X*(" @(" @/"]R9&8Z1&5S
M8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B
M"B @(" @(" @(" @('AM;&YS.GAM<%109STB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+W0O<&<O(@H@(" @(" @(" @("!X;6QN<SIS=$1I;3TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+T1I;65N<VEO;G,C(@H@
M(" @(" @(" @("!X;6QN<SIS=$9N=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+W-4>7!E+T9O;G0C(@H@(" @(" @(" @("!X;6QN<SIX;7!'/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R\B/@H@(" @(" @(" \>&UP
M5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^1F%L<V4\+WAM<%109SI(87-6:7-I
M8FQE3W9E<G!R:6YT/@H@(" @(" @(" \>&UP5%!G.DAA<U9I<VEB;&54<F%N
M<W!A<F5N8WD^1F%L<V4\+WAM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y
M/@H@(" @(" @(" \>&UP5%!G.DY086=E<SXQ/"]X;7!44&<Z3E!A9V5S/@H@
M(" @(" @(" \>&UP5%!G.DUA>%!A9V53:7IE(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @/'-T1&EM.G<^-3$N,# P,# P/"]S=$1I
M;3IW/@H@(" @(" @(" @(" \<W1$:6TZ:#XX-"XP,# P,# \+W-T1&EM.F@^
M"B @(" @(" @(" @(#QS=$1I;3IU;FET/E!I8V%S/"]S=$1I;3IU;FET/@H@
M(" @(" @(" \+WAM<%109SI-87A086=E4VEZ93X*(" @(" @(" @/'AM<%10
M9SI&;VYT<SX*(" @(" @(" @(" @/')D9CI"86<^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \<W1&;G0Z9F]N=$YA;64^07)I86PM271A;&EC350\+W-T1FYT
M.F9O;G1.86UE/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A;6EL
M>3Y!<FEA;#PO<W1&;G0Z9F]N=$9A;6EL>3X*(" @(" @(" @(" @(" @(" @
M/'-T1FYT.F9O;G1&86-E/DET86QI8SPO<W1&;G0Z9F]N=$9A8V4^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IF;VYT5'EP93Y/<&5N(%1Y<&4\+W-T1FYT
M.F9O;G14>7!E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T
M<FEN9SY697)S:6]N(#<N,# \+W-T1FYT.G9E<G-I;VY3=')I;F<^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O
M;7!O<VET93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&:6QE3F%M
M93YA<FEA;&DN='1F/"]S=$9N=#IF;VYT1FEL94YA;64^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O
M;G1.86UE/D%R:6%L350\+W-T1FYT.F9O;G1.86UE/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z9F]N=$9A;6EL>3Y!<FEA;#PO<W1&;G0Z9F]N=$9A;6EL
M>3X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86-E/E)E9W5L87(\
M+W-T1FYT.F9O;G1&86-E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N
M=%1Y<&4^3W!E;B!4>7!E/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @(" @
M(" @(" @/'-T1FYT.G9E<G-I;VY3=')I;F<^5F5R<VEO;B W+C P/"]S=$9N
M=#IV97)S:6]N4W1R:6YG/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z8V]M
M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^"B @(" @(" @(" @(" @
M(" @(#QS=$9N=#IF;VYT1FEL94YA;64^87)I86PN='1F/"]S=$9N=#IF;VYT
M1FEL94YA;64^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.F9O;G1.86UE/D%R:6%L+4)O;&1-5#PO<W1&
M;G0Z9F]N=$YA;64^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%M
M:6QY/D%R:6%L/"]S=$9N=#IF;VYT1F%M:6QY/@H@(" @(" @(" @(" @(" @
M(" \<W1&;G0Z9F]N=$9A8V4^0F]L9#PO<W1&;G0Z9F]N=$9A8V4^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IF;VYT5'EP93Y/<&5N(%1Y<&4\+W-T1FYT
M.F9O;G14>7!E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T
M<FEN9SY697)S:6]N(#<N,# \+W-T1FYT.G9E<G-I;VY3=')I;F<^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O
M;7!O<VET93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&:6QE3F%M
M93YA<FEA;&)D+G1T9CPO<W1&;G0Z9F]N=$9I;&5.86UE/@H@(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF
M;VYT3F%M93Y#86UB<FEA/"]S=$9N=#IF;VYT3F%M93X*(" @(" @(" @(" @
M(" @(" @/'-T1FYT.F9O;G1&86UI;'D^0V%M8G)I83PO<W1&;G0Z9F]N=$9A
M;6EL>3X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86-E/E)E9W5L
M87(\+W-T1FYT.F9O;G1&86-E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z
M9F]N=%1Y<&4^5')U951Y<&4\+W-T1FYT.F9O;G14>7!E/@H@(" @(" @(" @
M(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SY697)S:6]N(#8N.3D\+W-T
M1FYT.G9E<G-I;VY3=')I;F<^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IC
M;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O;7!O<VET93X*(" @(" @(" @(" @
M(" @(" @/'-T1FYT.F9O;G1&:6QE3F%M93YC86UB<FEA+G1T8SPO<W1&;G0Z
M9F]N=$9I;&5.86UE/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @/"]R9&8Z0F%G/@H@(" @(" @(" \+WAM<%109SI&;VYT<SX*(" @
M(" @(" @/'AM<%109SI0;&%T94YA;65S/@H@(" @(" @(" @(" \<F1F.E-E
M<3X*(" @(" @(" @(" @(" @/')D9CIL:3Y#>6%N/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D^36%G96YT83PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" \<F1F.FQI/EEE;&QO=SPO<F1F.FQI/@H@(" @(" @(" @(" @(" \
M<F1F.FQI/D)L86-K/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*
M(" @(" @(" @/"]X;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @/'AM<%10
M9SI3=V%T8VA'<F]U<',^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!.86UE/D1E9F%U;'0@4W=A=&-H
M($=R;W5P/"]X;7!'.F=R;W5P3F%M93X*(" @(" @(" @(" @(" @(" @/'AM
M<$<Z9W)O=7!4>7!E/C \+WAM<$<Z9W)O=7!4>7!E/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \
M+WAM<%109SI3=V%T8VA'<F]U<',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N
M/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @
M(" @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B
M/@H@(" @(" @(" \<&1F.E!R;V1U8V5R/D%D;V)E(%!$1B!L:6)R87)Y(#$P
M+C Q/"]P9&8Z4')O9'5C97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #B EP# 1$  A$! Q$!
M_\0 'P !  (" @,! 0            <(!08$"0(#"@$+_\0 5Q   00" 0 $
M"04,!@@% P,%!0(#! 8!!P ($1(4$Q46%U97EI?6(562U=<)&#$U-U)3=;31
MU.8B05%VD>49-G&5L[6VTR,F,F'2)*&F)2<S1F*!L<'_Q  = 0$  @(# 0$
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M'C3#N26 'G/.JH?058D&Y#"5.,N0"UC*Q)9%("M,J@+KJJ0LSBQN&6QT!4\
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M#J1M?E$@M:+[2X;#DEW>-;2C,B3*8E DB4Q"[&1\ZN[+(K%5"&]P&9=9\1.
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M@BU<N)TB=7%;: I0,F9/'+!99%98\656RK&PWXPW84Y9:67E"XHUVN+EZON
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MG6U*0XVI*T*RG.,Y\2R1R0R/%*CQRQ.T<D<BE)(Y$8JZ.C ,KHP*LK %6!!
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M> 2+KK4G4/9P+8KYY@"/L<156)J!V)FR 9]8(!SBA0*PQ!<P.;:A%TN$*W9
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MI_47?_\ =./^]Q[Z?D[^5^QOK!_!3WN^V_R9VK]7_NI]YETI_47?_P#=./\
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M (X_=QIP/,=*:\1R/6GR?V9_QQ^[C3@>8Z4UXCD>M7#Z,+1=P7;<BYPZ&G!
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M,F9896\W';[$0?'ESI3SK[S3#$:)&?D/O.(:9:6M6$YLJL[!5%V.@&@]N\V
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MFJP&F;SLNYK/YV)4<U#,0;498V JMV 0MJ>5'S'K2)<+%ITN!8,UHXPY7FR
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ME]/H[I/G L;@D'<9W1[UA/@4$8H89B0-;B:8!KL89:[,+0\%UZ:K]CIHP^J
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M#2"G#@3P:8,M2_\ R[+1_0PPYE7]/-E5A']'&?Z64YPG\.<9QCJYR1*@$FX
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M&F&&92W77%9^1*&T*4K/X,9Y>/:FRYG6*+:&"ED<A4CCQF'=W8[E5%<LQ/H
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ME+.5".E!\<U B'*M81$R6 =0YWJP1H\\>PY*$#7F7(LR3%P^MUY<%8UHA&-
MI!./<DYO90UCE.5E89O0MP3J?0/GO8AK/=<.EV*W%P&4@E=;M8C<+:^G=8',
MM]F&=)6@6"ZUFBUN':3)6QFW!V)/DV6&#H8=([9C[%PQ+*Q8B"-7F&-5V*OP
MR8_P[,J6Z.GL9<$D($V74X=U1G8JH50;9@223'X+"]F"RJQ!M;4'Q @6$Z%U
M10Q+&U\I  M)X[FUU)C901OT.X@FPO,%9Z<4IQ2M=MEL T@#+LMEF.P0\)X=
M&>>CCR1:4Y++DX885"ABP\2>5(SB14A"'08(^%*ERI<IEAAE:UXQRRJSL%47
M)N=X L 6)))   !))(  )-59E12S&P%O02;D@   $DDD   DDU7:W],34-<H
MA^["'K':'0D6!-:K"*M8ZF?,Q9L>W$79(B/>A-:;G1A8/7NP3A5Z.M[$*%23
M["TY)1V8+^=<)*SJA"KF)&;,K*",@L2A:Q)DC 'ISJ=QO6!L5$JLPS,5MX<K
M(QOF.F<+< ([$C<%/IL#*M3W#4[=>+AK^#@G&.U0B2BQUS!!:.)L\ % IZ[&
M7K1QV V$+,5P]<856.Q()*20%%V<=^C1V)L%Q_&\+HB2&V5@"0",REB^4,M\
MRYE0NI( *G0W!ME657=D%[J3Z#9@ N8JULIRLP5@"2#O N*E;F*LE=8/W6G=
M-FU'T6EBZA.DBB^U;? U[,*PW%QY<&LR!!HU84Q9+><*:=*1A#()[JZEJ'%B
M&6UMN)0O'SKRG;6Q&R^S9CPKM%+M+%)@7D0E63#-%--.%8;C*L0@;<3'+)8@
M@5\[\IVU\1LOLV8\*[12[2Q28%I4)5TP[1333Y6!N#(L0A/&.5[6-C7S?Q]5
MT6[5BK$:'94PR\=E$:Z0#3N')R5I<85,+-CV5KQ$4ER8J((B8DIBG(\/.6W8
M4Z/*S+^!+LW!XS#X>3!8@)*H"XN.=O&+$%I51;Y;%\D:YLLRI<%)%</\#79F
M#QF&PTF"Q 250$Q<<S7>]US2A ;)8N5B7-EF5-"CJV:8= ;8!]'/I5:@/Z>.
ME)8ITU7J;L9M$S,P/: !\I!$G&&7DX:20S)B.X.1DKAL119V.,7%8P\/7U<M
ML/:<.P>TNRY]E32/$98,)CQGS18B&>1(IPIL,^93WR@H%BG6,H+IIRNQ-IP[
M![2[*GV5-(\1E@PF/ ?/%B(9Y$BF4$6$F93WRW0+',L90!D-OL"LW^KE@_4A
M7]@D<]3S_P"1-_RI/_8U>II_\B;_ )4G_L:O@*YXDKQ)3BE.*4XI3BE.*4XI
M3BE.*5[H\A^(^Q*BOO1I49YN1&DQW%LOQWV5X<9>9>;4EQIUIQ*5MN(4E:%I
MPI.<*QC/+*S(RNC,CHRNCHQ5T=2&5E92&5E8 JP(((!!!%61WC=)(W9)$971
MT8JZ.I!5E8$%64@$$$$$7%=SW1!Z34W;4)RAW)J2]>*^-[V@ZS%=<B'Q$=;,
M?,HDXRWEF 786\RW(6]EJ.2RXEYC*9.76,^BO)_VTEV]&VR]HJ[;3PD/>#%+
M&3'B\.A5.\F*C+#B$+*LF;+',2'CLY:-?2'D^[:R=H(CLO:*NVU,)#W@Q*QL
M8\7AT*IWDS*"L6(4LH?-E28D,GCS+5Y.?3*^G5(6I_RDTK^\$#_B<E=X^<?Q
MI6 N/^MUI_O&<_YG*X;>?G/\:5KG(I3BE.*4XI3BE2=IG\J%-_6BOV.3RR><
M/V_P-*TBP?CXW^MR7[:]RM*Q'%*<4IQ2G%*<4JZO12_%-Q_6(G]FF<R1^G]G
M_6E6SYDI3BE.*4XI3BE.*4XI3BE< I%ES1LZ'!)2 TV3%?8BEHK$*5)&R'6U
M(:FL1B,>7 ?=C+SAUMJ9%D1EJ3A+S+B,J3F00""0" =0;@'V:$'D14$$@@&Q
M.X@ D>VQN.8(]E5QG:PV@)TGKX>FU*V=NS4KU1M02PV68P)1:;( &9!V@/,+
MQQR,M,72I%+A44V M!G$(^+)@V5S,FQEN*V!)$9G.7NH9<R,J@G*K&ZM:^N1
M@CY00#DL+7K 8Y!"@S=Y+'E92Q S,HLP+6_34LN8@FS7-SK5;3W0PNQFP,QT
MF:PY#A5<HXFU6:KT^\Q#>QR=-!12EH.4FYA+ .6BQW?RB/%W(;,8DUWY]$*;
M':ENM.[ Q:!;Y6N6%U5G0B,2$JH="I\*95%[C347 -83A6)M=;!3XBB.#(54
M9F1PPU<,QMKK8$7-21;-2[&+U/353+44=:!(* !@2)T.:-FW[4H@*+J29,"'
M:+E>6AEOOI@B)[LUN<(' V"MBQYA\%7FC%F1/A8UEC#S.KE2Q8@6(24DO8E4
M2Z( ;]RQ96) 9LJV-WBD98E*!@ H)O=XP MP&9[,Y(MWH 90#E6[7'%KVB+(
M6&GYL[7SVMS3N[M#W<?71%J@1:M*KVKMM0[+++%9%8LDR9?KD2KKQXQ<#E_B
M(?LYU=4BH&NO4P(59-.H*^/O!W,Z%BI+!I(BH #*!&@;*$6,V49S?QL*A86(
M-T[L]["X4,,I$<H:YRL2[%;EBX\1RBW@!K$@^CSLZ+3>F$$>B1F2NZ]?7D$
M5*(5Y, E=;&6WD09GC70T9J:FL+'[!J4%HOL!4[8&9$&>**3I-<K]8SB6GB+
M80ZVA="U@UPBB$6.;3/>-C:,".Q! #,U5$$@7%"VLR.!<K8NQF((MKELZB[^
M.XL?"JUE\]%BT42VA;/JVROCGX\2WDI\0!&K.O*JT=,V?HZLQ1<6EUD1##N
MR%.UG;%G&YB9KI,O-P_-D..9!H$/=2.C+*MP2@!8M(^55Q!OG8WS!Y$"VL H
M-OTBUCAV1@T;6MF-E"HMR8- H%K%8VS7WDZG=:6&:(9E=):5>96ODAP(H0M@
M7?AA"O2"-O($JT-'36K3)D&4VR#6 K47 L!0AH3-<=LC,N_%)4@I('9'8>\
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MNQ%[9W #/;,ULQ._YK#!$Q)9 UP1E8DJ ;7RJ250FPN5 .G&I=!!!-9"!ZV
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M5]&+0\C$9)#7(DRS#IR*%$C6&89L4.-6&Q8D*W$8AG"9"*W/;&AHC#9]#.+
MVM\O)043*/G7B.7W3/K:0B[]X<H"DM<FY*@&UR?#YNX6LJVQ=Q#IX ;+D -R
M M@+6).M@!??OUU-]IHVFM>ZY(S"M3$DHLV8DPC#A2TVNRMCVK$<59;$R#CV
M8V7C@&; ?RV7.M!&H#9>;$'ND$R/%@Y,6CS22 !R"!;<J+?*N5<Q506RJ++F
MO87M:YO9(D0DJ#<WWLS6S',ULS'+F;5LMKFQ-["I0YCK)5+NGOT99G2IZ/1N
MA@'8S%X %8-WH2ICJ(\.58PT4A#4(ER5Y2B.R<#E"HMJ0ZMN-$GR8,Z6KN\1
MSG4NVW9Y^TNPIL% 57&02IC,$7(5&Q$*R)W3L?-6:*62(,2%21D=KJA%=2[:
M]GF[2[#FP4)5<9!*F,P18A5;$1+(G=,QL%6:*62,,2%61D=CE4U\N>=?6W3-
MJ/5=,ROA3K@AQ9VN;:9(T"Q@U@GW)3^%Q)TJ$.D/2<1^\"E"C!R(8B36VQ+I
M%]AU]OSC[AQ.RL3/AL\$,_='O\/M19,%/"826:Z.Z1L6RYHC%-,LJ.!$9"I8
M>=!@L5LC$S8</!%,T1[[#[4$F!GA,#%C=79(VS%<T?=RRK*K@1&0@M5M.@1T
M$;'M'<FO=@3U29FJ=>G85NM-JR,D0ZO8S=?F1IP.FTHC-\$Y<,2"T3KLI@?%
M0#A!$Y0T062FQ8B^S]B>QF(VGM; XY\S;,P,R8K$XKNV7#8B:!U>'!X.1['%
MYI4_[Q+&H@2#02&5U0]F[%=BY]H[5P..D+-LW S+BL3B#&R8?$30.KPX3!R/
M8XH-*G_>)440I"+!S(ZH?J1L+:W0!QIM/:<=#DVT)Z\8[2UPGTI3UYSC&.M6
M<8Z\YQC'7\N<8YZ0F4M%*JBY:-U XDJ0!^TFO1TJEHI5479HW4#07)4@"YL!
M<GTZ5\3OWGO2/]6<SV@J/Q!SRM[WO;#XF?ZYL[^KKRO[WG;+XED^M[/_ *NG
MWGO2/]6<SV@J/Q!Q[WO;#XF?ZYL[^KI[WG;+XED^M[/_ *NGWGO2/]6<SV@J
M/Q!Q[WO;#XF?ZYL[^KI[WG;+XED^M[/_ *NGWGO2/]6<SV@J/Q!Q[WO;#XF?
MZYL[^KI[WG;+XED^M[/_ *NGWGO2/]6<SV@J/Q!Q[WO;#XF?ZYL[^KI[WG;+
MXED^M[/_ *NGWGO2/]6<SV@J/Q!Q[WO;#XF?ZYL[^KI[WG;+XED^M[/_ *NL
MQ#Z#_2F("3)R'J>:\*K_ (OP7EXLU)1B'XTD*B0.TTY94/O=XD)4WCN[3O8S
MCM.]A']+CWO>V/Q,_P!<V=_5T][SME\2R?6]G_U=8?[SWI'^K.9[05'X@X][
MWMA\3/\ 7-G?U=/>\[9?$LGUO9_]73[SWI'^K.9[05'X@X][WMA\3/\ 7-G?
MU=/>\[9?$LGUO9_]77.&=#+I$SR,*%(H>1,>5*98?)SS]:5"'LN+2ER9*3",
M2YBV(Z,Y=<1%BR)"TIREEEUS*49R0^3KM=++'&^RQ CNJM-+C,"8XE)LTCB+
M$R2%4%V(CC=R!9$9B <L'DX[7RS11/LKW.DCJK3RXO!&*%2;-)((L1)(5078
MB.-W(%E5F(![@-):3JFD*FU7J^UB43E89D6.QOM(00/$4(SCPCG5E68T"-E;
MC8T:AQ34-E2E*6_,?ERY/H#LWV;P'9K +A,(H>:0*^,QC*!+BI@+9FWY(DNP
MAA!*Q*2;M(\DC^A>S79K =F< N$PB]Y,^5\9C'4";%3 ><V_)$ER(802L:DD
MEI&>1YDYV&NQ5(6I_P I-*_O! _XG)7>/G'\:5@+C_K=:?[QG/\ F<KAMY^<
M_P :5KG(I3BE.*4XI3BE2=IG\J%-_6BOV.3RR></V_P-*TBP?CXW^MR7[:]R
MM*Q'%*<4IQ2G%*<4JZO12_%-Q_6(G]FF<R1^G]G_ %I5L^9*4XI3BE.*4XI3
MBE.*4XI3BE19NDI>0VN#I'7+*GK:Q*KR8:6QTPHX@>_91$>PO-1!P.U$,/LU
MUTJZQ+A5*X21[Z&R#51LV8WB2=EA"-(HD\VS7U URG*+EE'G6T+H#NSK>XQS
M%Q&QC\[PVT)TS#-H%8^;>Q".0=<K6L:<#[_TMX-H#I<J]NE,62^:N+'!QBK-
M9#!*L:IW1SAW\(*)" IJ'$CUN83W65>B3SE=7@X%2["LQR8PNJ6';,>$*GQ*
M,L<@4AK,6#SE&(8@W8"$:*WA;55'C&J'Q((NK>)XR05%@I2 . 0& RDRDC,I
MNNA)\+2!2'>D9FH7J;>9=E-78OKW2E@%!4!6ZT"!V0NQ/?OX"MN '8DIM\.1
M\- )PI5AGEF(<$5)FR'&2*')F-_<^=.["J@DF4F^9F4$=VS!KBQ&H.4"Y.@M
M5U[[*Y<L7,<3!<N50Q!+JMK&X.A&8FUK^W.B3VZ4:RN\G:(>Z&YCFLJ!:88W
M7 M-9NRK5863C=SUS6Y0>2[,C.AG1@1E1IAUL\,2?(SXA1E; WQ;4B'O(^[*
M*.\=29#F3*I&21@=#>Y\-K'* 0;F\AI>[?O%<GNT:R#*^<YLZ+;72RZC49B0
M= 1"4.)N8;@9.)/](&PQ4A3Y)V/5G]A1)#%#EU'>4@Q3!T>[O#YI+8M?O)#7
MM9HEJN\*+L&P#X=(M3,B.':N2AN8F$W $"ZJ+L$MGS0V<]W<"-D$C.B>!276
MQ8I?$!* ">^:P)LID'P966Z#/8F17**K. [#(P-LUIKU8%V7WC3!N;8-D+$Y
M);47;:D>=L_BT#$->.2E9&ER&PA4+95K56''8%<"V&S2D1"J8V2T  &9E0X0
M_#(T=I@%CO:+(XRW8KE#%1&>[3.+L54$KN+-8DY8Q)\$29+7DS*Q8A;@E02X
M[QLI\(9K VN%6X%6_P":M;5.*5&CE?VDI:\M[) -MY6K*$*UUVU(1G.<I1E?
ME@GMY2GJQE793VLXZ^SCKZL3IP/,=*C7B.1ZUX>3VU/677_=Q_./&G \QTIK
MQ'(]:>3VU/677_=Q_./&G \QTIKQ'(]:>3VU/677_=Q_./&G \QTIKQ'(]:>
M3VU/677_ '<?SCQIP/,=*:\1R/6GD]M3UEU_W<?SCQIP/,=*:\1R/6GD]M3U
MEU_W<?SCQIP/,=*:\1R/6GD]M3UEU_W<?SCQIP/,=*:\1R/6GD]M3UEU_P!W
M'\X\:<#S'2FO$<CUIY/;4]9=?]W'\X\:<#S'2FO$<CUIY/;4]9=?]W'\X\:<
M#S'2FO$<CUIY/;4]9=?]W'\X\:<#S'2FO$<CUIY/;4]9=?\ =Q_./&G \QTI
MKQ'(]:>3VU/677_=Q_./&G \QTIKQ'(]:>3VU/677_=Q_./&G \QTIKQ'(]:
M>3VU/677_=Q_./&G \QTIKQ'(]:>3VU/677_ '<?SCQIP/,=*:\1R/6GD]M3
MUEU_W<?SCQIP/,=*:\1R/6GD]M3UEU_W<?SCQIP/,=*:\1R/6GD]M3UEU_W<
M?SCQIP/,=*:\1R/6GD]M3UEU_P!W'\X\:<#S'2FO$<CUIY/;4]9=?]W'\X\:
M<#S'2FO$<CUIY/;4]9=?]W'\X\:<#S'2FO$<CUIY/;4]9=?]W'\X\:<#S'2F
MO$<CUIY/;4]9=?\ =Q_./&G \QTIKQ'(]:>3VU/677_=Q_./&G \QTIKQ'(]
M:>3VU/677_=Q_./&G \QTIKQ'(]:>3VU/677_=Q_./&G \QTIKQ'(]:>3VU/
M677_ '<?SCQIP/,=*:\1R/6HLO\ /#@I0^%M/>FC TU6<.BHE_J=2'2E9<5V
M4NCV+%>V7<Y6M/9PN,C^DI/5C.<XYQN.Q>QH6C3:6(V=$YUB3'3X6-M3:\:X
M@@ZD 74:D5QN-Q6R861-HXG9D3[XDQLN&1M38%%G<'4BUU&IJ11HO89*!$G!
M]K5&>+DL-N0)@W7\>5 D1LXZFG(DB+='([K&4XZFULK4WU8ZDYZL<WXWBD17
MB97C8 H\;JR,OH*LH*D<"#:M^-TD1'B>-XV4%'C(9&7T%&5BI6VX@D<*_25>
MVG@=/RK95?4G$*5E2<:Y[.<X\ YUXPKRQSU9SCY.OJSU?AZL\OIP/,=*OKQ'
M(]:ZI?%EQ]*QGLM_GO,-T]0_3_MIKQ'(]:>++CZ5C/9;_/>+IZA^G_;37B.1
MZT\67'TK&>RW^>\73U#]/^VFO$<CUIXLN/I6,]EO\]XNGJ'Z?]M->(Y'K3Q9
M<?2L9[+?Y[Q=/4/T_P"VFO$<CUIXLN/I6,]EO\]XNGJ'Z?\ ;37B.1ZU+M/$
M7I6JMP+:N8AN.WF@]Z853O"+D]NP2,,^#?\ *-'=_ KZUJ_\)WPN,]C^AU=K
M,@I9O"?1<9M^O_#2S<1R_P#FHB\67'TK&>RW^>\BZ>H?I_VTUXCD>M/%EQ]*
MQGLM_GO%T]0_3_MIKQ'(]:>++CZ5C/9;_/>+IZA^G_;37B.1ZT\67'TK&>RW
M^>\73U#]/^VFO$<CUIXLN/I6,]EO\]XNGJ'Z?]M->(Y'K6^ZN%7=>PZ<B/<1
M3#ZCL'#3RZCX=#:\N?(M3/E"UX3&/P]CPB.O\[')!2X\!WC]/^VFO$<O_FL%
M;1=T3:K,ERW"W'$V SAQQ-3\&E:\$I.%+PCQ^KL84KK5A':5V<9ZNUGJZ\B4
MN? =Y_3_ +::\1R/6M?\67'TK&>RW^>\BZ>H?I_VTUXCD>M/%EQ]*QGLM_GO
M%T]0_3_MIKQ'(]:>++CZ5C/9;_/>+IZA^G_;37B.1ZT\67'TK&>RW^>\73U#
M]/\ MIKQ'(]:>++CZ5C/9;_/>+IZA^G_ &TUXCD>M2/J(3>'-DU)$:Y"8[ZB
M2L-ON5#O"&U=UD9[2F?*%KPF.KKQV?"(^7/7U_)U9E2EQ92/;FOZ/^&FO$<C
MUK33HNYX-F<+MHM:\%2.%KQ5.QA2L2WL*5A/CY79PK/7G">UGJZ^KKSU=?(N
MGJ'Z?]M->(Y'K6*\67'TK&>RW^>\73U#]/\ MIKQ'(]:>++CZ5C/9;_/>+IZ
MA^G_ &TUXCD>M/%EQ]*QGLM_GO%T]0_3_MIKQ'(]:>++CZ5C/9;_ #WBZ>H?
MI_VTUXCD>M/%EQ]*QGLM_GO%T]0_3_MIKQ'(]:N'T80FQ'A=MR/OH6"E) 7A
MU+U&[[EQ68TOLY2KRHC>#PG&,XSCJ7VNOKZ\=75FZ%3>RD;OTK\?U::\1R_^
M:M)Y/;4]9=?]W'\X\OIP/,=*:\1R/6GD]M3UEU_W<?SCQIP/,=*:\1R/6GD]
MM3UEU_W<?SCQIP/,=*:\1R/6GD]M3UEU_P!W'\X\:<#S'2FO$<CUIY/;4]9=
M?]W'\X\:<#S'2FO$<CUIY/;4]9=?]W'\X\:<#S'2FO$<CUIY/;4]9=?]W'\X
M\:<#S'2FO$<CUIY/;4]9=?\ =Q_./&G \QTIKQ'(]:>3VU/677_=Q_./&G \
MQTIKQ'(]:>3VU/677_=Q_./&G \QTIKQ'(]:>3VU/677_=Q_./&G \QTIKQ'
M(]:>3VU/677_ '<?SCQIP/,=*:\1R/6GD]M3UEU_W<?SCQIP/,=*:\1R/6GD
M]M3UEU_W<?SCQIP/,=*:\1R/6GD]M3UEU_W<?SCQIP/,=*:\1R/6GD]M3UEU
M_P!W'\X\:<#S'2FO$<CUK>A$8K%'1F#)..6)MX=Q*(Q1N!3$G*GW5M9;']\G
M]W\&PIIE6.]O>$6VI[K1X3P:(J:QX.XU:R@I%F!'Q92O1)MC'2C,66VH='FU
M T4KMGCORE92TTX".!2PLEVU)3%ECY3;BL>"5GEF1E;*RD,0I"VU(<!EL/UE
M((X@BJJRL,RL"MV%P=+J2K:^P@@\"#6$UYM/7NV14PWKFUBK:*'RH,*=,%..
MJ1$E%*\$M@UE]#[3+K:B%8L@ _"4IO")0DP.G,*7'E-+5,D4D1"R(4)N0"+;
MF9#R964\""*A)$D!*,& L"1Z+J&'-2#\Q!K?^4J].*5J-EOU*II*H![5:0E?
M*WZP>2M*'EB$>'+L]C\732WB8,R\M*YL_P 7CIDG##6,JRAGLX_\1QI"[*CN
M&*J6"+F<@7"K<"YX"Y%59T0J&8*7;*@)MF:Q-AQ-@3;V5MW*U:G%*<4J*[+N
MG7=2CVF0=-/Q?(ZPQ*N<C-B"TJ<@O,J4&]MH@0HL)V26AM5":H]+)#&I0^'#
M&G>\R6G@)=J'E6&1\N4 YU+ Y@!8.4U).AS"P!L22MAXA?$TR+FS$C*V4BQ)
MN5SZ ;QE\5QH &OJI QM>WWKFSV(?61DFQ8EF3QNK!",ZG6D?735DK@HD<-
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M= 3H#Z3I7H%[@U>9/RZP,OE6E&XD6OSNY(-C\+FPK2R)? 3!*U2,-F(A-!\
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MF3"A:9K$B*MV.[TWMUVAE[.;!EQ6%(&-Q4R8+!LP#"*65))'G*G0F*&*1DS
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M@I<8BZ6&1E5POA8N Q*J/@P&8DL190#YQT)NH);2C2HK%23F4*2 "Q\9*J
M"221N&H&IL-:_(^[J!+"9,191V3+05E GZE&J=FD7^(9@RVH<\?,HC(IRTQ>
MY.2(TE^>\,0)P*EP3C9!P(0@D9+N9 ;$*!;,'+*(R+$@A[Y3>Q %[W!6UP14
M=\EKW-[Y2N5LX-[6*6S"W&UK:WM8TH^\M9['+Q@U-/22[\^OILXN9XAL$$08
M#X'U,I+>$F2(N(,(2!D*]5%9:#'DKF#7S;4*6PW.A%8T \,D8+.M@&RGQ*2#
M=U%P"2 2C@$BQRD@V())-'(0$8FZY@<K $64FQ( -@ZW -Q>V\$"6^8JRUUF
M9^YPA9)<F9+WX29FRRTJ5 >(:Y8DO"@IO;/2MV1<*Y'=D6M_/BVYB>DO#IMC
M:;2S&+0=?,R2<2='/,BJ_P C^4&L%"%0  0)" 2(\*BL;(-5.&SK>]B^A!6[
M<?[A%[EP?%?5+V4R8AV75MSB<*W$)J"" ,*G[FZ2#!7@=*W""K4,C6Y-/*L8
MU4\Y!P"):7Z+6KBT@5 %[#"-03THST8HEJ8(OKFQ8[-Z+BI Z?+&-&B4_E $
MW>$L0X<'O=<PEQ,@!)C:ZY<25(%B>[4@@'*(]PD*564+=,A^#/FF+#QD@"1;
M,3!FO<BSD$$BYX\3[F3#>A6@7:-ICK6-L-MN-H6R6UV_)42EV'7&\J2(.6Z/
M*O4D/8[X&+;B'6F;=4"!A,W)U[7([J8BXP&75Y.T3=&2(J41$TDM;++#(0A"
M75"(2@2Y"B1CJ2P<,!HRM(&#,S6*;RT<R!GNY#.#*&+V!)C4:67+@+5]S(LU
MLC;7C3=N:C:>VO9AQ4P::Z-*/*!00)2K?4P8LA-<VXY!G'H!>T(V+-OPX6"N
M]@O,67*,''Q$H8* V3:2H8B(9;1*0J^Z=,S.CL1\""%(4QA"618R %N"6AL
MS"3X6*\C D]Q8V".J@GO""P+9S( KE[DM8@"Q&^.AB9WH5HYV5O&R4\KJC7P
MD1K)P)5:^1C#=HC;96+LO95FQ8E%2)F*Z>UYKE; &N%*78(T -9!>;X^/N1&
M/&UX,8( X$*L)78R79@3$R,G=IER@'+))XF#J2RG("@)S384S%&,I5HD CLH
M($@97SG-<D$HFBE6 ##/9R*O4C"\(1AQ25.82G#BD)RA"E]6.TI"%+<4A.5=
M>4I4M>4XZL96K..O.E6Y7EQ2G%*@V\Z$JE]MY*XE"1J-+*Z[+T&2-B.PO%27
MIX^S!!MR:8?AO/-VROUZ\WJOCI:9'<WQ-LGQR,*8J*+<A9DG9$" +82![F]]
M"I*7OYC,B,1:]T!!%S?"\*NQ8D@E"A M;4, VHOF4.X!O:S$$'2M."]$C5X
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MXZLYC(/73F?PTN>!^[K6*\IR'H3;?\*S\2\9!ZZ<S^&ESP/W=:>4Y#T)MO\
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MRM;*7SN%8%76)$D4'SUM7RA]L9IDQ"XD[+PTX,N%@P^'@[LQAK"\L\4LLS
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MF)9E.Y3CF-X'C3.Q4:H,F8%QG4N"0#IX0#8ZZBX%729'<HH8V#',5(4Y&"D
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M6G*\*R%64'(06(D(>\A#-X 0710J.^8Y0H%@<MJ]0]WH9BY4"5'!7./*%K"
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MG$G(2&VCQ7W=I#K+$N3B0J3'>4G'Q79^/,T)P^,;#LF&"20OB"HDO=%3QR.
M>Y0?!Y0"%=@Q92 /C&S<>V(B.'QK0.N&$<D#8C*)"<RJISR.+]T@'=E0"%=K
ME@U8W5A[8NYNDCI%J*IQ1V3L^DQJS"$L/1Q@-;5H&D94D=&PX[B''@J2Z7)2
M,NJ[NPRIUUQN)&90S39L^/VMM_8X4DS-M'!IATB5ECA(Q$;LT:W.14UED:YR
M@%B0JBV/9L^/VOV@V.$)[YMHX-<,D2E8X<N(C=G1;G*$L99&OX54DD(JA?M@
M.?B4Q^JR'[(]SUZ_F-_PM_ UZ[?S&_X6_@:^ /GB&O$-.*4XI5MNA]KS9UIV
M<-LM%(R:P(K,EI5FLZF5.P%P'<H7(KN8J\H8+22S*>QF M7@XS?8(O+86Q%6
MOOOD^V1MK';:AQNS)GP6'P3J<;C<N:)HF(+X/(;+B'Q"BQC/AC6TS%66+-]
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M4#TM TJ^@$D$#H.T/*3V4V?B&PWNO$8QT8I(^!A::%&!L0)GDBCE ]:!I5]
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M*2.2.1%DCDCR.DB. R.CJ"K(RD,K*2&!!!(-<M&\<J)+$ZR1R*KQR1R9T='
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MSB*0*"0Y18G6WC8\U'L(QBL**FFI8AO=;!K=E29<X?(%8J?$7"+<Q-+;.20
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M6)R'42<AF$BU.9@Y6PJ5D=2"KL"H*BQW*26(^;,2UMUS??4%$8$%0;G,=-[
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MW&E)AL818RR'0NQ&;/J3Y]R<QXM=F-]^IXFJB.,;D4>')N'FV R_-95%O8.
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M#%#+%C)!/C=D;&E6-&.#Q>) GVGBX[1XV5!&AE0R2/W-8QA..K'_ -_PY_\
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M8](P=@Y9:D7PY&9<<\)_12[(;US+<:1G/X5HC/*3_4VK\') 2X\3;Q^B./\
MQTUX#F>E8.V3;_FU6;+M9IZ'<V SEU#=Y-.MH<R1DY6EMU6O&5.(2KKPEQ3+
M2EIQA66T9SE.!"7/B;>?T1Q_XZ:\!S/2M?[Y>_1RI>VICX!Y%D]9OHC\=->
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MG] =8>]VU_8CQIQ/(=::\!S/2GC;<_H#K#WNVO[$>-.)Y#K37@.9Z4\;;G]
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MQ2G%*<4IQ2G%*<4IQ2G%*<4J-=Q7DMK+6%YV&% #;3,I59,6A8 G8)589*Q
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M/XFV)RQ_]93_ $NNY_5EK#_\K^O^/^S1V5^/^T'_ .._HJ>_WVC^)MB<L?\
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MHN^HG6WLW#_^/'OG>4'Y8;>^OS=:>]_V)^3&Q_J<?2IXKU= U((,K=8#C@
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M+[\G^W_]?^3\./P\7/LY#I5;#V\SUIC503..O%IV=G'X.O&U+[G'7_9UX/\
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M#EE2>K4FN8BPHH]$5D7%$8A&'79$YV>0F3I3C<=N ,:@*E$]144Q2/=LZL@
ML,N5LUR3O)N-!8 <3>PVF9A*BV7(RN2;G-F6U@!:P%B;FY).EA:YKI9>F,V$
M/DQJ*4EB#5KS:Z_9'3!F0/FSJ[7J1OX] -UCPX=@.4>/']$E!L-4 N7#LLS4
MB9I2+<85AKM8SKA,R@YR2T:,H4 @,TD"D-XK@!9P3< ^D#(59M=L5E)&3179
M6);]$),P8:6U,1MJ1J 2&NJ_H+I=%[B8 B*QK9,9*;C5*M>"5E/3P[(-ZP[6
MV5J]^*$$SZT.LA$BP_JVP%$-6(-4G&$30\&7#1.>F1X1L*$#%I/T'9 JWS98
MHY=2&*@'O5%U+@V8@V )D8DN5"Q_I*KEB1ES2/&; J&)'=DV8+H1<7N*R&R-
M_P"Q:;=K*.K0NI;! 5ZQZNKA,-7A\B/9:\5V'MK2M''UB;9+!=P-6-7([5+U
M=+2R*8B@X-&;ATB1;"<J'9AB#<1P1NBEBT;,LC L?"P2*9RP549PBO&B$^(R
M7?* 5-DDTB.P4*ZAHU(4&ZEY8D"EF<*7979K64)9"Q(89N6[T@+I(H%BLTH=
M7==%1NQ;/38 ZU#\7*PR5B;'8006LCZ-2KVVW9KH;=%C&VW!E_@@&69I4P](
M9B 9<-QW"!U4%I 8U<E3D755)<N\?@07.^,M<!;78&I[Y\C$A8R'90&&9M"0
MJY$?Q,=-0^7>38"U9G4&YM@W.\0JY=!-0$>-0&RY3X #XPEEZ:>U/9-;5,K$
M*V!XO(@60=<)5ZE6"M28E>K685?@C5J6?\:*FQ8FAC1"R%S9H[,U@'659&!"
MY05*9 K79KL3YMK5,4KNX5PHNLARB]U,31J;M<A@^?,I"KX0/.O>K4\U:V:B
MJ5HW3\YD9'F:WJ$E@-.LQ(4T\&B+;'D+G?0^TK7,BIRCJ9D6'8M>!W0JXGJ5
M,L0J$2=RJ0PA6,HFE!)$C D*#KO"(8U'[L;,@X*2-QK&88C:Z+H6(TW%G$C'
M]YU#GBP!WBMKK=&IM.F6HA5*P#KLZ\V-ZWW&6'&Q8$BS6B3 @#)!XT[';0N>
M4>@"Q\5V9(RMU;45K"E9SC.<T9W<*&9F"+D0$DA5!)RK?<+DFPXU941"Q554
MNV9R  68@ L>)L!J:VKE:M3BE.*4XI3BE.*5CUB12UR7%C!ZW)DN#/F+7"C*
M7+GBU15C)LE66\J?ECEP82H,EW*WHBH<54=;>8[643<\3H"!KZ#O'S&YOQO4
M6&N@U()T&I%K$^T6%CZ+#A2,)%PU1%PQH^(N /2)@KC0XS"H8M&6<H&Q%--H
MS''HS'CY3#9RB,G+#.<-XRTCLB2;W)-S<W.\\3[?;0 "U@!86%AN' >SV5YI
M&CDX;PF!"3AJ:\2:PF*QC#9&0M]<B>WC#?4B:^N3)6]*3U/NKD/J6XK+KF5+
MGB=UM_HX?-H-/92PX#??]O'YZ_<CAZDN(5 A*0[-9(NIS%8REPA'=8?8GN)R
MWU+FL/1HSS,I6,OMNQV'$.)6TWE*YXG=;?Z#>X^8W.GM-+#@-]_V\?GKF<BI
MIQ2G%*<4KA+&CG&Y[3D"$MHJM3A1I<5A39):HK$%2YZ%-Y3,6J%%C0U*D8<S
MF+'8CYSX)IM"9N=-3INUW:WTX:DG3TF]18:Z#7?IOT UXZ #Y@*TZP:LUQ:I
M[1.PTFN%IR";1>0_+%QE9*SX]=-U2*NP-I0EJR1X8"QF($*"?02@P\R6Y<6,
MU.A09,:RRR*"%=@+6L"= 6#'+ZMV4$E;$[B;$@U:.-C=D4F][D#4Y677UAE8
M@ W ONN!7*L>O*9;!Z!1P#%D#L3&)CT2*Y)%M3O 3!T]R 4P*>A**A",D2,\
M=@"2I00_'@QH9L>0AM)C\+(ZFX8WM:YL2-" 1>^5A<Y6%F6Y*D&C(C"Q46O<
M@:7U!UM:X-A<&X-K$$5SI]*II64B:3J59(S&VYK3<N>!%3)2&B3J'R+:)$B(
MXZEN>^VAZ:A*\)E.H0X_AQ:<*Q =P+!V -K@,0--!I>V@W<*DHAWJIW[U!W[
M_1Z?3QK]G4RGD\.))52M$$NRX1!U,X$+EX<GC')#PV:YB1%<PN6/>ERW84E7
M6]$<E2%L+;4\YE0.XW.PT(T8C0[QOW&PN/3;6A53O53N.H!U&X[O1Z.%;+RM
M6IQ2G%*]3[#,EEZ-)9:D1Y#3C$B.^VAUE]EU&6W67FG,*;=:=0I2'&UI4A:%
M92K&<9SCC=NIOWUCR(((8CQ(A<,**11\R&1@1B(^).CPB ]7;@3HC,EEUN-,
M@K_IPY3*4/QE?TF5HS\O)#,+D$@D$$@D7!W@VW@^D>FH(! ! (!! (! (W$>
MT>CA7#C5&J0W9#\2L5Z*],*NGI;T8*-8=E''Y$24\9D.-1DK?*O2H$&2Z1=R
MJ8Y(A1'EO9<C,J1.=S8%F( RCQ'1;$6&NZQ(MNL3495!)"J"3<FPN3IJ=-^@
MUWZ"MAY6K5&NWM7 -R:]L6O+)EQJ"=BHPQ/80E<H23B.HE#"L7"\IPIV#,::
M=4SE:$2H_AX;JL,R'>OI?E"[#;)\H_9';'9#;)>/"[4@40XN)0T^S\= ZSX'
M'P E0TF%Q,<;M$61<1#WN&D813/78NRG:7']D=O[/V_L[*\^"D)>"0D18K#2
MHT6)PLI%R$FA=E#@,8I,DR#/&M=)!WH2;PHQ66,Q7+&?A]DHS&LE&7 ,##,*
M6EAEF+XK<?CEPSK[+;C17)1G$9]J1AEG+K4#M%_S+VM_AF\I_9C'XC _D;;&
MUL-;'1P;9[+MA=HX+:6&G$4<<!P+20[0V;)+&CICSCH^XE281QL\>$)VA[*P
M7EE[&;:PL6)_*&S\%-?#/)L[;0Q&$Q.#FB+L\GNI4DPF,5'<-A1AG[R-HR[6
M>>V$LGT6^@I8@E\$;,VNRX-'5B1"*5BI3W8$DW/-PFV7()([@9,(P!XX7+0F
M8/'(G/SWWV(J"#4-F.['F_9_(7_A;VQLSM5L_MKV]B;!8+8<V%QVP^S^+DPD
MVT\7M/#)&V&QNU!@<3C,)@\'@<0JXC!X-<7-BY9(H4Q<>&CA>+$_._*9Y;-G
MXW8>+[.=EW7$8C:238;:6U8$GCP4&"F9UGPV"]TPX>>?$8F)C%B,08$@1'E;
M#M,TBR0]KAE&7 Y5O&<8RX-G(QG/X,95%=3C.?\ VQU\]]8F(SX?$0J0&F@E
MB4F]@9(V0$VN; FYL";5Y;A<1S12$$B.1'(&\A6#$"^ER!I7S@?>UV;T@!?0
M(?PW/S3_ .Q'VX^6'93_ .GM?^AKV+_VE.S/R?V[]/9_]33[VNS>D +Z!#^&
MX_[$?;CY8=E/_I[7_H:?]I3LS\G]N_3V?_4T^]KLWI "^@0_AN/^Q'VX^6'9
M3_Z>U_Z&G_:4[,_)_;OT]G_U-3KK35PV@1%O.K:(V"6G*)A/#><(:9RK&<0X
M"5X[;4?'4E3R\]3LIS&%N=EM#++7J[R'^0C8ODBV=)B9Y(-L]L-H1F/:6W!$
M5CP^&+AEV9LE)1WF'P0*H^)E8+B,?.HDGR118;#8?X5Y2_*AM+M_C$AC679_
M9_",&P>S"X+RS6(.,Q[(<DN(-V6)!>+#1DI&6=Y9994Y]]KY73BE3+2OR1;I
M_P!NN_\ J.1RP\UOW?XTJ&N5I3BE.*4XI3BE2%J?\I-*_O! _P")R5WCYQ_&
ME8"X_P"MUI_O&<_YG*X;>?G/\:5KG(I3BE.*4XI3BE2=IG\J%-_6BOV.3RR>
M</V_P-*TBP?CXW^MR7[:]RM*Q'%*<4IQ2G%*<4JZO12_%-Q_6(G]FF<R1^G]
MG_6E6SYDI3BE5RG=']<R5.'XO19FB3['=+*]44Q'VI*W=DF4F;Z#D'X1>$J7
M6C4B99'($22+<+@I-DE+@G<P8 P;%U#A;DCO#W1>1\EC?X5LTJEPPNC7>RE;
MJ7\XJ H[1'VE$:1R'9\#;1CPN PBXTNI11LK#]QLW$+AI(9,F+PZQX42NDP@
MQ*85!)AA))-,_I$='6*%A5N''MTV7Y*V.EG!;Y(>Y(?7'H]!(ZY$PI[[):+)
MF2E YC$I\DM].9!:'WF7$E19+\+,+A H4=X24>-@2+W$<1A4-X@3X3>]]6%R
M"-*M/VH?$/BW?!1I[MPF/PTRQ2!%#;1VE%M6:2-6A=(U&(1D6(+9(7RQNCHL
M@Y\+H\UQ8(/7#Y!XH("^4K@^$-9E@VACMGM0NRS(P!W!4C. !(S(I($>%'34
M,C@9(L)'OQ [H\6,L,*F548DJN:P6ZV+.'(4AB54!0H52 %+ 64@+CD[38H8
MB?%8:-89L1[D$LDK)B&F&$P4V$C?$@PQ1XG$.TQQ,L\L9:7$10SRK)B%EFFX
M6>BQK#P8I*9-V0Z'7!7$EHN);$I>!=CG6T:W)=RO/>&8%@GK(1&W$Y3'5&@-
M-80Q!C-MQ[BATUDNMK'O&OHQ<#@0'8L+C0VM8 5?\\-KWFNN 99^\SHV!@*7
MFPL>"E*+;PF3#1B-R-7#2%KM(Y/,9Z,>L&8:(.$V93"714A>?*4@T])D" <(
M#&>ER(RF'Y3CS T=-FY><7B:3A,S9&%JRZET,%"!;Q_HD^,ZE5"B]K7N ";[
MR+FJ-VLVNSF0G"9B)E'_ '2)E59\1)B75%<,J*K32QQY0#'#(T:D64K--9KH
MVHUT'5PR'FQ->%00XY$AY<F1B&/CMQF/#R'.MQ]_+;:<O/+SE;KF5.*_I*SS
M91%C146^5%"BYN; 6%R=Y]M<#B\5+C<5B,7.0TV)FDGE*J$7/*Q=LJC15!-E
M4: 6 W5FEH0XA;;B$N-N)4A:%IPI"T*QE*D+2K&4J2I.<X4G.,XSC.<9QG&>
M6K7K'O!A$B,U"?%#7X;$1Z Q$>@Q78S,&1&S"?A-,+:4TW$?AYS$>C(1AER-
MG+"T*:_H<FYO>YO>][F][WO?C?6_&HL-UA:UK6]&ZWS6TKF+C1W'V9+C#*Y,
M=#S<>0MI"GV$2/!^'0RZI.7&D/\ @FO#)0I.'?!-]O"NPGJBYW7T.\<;;JFM
M:>H=&D9)YD4RIOY-3U%3.7JZ'=R6*+A21JR1/*X:N_SUCIDN J9*\+(5"E28
MN7,L/NMJL'<6L["PL+,=!<&PUT%P#8:7 /HJN1-?"NIN?"-3:USIJ;$BY]!M
M7NBTRGP8;0Z#5*U#'LK%.,P8H(7'AM. IV281;45F*AAM8<DI1 4I*,*'SE9
MEQ,LR,Y<X+N3<LQ.NI8W\0LVM_2-#Q&AID2ULJVTTRBVAN-+>@ZC@=U>INBT
MEHS+L;5.JK5A(+9<GGFZ\(09FKCRX9".N643#Q.DK8GCA\UE3SZ\M2X$.2C*
M7HK"T,[V"YVRC<N8V&A&@O8:$CYB1Z:9$N6RKF-KME%S8@BYM<V(!'M X4,4
M6D6%IR.?IU5.,.R,2W63%>$$VG927)3J9+C<V&^A<A+LZ:[AY2<N8<F2EX5V
MI#N5@[KYKLNEM&(TTTT.[0<APH41O.13Z=5!UXZCVGG7/&UJN!I<J>'KX05.
MG1!L";-&BH$&7,@AX^8@B'*DQ6&GI$05%SF,-CNK6S!CYRS%0TWGL\%F8 %F
M(!) )) )-R0"="3J3Z3OJ0J@W"@$@ D  D#0#3T ;AZ/16;Y6IKYZ3>ZMR-&
M2[36VMF---$Y[;;;=\M*&VVT2W4H0A"2N$H0A.,)2E.,)2G&,8QC&.9[#@.0
MK!<\3S-8SSW;G];NS_;ZU_6W%AP'(4N>)YFGGNW/ZW=G^WUK^MN+#@.0I<\3
MS-//=N?UN[/]OK7];<6' <A2YXGF:>>[<_K=V?[?6OZVXL. Y"ESQ/,T\]VY
M_6[L_P!OK7];<6' <A2YXGF:>>[<_K=V?[?6OZVXL. Y"ESQ/,T\]VY_6[L_
MV^M?UMQ8<!R%+GB>9IY[MS^MW9_M]:_K;BPX#D*7/$\S3SW;G];NS_;ZU_6W
M%AP'(4N>)YFGGNW/ZW=G^WUK^MN+#@.0I<\3S-//=N?UN[/]OK7];<6' <A2
MYXGF:>>[<_K=V?[?6OZVXL. Y"ESQ/,T\]VY_6[L_P!OK7];<6' <A2YXGF:
M>>[<_K=V?[?6OZVXL. Y"ESQ/,T\]VY_6[L_V^M?UMQ8<!R%+GB>9IY[MS^M
MW9_M]:_K;BPX#D*7/$\S3SW;G];NS_;ZU_6W%AP'(4N>)YFGGNW/ZW=G^WUK
M^MN+#@.0I<\3S-//=N?UN[/]OK7];<6' <A2YXGF:>>[<_K=V?[?6OZVXL.
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0 %8_M+<6' <A2YXGF:__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
